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Thesis abstract  
 
Previous literature suggested an increase in the risk of fractures in diabetes. The risk seemed 
to be higher in T1D than in T2D but the effect of several features such as fracture site, gender, 
age, BMI and diabetes-related features such as DM duration, insulin use and the presence of 
complications has not been fully explored. This thesis investigated the risk of fractures in 
diabetes. The first meta-analysis (chapter 3) investigated the risk of hip and non-vertebral 
fractures in diabetes and how this risk was affected by several features associated with the 
patients and the disease. A significant increase in the risk of fracture in diabetes was found 
both for hip (RR 1.52, 95% CI 1.42-1.63) and for non-vertebral fracture (RR 1.20, 1.14-1.27). 
The increase in the risk was greater for insulin users and longer diabetes duration, at both 
sites.  At the hip, the risk was higher in the younger population, women, and those with T1D. 
The second meta-analysis (chapter 4) investigated the risk of peripheral fractures in diabetes, 
since the wrist and ankle are the sites assessed by HR-pQCT. There was a discordant pattern 
and while at the wrist the risk of fractures was decreased (RR 0.85 95% CI 0.77 – 0.95) at the 
ankle the risk was increased (RR 1.30 95%CI 1.15 – 1.48). The sample included mainly T2D 
participants and the pattern was similar to the risk pattern observed in obesity. 
Finally, a clinical study was conducted to assess axial DXA and peripheral microarchitecture in 
patients with type 1 diabetes with and without neuropathy. HR-pQCT was used to evaluate 
the standard site and also a less distal (14% limb length) site. There was no difference in DXA 
at lumbar spine or proximal femur between the groups. On HR-pQCT, the 14% site showed 
preserved trabecular structure particularly in the group without neuropathy and no 
abnormalities in the cortical compartment in the diabetic groups. At the standard site, cortical 
porosity was increased in the group with diabetes and neuropathy at the tibia. However, 
there were no differences in bone strength estimated by finite element analysis. Since bone 
turnover markers are decreased in diabetes, bone turnover is suppressed. This could suggest 
that the bone turnover suppression could prevent bone loss and preserve trabecular 
microarchitecture. Conversely, cortical porosity was increased only at the tibia in the group 
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with neuropathy. This finding suggested that vascular and/or neural integrity might also be 
important to bone remodelling and consequently, bone microarchitecture. 
In summary, there was an increase in the risk of hip, non-vertebral and ankle fractures and a 
decrease in the risk of wrist fracture in diabetes. Our findings suggested that bone 
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 Introduction  
 
Introduction  
Diabetes is a chronic disease characterized by hyperglycaemia. The incidence has been 
increasing worldwide for years and one in eleven adults has diabetes (1). According to the 
International Diabetes Federation Diabetes Atlas, 415 million people had diabetes in 2015 
and a 5% increase in the number of patients is expected annually. Huge economic, social and 
medical burdens are associated with the disease (1).  
 
Diabetes diagnosis  
Diabetes diagnosis is based on hyperglycemia. According to the American Diabetes 
Association, diabetes diagnosis is based on a fasting blood glucose concentration above 7.0 
mmol/L (126 mg/dL), a random blood glucose concentration above 11.1 mmol/L (200 mg/dL) 
with symptoms, or an abnormal result from an oral glucose tolerance test. In the absence of 
symptoms, the test should be repeated. Glycated hemoglobin can also be used, and 
concentrations above 48 mmol/mol (6.5%) are considered diabetes diagnosis. There are two 
main types of diabetes, type 1 and type 2 (2). 
 
Type 1 diabetes  
Type 1 diabetes (T1D) is a chronic disease characterized by autoimmune destruction of β-cells 
leading to insulin deficiency and hyperglycemia. The immunopathogenesis is described in 
Figure 1-1Error! Reference source not found.   (3). In children, T1D onset commonly presents 
with polyuria, polydipsia and weight loss and approximately one third of the patients have 
diabetic ketoacidosis. Although juvenile onset is considered typical of T1D, people of any age 
can be affected and up to 50% of cases start in adulthood. Furthermore, adults might not 
present the classical symptoms and as many as 50% of the adults might be initially 




Figure 1-1The immunopathogenesis of type 1 diabetes 
The development of type 1 diabetes is thought to be initiated by the presentation of β-cell peptides by antigen-presenting 
cell (APCs). APCs bearing these autoantigens migrate to the pancreatic lymph nodes where they interact with autoreactive 
CD4+ T lymphocytes, which in turn mediate the activation of autoreactive CD8+T cells (A). These activated CD8+ T cells 
return to the islet and lyse β cells expressing immunogenic self-antigens on major histocompatibility complex class I surface 
molecules (B). β-cell destruction is further exacerbated by the release of proinflammatory cytokines and reactive oxygen 
species from innate immune cells (macrophages, natural killer cells, and neutrophils; C). This entire process is amplified by 
defects in regulatory T lymphocytes, which do not effectively suppress autoimmunity (D). Activated T cells within the 
pancreatic lymph node also stimulate B lymphocytes to produce autoantibodies against β-cell proteins. These 
autoantibodies can be measured in circulation and are considered a defining biomarker of type 1 diabetes (E). In the 
pancreatic islet: green cells- beta cells; purple cells – alpha cells; blue cells- delta cells; red dots capillaries  
Reprinted from The Lancet, (3) with permission from Elsevier. 
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T1D is a polygenic disease with sibling risk of 6-7% and offspring risk of 1-9%. The average 
lifetime risk is one in 250 people; however, it varies according to several factors such as 
geographic region and income. Both incidence and prevalence are increasing worldwide. 
Currently, the peak incidence is in children aged 10-14 years but incidence is increasing 
particularly in children younger than 5 years old. Most people living with T1D are adults (3).  
 
Type 2 diabetes  
Conversely, pancreatic -cell disfunction and insulin resistance in target organs leads to 
relative insulin deficiency in T2D. Frequently, the disease is asymptomatic. Recently, the 
combination of an ageing population, sedentary lifestyle and high obesity prevalence resulted 
in a substantial increase in the incidence and prevalence of T2D.  More than 90% of patients 
with diabetes are affected by T2D (4).  
In this population, the main cause of morbidity and mortality is cardiovascular disease. 
Glucose and lipid lowering strategies and blood pressure control reduces the risk of 
complications and cardiovascular disease progression (4).  
 
Diabetes chronic complications  
Despite diverse pathophysiology, hyperglycaemia is the common hallmark in T1D and T2D. 
Chronic hyperglycemia is the central initiating factor for microvascular disease (MVD). The 
common feature in the pathophysiology of MVD is a progressive narrowing of vascular lumen. 
Eventually this leads to occlusion and inadequate perfusion, hypoxia and impaired function. 
In addition, hyperglycemia activates several metabolic pathways. The four main pathways 
affected are; i) the polyol pathway; ii) the formation of advanced glycation end (AGE) 
products, iii) activation of protein kinase C; iv) hexosamine pathway flux. 
 
The polyol pathway  
The polyol pathway converts toxic aldehydes in inactive alcohols, through the action of the 
aldolase reductase enzyme. When glucose is high, aldolase reductase converts glucose to 
sorbitol. The process consumes NADPH, an important cofactor in the regeneration of 
glutathione, a critical antioxidant. This reduction of intracellular antioxidant increases 




Figure 1-2Hyperglycemia increases flux through the polyol pathway 
Reprinted from Diabetes (5) with permission from Elsevier. 
 
The production of AGEs 
Glucose and other sugars can react with proteins producing AGEs. This post-translational 
modification might influence the protein function. Intracellularly, this could influence several 
interactions, including the regulation of gene transcription; on the extracellular matrix, this 
could modify the interaction with extracellular matrix nearby. Finally, modified proteins might 
circulate in the blood stream. There are receptors for AGE and the activation of this receptors 




Figure 1-3 Increased production of AGE precursors and its pathologic consequences. 
Reprinted from Diabetes (5) with permission from Elsevier. 
 
Protein kinase C activation 
Protein Kinase C (PKC) is a multifunctional protein involved in a variety of important cellular 
pathways. Diacylglycerol is a critical activation cofactor of many isoforms of PKC. 
Hyperglycemia increases the synthesis of diacylglycerol, leading to several effects on gene 
expression (Figure 1-4) (5).  
 
Figure 1-4 Consequences of hyperglycemia-induced activation of PKC. 





Increase hexosamine pathway activity 
In hyperglycemia, most of the glucose is metabolized thorough glycolysis. The excess of 
glycolysis generates products that might react with transcription factors and result in 
pathologic changes in gene expression (Figure 1-5) (5).  
 
Figure 1-5 Hyperglycemia increases flux through the hexosamine pathway 
Reprinted from Diabetes (5) with permission from Elsevier. 
 
 
Although these pathways are not directly linked their activation eventually results in increase 
in oxidative stress (Figure 1-6) (5). 
 
 
Figure 1-6 The unifying mechanism of hyperglycemia induced cellular damage. 
Reprinted from Diabetes (5) with permission from Elsevier. 
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Although hyperglycemia is a systemic phenomenon in diabetes, microvascular complications 
are restricted to specific sites; retinopathy affects the retina, nephropathy affects the kidneys 
and neuropathy affects the nerves.  The reason for this finding is that most cells control 
glucose transport and maintain intracellular glucose concentrations constant despite 
extracellular hyperglycemia. However, endothelial and mesangial cells at the retina, 
glomerulus and nerves do not control glucose influx and develop intracellular hyperglycemia 
(5).  
Since patients with neuropathy were involved in the clinical study, neuropathy will be 




Definition and symptoms  
Diabetic neuropathy is a result of nerve damage and typically presents as sensory 
abnormalities. The Toronto Consensus Panel on Diabetic Neuropathy defined Distal 
symmetrical polyneuropathy (DSPN) as ‘a symmetrical, length dependent sensorimotor 
polyneuropathy attributable to metabolic and microvessel alterations as a result of chronic 
hyperglycaemia exposure (diabetes) and cardiovascular risk covariates’ (6). Neuropathy can 
cause negative symptoms such as impaired touch, vibration, pinprick, hot and cold sensation 
or positive symptoms such as paradoxical pain and hypersensitivity. Symptoms are typically 
distal, with the classical stocking–glove pattern (Figure 1-7). DSPN is the most common form 
but other manifestations include mononeuropathy (while affecting single nerves), plexopathy 
(while affecting a nerve plexus), radiculopathy (while affecting nerve roots) diabetic 




Figure 1-7 Diabetic neuropathy presentations 
Reprinted from Nature reviews (7) with permission from Elsevier. 
 
Epidemiology 
Diabetic neuropathy is a common complication of diabetes. In the Rochester Diabetic 
Neuropathy cohort, a neuropathic disorder was reported in 59% of T1D patients and 66% of 
T2D (8). The most prevalent manifestation is DSPN, present in around 50% of patients with 
diabetes (8).  Around a fifth of patients with diabetes develop DSPN. Burning, ‘electric-shock 
type’ and sharp pain are the most common symptoms, but aching, itching, cold pain and 
others are often described. Symptoms are often worst at night. Most of the patients grade 
the pain as severe. Quality of life is often impaired (9).  
 
Mechanisms 
Several vascular and metabolic mechanisms are associated with the impairment of nerve 
function in diabetes (5, 7, 9). As previously discussed for MVD, the several metabolic 
pathways activated and the increased oxidative stress leads to abnormal nerve function and 
nerve injury (Figure 1-8). 
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Figure 1-8 Pathogenesis of diabetic neuropathy 
Diabetic neuropathy has a complex pathogenesis involving interaction of axonopathy, schwannopathy and 
microvasculopathy. The figure shows the anatomical organization of myelinated and unmyelinated axons within nerve 
fascicles. Their nutrient supply is secured via endoneurial capillaries which, together with the perineurial membrane, form 
the blood–nerve barrier. a | Human skin biopsy samples immunostained with PGP9.5 to show progression of peripheral 
nerves from the dermis into the epidermis, where they exist as small unmyelinated C-fibres (scale bar 40 μm). Left panel 
shows loss of fibres in a patient with diabetic neuropathy and right panel shows fibres in a healthy individual. b | Changes 
in axons and myelin in diabetic neuropathy, showing degeneration of Schwann cells and nerve fibres, culminating in nerve 
and intraepidermal fibre loss. c | Endoneurial capillaries from patients with diabetes. Top panel shows a capillary from a 
patient without diabetic neuropathy, and bottom panel shows a capillary from a patient with neuropathy, in which 
endothelial cell hyperplasia and basement membrane thickening have reduced the size of the capillary lumen. d | 
Narrowing of individual capillaries might not prevent blood from passing through the endoneurial capillary bed per se, but 
the resulting increase in velocity of blood through endoneurial functional shunts or epineurial arteriovenous shunts prevents 
efficient oxygen extraction, causing hypoxia. Reprinted from Nature reviews (7) with permission from Elsevier. 
 
 Besides the four main pathways reported, other mechanisms might also be involved as 
myoinositol and neurotrophin depletion, reduced Na+, K+, ATPase activity, schwannopathy, 
mitochondrial disfunction and increased inflammatory response (Figure 1-9) (7).  Despite 





Figure 1-9 Hyperglycaemia-driven Schwann cell stress and neurodegeneration. 
Hyperglycaemia and dyslipidaemia ultimately lead to reduction of neuronal support from Schwann cells and microvessels. 
In Schwann cells, RAGE (receptor for advanced glycosylation end products) signalling leads to increased glucose metabolism 
by aldose reductase, which generates local oxidative damage, causes inflammation and drives cells to an immature 
phenotype. It also affects mitochondrial function, which increases oxygen consumption, and reduces production of desert 
hedgehog (DHH), which affects endothelial cell function. Endothelial cells also express aldose reductase, and increased 
polyol pathway flux activates proinflammatory and prothrombotic pathways that reduce nerve blood flow. Disruption of 
neuronal support by Schwann cells and the vascular system contributes to neuropathy, in conjunction with the direct effects 
of diabetes on neurons themselves. Reprinted from Nature reviews (7) with permission from Elsevier. 
 
Risk of fractures in diabetes  
 
A number of meta-analyses have reported an increased risk of fractures in people with 
diabetes (10-14). Janghorbani et al (10) and Vestergaard (11) published the first meta-
analyses in 2007, and since then, other authors have observed similar findings (Table 1.1, 








Table 1.1  Risk of hip and spine fractures inT1D and T2D according to meta-analyses 
Study, Year N  Age 
range 
Hip fractures  Spine fractures 















- 0.93 (0.63– 
1.37) 





Dytfeld, 2016 765,121 > 50  - 1.26 (1.07 – 
1.57)* 
- 1.13 (0.94-1.37) 
Shah, 2015  4,391,425 > 20  3.78 (2.05-6.98)* - 2.88 (1.71-
4.82)* 
- 
Wang, 2018 NR 20-84 4.35 (2.91-6.49)* 1.27 (1.16-
1.39)* 
 1.74 (0.96-3.26) 
* statistically significant; N (number of participants) and age range for the whole analysis; the 
authors did not report individual data for each analysis.    
 
The risk varies according to the type of the disease and the skeletal site. The highest risk was 
found at the hip ranging from 3 to 7 fold in T1D (10-12, 14) and from 26 to 70% T2D (10, 11, 
13, 14). For vertebral fractures, no increase in risk was found in T2D (10, 11, 13) and Shah et 
al described an increased risk in T1D (14) . In the ‘any fracture risk’ analysis, a greater risk was 
observed in T1D (Table 1.2) (14).  
 
Table 1.2 Risk of any fractures in T1D and T2D according to meta-analyses 
Study  Any fractures N participants  Age range (y) 




- 1.2 (1.01-1.5)* 836,941 all ages 
Vestergaard 
(11) 




- 4,391,425 > 20  
Wang 1.51 (1.35-
1.68)* 
1.22 (1.13 to 1.31) NR 20-84 
* statistically significant N (number of participants) and age range for the whole analysis; the 
authors did not report individual data for each analysis.    
 
Table 1.3 Fracture risk in T2D according to Janghorbani et al 
Site RR 95% CI 
Hip*  1.7 1.3 – 2.2 
Any fractures* 1.2 1.01 – 1.5 
Foot * 1.3 1.1 – 1.7 
Distal forearm  0.98 0.8 - 1.2 
Ankle 1.3 0.9 – 2.0 
Proximal Humerus 1.3 0.8 – 2.2 
Vertebra 1.2 0.7 – 1.2  
* Statistically significant  
 
Janghorbani et al evaluated other skeletal sites in T2D, such as the distal forearm, ankle, 
proximal humerus and foot and only in the last one a significant increase in the risk was found 
(Table 1.3) (10). 
A large study from the Scottish National Registry showed interesting data. More than 3.86 
million people were evaluated, 3.66 million non-diabetic controls, 21,033 T1D and 180,841 
T2D (15). There was an increase in the risk of hip fracture in T1D (RR 3.28 95% CI 2.52-4.26 in 
men and 3.54 95% CI 2.75-4.57 in women) but in T2D there was no increased risk in men (RR 
0.97 95% CI 0.92-1.02) and a small increase in the risk in women (RR 1.05 95% CI 1.01-1.10). 
Nevertheless, the risk was increased in T2D with more than 7 years of disease duration in 
both genders (RR 1.25 95% CI 1.08-1.45 for men and RR 1.55 95% CI 1.38-1.75 for women) 
(15). This data suggests that bone could be a target to diabetes complications, clinically 





Bone quantitative analysis in diabetes 
 
Bone mineral density 
Bone mineral density (BMD) is one of the main tools used to evaluate the risk of fractures in 
clinical practice. Estimates suggest that 70% of bone strength could be attributed to BMD 
(16). Usually, an inverse relationship is observed between BMD and the risk of fractures, 
however in the diabetic population, the findings do not follow the expected pattern.  In T1D 
patients, BMD is decreased. Vestergaard described a decrease in BMD Z-score in spine (mean 
SEM  -0.220.01) and hip (-0.370.16) (11) and Pan et al, also in a meta-analysis, described 
a more comprehensive evaluation (Table 1.4) (17).  
Table 1.4 Pooled mean difference (MD) of BMD between T1D and non-diabetic individuals according to meta-analysis by 
Pan 
Bone sites MD (g/cm2) 95% CI p 
Total body -0.06 -0.1, -0.01 0.013 
Spine -0.03 -0.08, 0.02 0.238 
Spine female -0.01 -0.04, 0.01 0.327 
Spine males -0.04 -0.07, -0.01 0.003 
Femur  -0.06 -0.13, 0.00 0.049 
Femur <20y -0.04 -0.05, -0.03 <0.001 
Hip female>20y -0.05 -0.08, -0.02 0.001 
Hip male > 20y -0.02 -0.06, 0.02 0.001 
Forearm fem>20y -0.01 -0.02, 0.00 0.023 
Forearm male>20y 0.00 -0.02, 0.02 0.777 
MD: mean difference; CI: confidence interval; y: years; fem: female  
Adapted from ref (17). 
 
A number of features could contribute to the decrease in BMD in diabetes. In early-onset T1D, 
hyperglycaemia and poor metabolic control may compromise growth hormone and insulin-
like growth factor 1 (IGF-1) actions in bone modelling (18), leading to a suboptimal peak of 
bone mass accrual (11). Furthermore, the lack of insulin’s anabolic effect and the glucose 
toxicity may also affect bone remodelling and result in a decrease in BMD even in adults (11, 
19).  It would be expected that this decrease in BMD would result in an increase in the risk of 
fractures, however, the increase in the risk of fractures observed, for example, at the hip (RR 
6.94) is much higher than would be expected (RR 1.42) for the given BMD decrease (11). 
Therefore, BMD should be interpreted with caution in diabetes. Schwartz et al evaluated the 
association between BMD and the risk of fractures in T2D (20). In this study, femoral BMD 
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was associated with the risk of fractures, however, for a given T-score and age, people with 
T2D have a greater risk of fractures than people without diabetes. People with T2D have 
fractures in a higher BMD than general population, suggesting that BMD cannot capture the 
abnormalities in diabetes.  
 
Computed tomography 
Bone involvement in T1D was also evaluated by computed tomography. Ishikawa et al 
assessed femoral and spine structure using quantitative computed tomography (QCT) in 17 
male T1D diabetics with a mean duration of the disease of 15.6 (8.6) years, mean 
haemoglobin A1c 7.4% 0.9 (ranging from 6.4 – 10.3%) and 88% of them without retinopathy. 
A significantly lower cortical volumetric BMD (vBMD) in the femoral neck and vBMD cortical 
thickness and cortical cross sectional area (CSA) in the intertrochanter were described, but 
no difference was detected at the spine (21). T1D adolescents were evaluated using 
peripheral quantitative tomography (pQCT) and reduced bone mineral content and smaller 
bone CSA were detected (22). Therefore, a reduction in CSA (pQCT) has been reported in 
adolescents and in cortical CSA (QCT) in adults without MVD. 
In T2D, the evaluation of bone structure by quantitative computed tomography showed 
greater hip areal bone mineral density (aBMD) associated with greater trabecular vBMD (23). 
Cross sectional area, cortical thickness and cortical vBMD were similar between T2D group 
(n=49) and healthy controls. There were no data in regard to the length of the disease or 
metabolic control in participants with diabetes (23). The data are in accordance with 
densitometry measurements suggesting that bone quality and not quantity is affected in T2D.  
 





High resolution peripheral quantitative tomography (HR-pQCT) evaluates vBMD and bone 
structure at the radius and tibia in vivo. The 82 m resolution enables this tool to assess 
structural properties of bone near to a trabecular level (Figure 1-10) (24). The device was used 
to evaluate adult patients with diabetes with and without MVD (25). Summary of HR-pQCT 
findings in diabetes is described in Table 1.5. In T1D, the group with MVD exhibited lower 
total, trabecular and cortical vBMD and thinner cortex at the radius and lower total and 
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trabecular vBMD at the tibia, compared with healthy controls. No difference was reported 
between diabetics without MVD and healthy controls. In regard to cortical porosity there was 
no difference between any of the groups.  
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Table 1.5 Summary of HR-pQCT findings in T1D and T2D 
Study  Group/ site 
assessed (n)  
Trabecular findings  Cortical findings  Finite element analysis  
  Radius  Tibia  Radius Tibia Radius Tibia  
Shanbhogue (25) 
a 
T1D MVD + 
(n=26) x 
healthy 








   
 T1D MVD+ (26) 




 total vBMD 
(11%)  
 Tb vBMD 
(18%)  




 total vBMD 
(17%)  
 Tb vBMD 
(20%) 
 Tb.Th (14%),  

















 total bone 
stiffness 
(14%,)  







load (15%)  













   

















   vBMD 
 cortical 
thickness 
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Study  Group/ site 
assessed (n)  
Trabecular findings  Cortical findings  Finite element analysis  
healthy 
controls (n=26)  
 cortical 
porosity  
Patsch (29) c Distal scanning 
(24.5 mm from 
reference line 
at radius and 




x T2D without 
fracture (n=20)  
 trabecular 
heterogeneity  
  relative 
porosity  





 porosity  
 
endocortical 
bone surface  
  






 BV/TV (+15%) 
 
 BV/TV (+11%) 
 
    






   vBMD (1.7%),  







area (11.5%)  
 





Samelson T2D (n=129)  
Controls 
(n=940)  






Study  Group/ site 
assessed (n)  
Trabecular findings  Cortical findings  Finite element analysis  
(40-87 y; mean 
64 8) 
 CSA  
 T2D with 




















vs no fracture 
(n=633) 
 
 Tr vBMD,  
 Tr.N,  
  Tr.Sp, 
  Tr.Sp SD;  
 Tr.Th 
 Tr vBMD,  
 trabecular 
number,  
  trabecular 
separation, 



















     
Farr  T2D (n=30) vs 







for covariates  
 
 
 no difference 
after adjustment 
for covariates 
   
a no difference was found between T1D without MVD and controls  
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b no difference was found between T2D without MVD and controls 
c no significant difference was found between T2D without fractures and controls; there was a trend to lower cortical pore volume and lower 





Figure 1-10 HR- pQCT bone images. A – radius; B tibia;                                                                                                                   
 
T2D trabecular compartment  
Several studies reported HR-pQCT data in T2D and results were inconsistent. In the trabecular 
compartment, Burghardt et al reported increased vBMD adjacent to the cortex and trabecular 
thickness at the tibia. There was no difference in other trabecular features at the tibia or 
radius (26).  Individual trabecula segmentation (ITS) analysis characterises the morphology of 
trabecular bone. ITS analysis comparing T2D and controls without diabetes reported greater 
plate-like and less rod-like trabecular network in early T2D (less than 10 years duration) but 
not in people with longer diabetes duration (30).  Furthermore, a Swedish study assessed 75-
80-year-old women, one quarter of them with newly diagnosed T2D, reported greater BV/TV 
at both the tibia and radius. No other study reported significant findings in the trabecular 
compartment in T2D (31). 
 
T2D cortical compartment   
In the cortical compartment, the most common finding was on cortical porosity. Five studies 
compared T2D and healthy controls with four reporting an increase in cortical porosity; three 
of them at the radius (26, 28, 32) and one at the tibia (27). Conversely, the Swedish study 
reported a decrease in cortical porosity at the radius. This finding came from a non-standard 
site (at 14% of the bone length, less distal than the standard site), a site rich in cortical bone. 
No difference in cortical porosity was found in the standard analysis (31). Conflicting results 
were also found while comparing T2D with and without fractures. Patsch et al analysed the 
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standard site but also a less distal site, at 22.5 mm from the reference line at the radius and 
37.5mm at the tibia. At the less distal site, an increase in cortical porosity at the radius was 
found in the T2D group with fractures (T2DFx) compared to T2D without fractures (29). 
Conversely, Samelson reported a decrease in cortical porosity at the radius at the standard 
site in T2DFx, compared to T2D. Interestingly, in the study by Samelson, other cortical indices 
were worse in the T2D group with fractures (lower tibia cortical vBMD, lower tibia cortical 
tissue mineral density and lower radius cortical thickness) (32).  
 
 
Bone strength in diabetes  
Conflicting results were also found in the bone strength analysis. In accordance with the 
favorable microarchitectural findings, failure load and stiffness calculated by finite element 
analysis were higher at the radius and tibia in the proximal analysis reported by Nilsson 
(comparing T2D and controls) (31). In the other studies comparing T2D or T1D and controls 
there were no differences in bone strength assessed by finite element analysis. 
Samelson et al, while comparing individuals with and without fractures, found lower failure 
load at the radius both in T2D (T2D with fractures vs T2D without fractures) and controls 
(controls with fractures and controls without fractures) and also lower failure load at the tibia 
in controls with fractures compared to controls without fractures (32).  
 
Reference point indentation 
Reference point indentation (RPI) is also used to evaluate the toughness of the bone. It 
measures the distance that a probe (Osteoprobe ) descends into the bone for a given 
applied force (33).  The greater the distance, the lower is the bone material strength (BMSi). 
In postmenopausal women with diabetes (n=19) BMSi was 9.2% lower than in the controls 
and was inversely associated with the duration of the disease (33).  
Two studies have assessed both microarchitecture and BMSi.  Farr et compared 30 
postmenopausal women with T2D >10 years and 30 non-diabetic age-matched controls. 
Microarchitecture was not different between the groups but BMSi was around 10% lower in 
the group with diabetes. In T2D patients, BMS correlated negatively with the average HbA1c 
levels in the last 10 years (34). 
Furthermore, Nilsson et al, in the Swedish study also reported lower BMSi in T2D compared 
to controls despite lower cortical porosity (31). BMSi is suggested to be an in vivo measure of 
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bone material properties. These findings suggest that impairment of bone matrix properties 
could contribute to bone fragility in diabetes.   
 
Histomorphometry in diabetes  
There are not many studies evaluating bone histomorphometry in people with diabetes. 
Armas et al found no differences in structural parameters when comparing T1D (n=29) 
without MVD and healthy controls (Figure 1-11) (35). While evaluating a subset of patients 
with previous fragility fractures, subtle differences in structure towards lower bone 
remodelling parameters (non-significant lower  bone volume/ total volume- BV/TV and 
trabecular thickness TbTh) and mineralization (significantly shorter mineralization lag time) 
were observed (36, 37), suggesting an impairment in bone formation in this group. 
 
 
Figure 1-11 The 3D- image of bone biopsy. Trabecular bone. 
“This research was originally published in Bone. Armas LAG, Akhter MP, Drincic A, Recker 
RR; Bone histomorphometry in humans with type 1 diabetes mellitus. Bone. 2012; 50 (1): 
91-96 © copyright holder” 
 
In T2D, decreased bone and osteoid volume, decreased osteoid thickness and lower 
osteoblast surface were observed in post-mortem iliac crest samples of T2D (n=26) compared 
to controls (38). These findings were considered suggestive of decreased bone formation (38). 
In a comparison of iliac crest samples between T2D (n=5) and healthy controls (n=4), no 
differences in trabecular parameters were found, but cortical width and area were 
significantly decreased in people with diabetes (39). In regard to dynamic indices, mineralizing 
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surface, bone formation rate, osteoid and osteoblast surfaces presented significantly lower 
values (Table 1.6) (39).  
 
Table 1.6 Histomorphometric indices in T2D and healthy controls in trans iliac biopsies (39) 
Histomorphometric indices  DM2 (n=5) Healthy controls 
(n=4) 
p 
Mineralizing surface (%) 2.65 1.9 7.58  2.4 0.02 
Bone formation rate (m3/um2.d) 0.01 0.1 0.5  0.2 0.02 
Osteoblast surface (%) 1.23  0.9 4.6  2.5 0.03 
 
Recently, Andrade et al compared bone biopsies of 26 T2D premenopausal women with 15 
age, sex and race matched controls. Bone volume was greater in T2D compared to controls. 
Within the T2D group, the effect of metabolic control and MVD (retinopathy and 
nephropathy) was assessed. Poor metabolic control showed a decrease in static parameters 
of bone formation when compared to good metabolic control. Static parameters correlated 
negatively with HbA1c levels. MVD was associated with reduction in static (osteoid thickness 
and osteoid surface) and dynamic parameters (mineralizing surface, bone formation rate, and 
mineral apposition rate) of bone formation and mineralization.  These findings suggested a 
decrease in bone turnover in T2D, associated with poor metabolic control. MVD exacerbated 
the findings (40).  
 
Bone turnover markers (BTM) in diabetes   
Several studies reported a decrease in bone turnover markers in diabetes (25, 28, 29, 41-43). 
Shanbhogue et al reported lower levels of C-terminal cross-linked telopeptide of type 1 
collagen (CTX), osteocalcin (OC) and procollagen type I amino-terminal propeptide (PINP) in 
T1D (25) and T2D(28).  A meta-analysis described a significant decrease in OC and CTX in 
diabetic patients and no difference in the other BTM and calciotropic hormones (alkaline 
phosphatase, N-terminal cross-linked telopeptide of type 1 collagen (NTX), parathormone 
(PTH), 25-hydroxy-vitamin D (42). A direct influence of glucose on the measurements was 
excluded by a methodological study that evaluated the effect of adding glucose to fasting 
samples (42). Although there are some discordant results, in general, BTM are lower in 




Advanced glycation end products 
 
Type 1 collagen is the main component of the organic bone matrix. It is composed by three 
chains in a helical conformation. Enzymatic hydroxylation promoted by the lysyl oxidase (LOX) 
establish intra and intermolecular crosslinks that confers stiffness to the structure (Figure 
1-12)  (44). 
 
 
Figure 1-12 LOX mediated collagen cross-linking 
 “This research was originally published in Journal Essays in Biochemistry. Yamauchi M, 
Sricholpech M; Lysine post-translational modifictions of collagen. Essays Biochem. 2012; 52: 
113-133 © copyright holder”  
 
 
Since early embryonic life non-enzymatic post-translational reactions occur in several 
molecules, including collagen and they continue throughout lifetime. The accumulation of 
these reactions has been associated with normal ageing, pathologic processes and 
neurodegenerative diseases (45). The addition of sugar residues, called glycation, is one of 
these post-translational modifications. In a diabetic environment, the glucose excess can 
promote glycation of residues leading to the formation of AGEs (45). They include crosslinking 
modifications within or across collagen fibres such as pentosidine, vesperlysines and 
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crosslinking and non-crosslinking modifications such as carboxymethyllysine, 
carboxyetillysine and  pyrraline (46). The low turnover of collagen fibres favours the 
accumulation of these products and can result in modifications of physical properties of the 
fibres such as stiffness and enzyme resistance. 
The charge profile of the molecule can also be modified, affecting the interaction within the 
fibres and between fibres and cells, which could affect repair of tissue damage (46). It has 
been demonstrated that AGEs influence normal osteoblast development and function like 
attachment to the collagen matrix (47). Analyses of human bone in vitro showed that 
cancellous bone is more prone to the formation and accumulation of the glycation products 
(45).  
Pentosidine is the best characterized AGE in the bone field. The molecule is formed by 
reactions involving pentoses that are not the main sugar in human metabolism. Therefore, 
pentosidine accounts for less than 1% of AGEs in bone (Figure 1-13) (45). However, the 
molecule can be measured by immunoassays in blood and urine. Furthermore, pentosidine is   
fluorescent and fluorescence can be measured in tissue samples in vivo. These characteristics 
make the molecule an accessible AGE (34). The evaluation of cadaveric vertebrae has 
reported a negative relation between bone pentosidine levels and mechanical properties 
(16). In a 5-year prospective study, urinary levels of pentosidine have been described as an 
independent risk factor for osteoporotic vertebral fractures in non-diabetic women (48). 
Higher urinary pentosidine levels were also considered a risk factor for fractures in T2D men 
and women aged 70-79 years (49). In addition, serum pentosidine levels were significantly 
higher in T1D with previous fractures and in multivariate logistic regression, pentosidine was 
considered an independent factor associated with prevalent fractures (50). More recently, 
Farlay et al evaluated bone histomorphometry and pentosidine content in iliac crest samples 
in T1D with and without fractures and healthy controls. Although the sample was small (n=5 
in each group) a significantly higher content of pentosidine was reported in T1D with fractures 




Figure 1-13 Schematic representation of the main steps of Maillard reaction. 
In the initial step, a given sugar attaches to a free amino group present on the protein surface, and then, through a 
sequence of different reactions, an advanced glycation end product is formed. As the example, we show pentosidine as the 
final glycation product.(33) 
Adapted from Sroga GE, Siddula A, Vashishth D (2015) Glycation of Human Cortical and Cancellous Bone Captures 
Differences in the Formation of Maillard Reaction Products between Glucose and Ribose. PLoS ONE 10(2): e0117240. 
doi:10.1371/journal.pone.0117240 
Copyright: © 2015 Sroga et al.  
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. 
 
The autonomic nervous system in diabetes 
Animal studies have suggested that there is a hypothalamic control of bone mass regulated 
by leptin and mediated by the sympathetic nervous system (51). The activation of the 
sympathetic signalling related to stress have been associated with low BMD in human and 
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animal models (51).  Furthermore, the reflex sympathetic dystrophy, a human disease 
characterized by localized increase in sympathetic tone and bone loss, is another evidence of 
the influence of autonomous nervous system (ANS) in bone mass (51). In addition, 
retrospective and prospective studies suggested a reduced fracture risk and increase in BMD 
in beta-blocker users, but data is still unclear (51). These findings suggest a role for autonomic 
innervation in bone homeostasis. 
Diabetic autonomic neuropathy (DAN) is a common complication of diabetes. The prevalence 
varies widely, according to the reference population and the methods used to establish the 
diagnosis (52). A community-based population study in Oxford, which defined DAN as 
abnormal heart rate variability in one or two test results, described a prevalence of 16.7%. 
Autonomous nervous system may be affected in any organ, including the control of micro 
vascular blood flow (52). Therefore, innervation may influence bone health by a direct effect 
of sympathetic autonomous system or by an indirect effect in the regulation of bone blood 
flow. Both of them could be compromised by autonomic diabetic neuropathy.  
 
Bone vascularization and diabetes 
The development of MVD in diabetes is related to the inability of endothelial cells to regulate 
glucose transport. Once exposed to extracellular hyperglycaemia, they develop intracellular 
hyperglycaemia that has deleterious effects.  Before structural changes are evident, 
abnormalities in blood flow and vascular permeability are detected at retina, glomerulus and 
peripheral nerve vasa nervorium. Hyperglycaemia leads to micro vascular hypertension and 
increase in the vascular permeability and then irreversible micro vessel occlusion. The 
progressive narrowing and occlusion of the lumens are followed by vascular and local cells 
loss (53). Bone tissue homeostasis is closely related to endothelium. Bone remodelling occurs 
throughout lifespan and both osteoclast and osteoblast develop from precursors that come 
through the endothelium. Micro vascular supply involvement may affect the highly regulated 
remodelling process, resulting in decrease in bone formation and micro damage repair (54).  
Microarchitecture was negatively affected in T2D with MVD but not in patients without MVD 





In summary, it is known that overall there is an increase in the risk of fractures in diabetes. 
However, it is not known if this risk is affected by skeletal site, gender, age or BMI. 
Furthermore, it is not known if diabetes type, duration, complications and treatment will 
impact the risk.  
In addition, the mechanisms associated with bone fragility in diabetes are not established. 
There is some evidence suggesting abnormalities in bone microarchitecture, but results are 
inconsistent. Some studies have suggested an influence of metabolic control and 
microvascular complications, but data are unclear. Therefore, it is important to investigate if 
there is an increase in the risk of fractures at the wrist and ankle, the sites assessed by HR-
pQCT. In addition, it is important to investigate the effect of diabetes and microvascular 
complications on microarchitecture at these sites. This information could help to clarify the 
mechanisms associated with bone fragility in diabetes and if microarchitecture is an 
important feature.  
 
 
Aims and objectives  
 
The aims of this thesis were to assess fracture risk in diabetes and to investigate bone 
microarchitecture in peripheral sites in diabetes.  
 
Chapter 3 
The aim of this systematic review and meta-analysis was to assess the risk of hip and non-
vertebral fractures in adults with diabetes compared to adults without diabetes in 
observational studies. Additional aims were to assess if gender, age, BMI and diabetes-related 
features such as DM type, duration, insulin use and the presence of complications affect this 
risk.  
 
Chapter 4  




Chapter 5  
The aim of this study was to investigate if there is an impact of T1D on bone mineral density 
and microarchitecture at peripheral sites and if this impact was influenced by the presence 
of neuropathy.  
 
In summary, this thesis summarised the risk of fractures in diabetes and investigated if bone 
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Section 1 Systematic review and meta-analysis methods  
 
Introduction 
This thesis reports the result of two systematic reviews on the risk of fractures in diabetes. 
One review investigated the risk of hip and non-vertebral fractures and the other investigated 
the risk of wrist and ankle fractures in diabetes. The specific methods used in each review will 
be described later in the respective chapters (chapters 3 and 4). This chapter will discuss the 
principles of systematic review methods and how they were applied.  
 
What is a systematic review?  
According to the Cochrane glossary a systematic review (or systematic overview) is  
 
“A review of a clearly formulated question that uses systematic and explicit methods 
to identify, select, and critically appraise relevant research, and to collect and analyse 
data from the studies that are included in the review. Statistical methods (meta-
analysis) may or may not be used to analyse and summarise the results of the included 
studies.” {Higgins, 2011, Cochrane Handbook for Systematic Reviews of 
Interventions  Version 5.1.0;Higgins J, 2011, Cochrane Handbook for Systematic 
Reviews of Interventions Version 5.1.0 [updated March 2011].}. 
 Systematic reviews summarise the available evidence on a topic in a systematic way. The aim 
is to gather high quality evidence while minimising the risk of bias and random errors.  The 
methodology should be clearly described to allow other people to reproduce the review. The 
review objectives and the eligibility criteria for studies inclusion should be pre-defined. 
Searches should be broad enough to try to identify all studies that would meet the eligible 
criteria. Once selected, studies need to be assessed for the validity of their findings and the 
risk of bias. The information gathered should be collated, analysed, summarised and 
described in a clear way. A qualitative analysis should always be reported (narrative synthesis) 
and on the availability of suitable data, a quantitative analysis (meta-analysis) should be 




Systematic reviews and meta-analyses are considered the highest level of evidence in 
research, due to several features. Firstly, these studies are usually able to report data from 
large samples. By pooling together many studies it is possible to reach sample sizes that could 
not be reached in individual studies.  In addition, gathering all the available evidence together 
allows the analysis of how much that topic has been explored and in how much depth. It is 
possible to acknowledge which information is available and determine if there is enough 
evidence to answer questions and make conclusions. If the information is not available, the 
review makes it clear what information is lacking. This is particularly helpful in guiding the 
next research steps. Furthermore, the method reduces the influence of single study problems 
such as flaws or errors. As many studies are polled together, the effects of flaws and errors is 
diluted.  Finally, systematic reviews allow the possibility of new insights into the topic, that 
might come from gathering evidence from different sources and analysing them together 
(55).  
 
How was it done? 
In order to make the process transparent and reproducible, the systematic reviews were 
conducted following a structured method. Reviews were carefully planned, conducted and 
reported. Before the review, the rationale was assessed and the research question 
established. A protocol was developed and the reviews were conducted following high 
standards, according to the pre-established strategies defined in the protocol. Finally, the 
reviews were also reported in a systematic way.  
 
Review question 
Systematic reviews are conducted to answer research questions. The question should be clear 
and broad enough to justify conducting a review. There are some key principles that guide 
the development of the research question. These key principles are summarised by the 
acronym PICOS or PECOS, for reviews of observational studies. The acronym refers to P- 
participants; I- intervention, or E- exposure, in reviews of observational studies, C- 
comparator, O- outcomes and S- study design.  
Initially, the participants need to be clearly defined. It is important to state which population 
will be investigated. Several populations have different characteristics that might influence 
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the results of an intervention or exposure. For example, in both reviews in this thesis, the 
participants were adults. The epidemiology of fractures and the risk factors are different in 
children and adults. When the population was defined as adults, the question was focussed 
on this specific population.  During the search process, we found some studies that included 
data in regard to children in their overall analyses. These data could not be included, as they 
were considered out of the scope of these reviews.  
The second letter of the acronym refers to the intervention, or exposure. Diabetes is an 
exposure that might be associated with fractures. For this reason, the PECOS acronym was 
applied. In the reviews described in this thesis, we investigated the risk of fractures in people 
with diabetes mellitus, defining diabetes mellitus as the exposure. We did not specify 
diabetes type, therefore we collected data from type 1 and type 2 diabetes, but we only 
collected data about the risk of fractures in this specific disease.  
The third letter of the acronym refers to the comparator. The reference group should be 
clearly established. Several groups will have different baseline characteristics, and how much 
an intervention or exposure would modify one feature is directly related to which group is 
used as a reference. It is possible to assess multiple comparators; the main reference group 
will be addressed in the primary outcome and additional comparison groups, if applicable, 
will be addressed by secondary outcomes. However, the comparators should be established 
in advance in the protocol. In the reviews reported people without diabetes constituted the 
main reference group. The main aim of the reviews was to report the risk of fractures in adults 
with diabetes compared to adults without diabetes. The peripheral fractures review reported 
just this main comparator. Conversely, the hip and non-vertebral fractures review considered 
people without diabetes as the main comparator group, but a second comparator (the 
comparison between people with type 1 and type 2 diabetes) was also considered. However, 
as it was not possible to anticipate if enough data would be available, the protocol describe 
that this second comparison would be only done if possible.   
The following letter is O, for outcome. The review question should address a specific outcome. 
The question needs to state clearly what the outcome of interest is to avoid any 
misunderstanding and to allow a clear definition of the research strategy. In this setting, the 
outcome was fractures, however, it was different in each of the reviews conducted. One 
review addressed the risk of wrist and ankle fractures, while the other review addressed the 
risk of hip and non-vertebral fractures. Although both of them addressed the risk of fractures, 
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the clear definition of which fractures would be included resulted in two independent 
processes; one specifically about the risk of peripheral fractures in diabetes and the other 
about the risk of hip and non-vertebral fractures in this disease.  
Finally, the design of the studies to be included in the systematic review should be defined. 
Commonly, systematic reviews investigate the effect of interventions and randomized 
controlled trials are the preferable design. However, as diabetes is an exposure, it is not 
possible to investigate the effect of the disease on the risk of fractures through randomized 
controlled trials. The effect of exposure is usually described in observational studies. Both 
reviews focused on observational studies. Once the review question is clearly defined and the 
PECOS characteristics established the inclusion criteria for the review are defined (55).  
Exclusion criteria should also be established to make sure only the suitable information will 
be included. In the reviews reported in this thesis, we excluded papers where the diagnosis 
of diabetes was made following the fractures or where the sequence between the diagnosis 
and the fracture was not clear. This was important to ascertain the association between the 
fracture and diabetes. In the hip and non-vertebral fracture review, only studies that included 
risk estimates adjusted for age and gender or single gender studies were included.  
 
The protocol  
The protocol is the review plan. It includes the background information, the research question 
to be assessed and the methodology of the review.  The protocol makes the review process 
transparent and reproducible. It should be defined before the review and it will state the rules 
that will be followed during the review process. It is important that these rules are developed 
a priori to avoid the risk of changing the strategy motivated by the data collected. The 
protocol also allows standardisation of the process, especially when reviews are conducted 
by a team.  
The protocol establishes the review methods such as the literature searches, the study 
selection process, including the eligibility criteria, the quality assessment, the data extraction 
strategy and the data synthesis. While developing the protocol the team should try to 
anticipate potential challenges that could be faced during the review process and how to deal 
with them (55).  
Protocols were developed for both reviews reported in this thesis, but the process was not 
the same for each review. For the peripheral fractures systematic review, I developed the 
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protocol. For the hip and non-vertebral fractures review, the protocol was developed by 
ScHARR and discussed with the clinical team (myself, Richard Eastell). The process allowed 
the appraisal and contribution from both teams.  
Protocols should be registered on the PROSPERO website. Registration aims to make the 
process transparent and reproducible.  It also helps avoid the possibility of reviews addressing 
the same question being conducted simultaneously. Registered protocols can be amended, 
allowing some justified modifications, without compromising the review transparency. The 
peripheral fractures review protocol was not registered. The hip and non-vertebral fractures 
review protocol was registered in PROSPERO (protocol record number CRD42018090378) and 
subsequently amended, focusing the research in studies that report risk estimates adjusted 
for age and gender.  
 
The review report  
The review report describes the review process and results. Initially, the report includes the 
background information, introducing the topic and explaining the rationale for the review. 
Following this introduction, the report describes in detail the methodology used to keep 
transparency and to enable reproducibility. The report also describes the results of the 
review. The data collected is tabulated, described and analysed. Finally, the findings are 
discussed, including how the review contribute to the current literature, what the 
implications of the findings are, and what the proposed further steps to be investigated are 
(56).  
 
The background information  
Background information is important to contextualise the review. This section introduces the 
condition or the disease explored and establishes the rational for the review.  
Although both reviews explored the risk of fractures in diabetes, background information was 
different for each review.  Hip and non-vertebral fractures, reported in one of the reviews, 
are fractures associated with osteoporosis. These fractures are end points commonly 
reported in clinical trials. In regard to the other review, wrist fractures are also associated 
with osteoporosis, but not ankle fractures. Ankle fractures are not considered typical 
osteoporotic fractures. In addition, the epidemiology of all these fractures is diverse, 
something which was addressed in each specific review’s background information section.  
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Review methodology and results  
 
Search strategy  
The search strategy includes the definition of the study sources, the terms to be used in the 
search and the limits to be applied. Several databases can be used for electronic search, such 
as MEDLINE, Embase and The Cochrane databases. Conference abstracts and reference lists 
of key papers can also be a source of studies. The key terms should be selected including free-
text and thesaurus terms (where available) and combined using Boolean operators. Any limits 
such as date, human or animal studies or language can be applied (55). 
Both reviews combined terms for fractures and diabetes mellitus and related synonyms, but 
they followed different search strategies. In the peripheral fractures review, the search was 
focused on wrist and ankle fractures, but the remaining search limits were broad. No 
restriction in regard to date and language were applied. In addition, conference abstracts 
were also searched adding grey literature as a source of data. Conversely, the hip and non-
vertebral fracture review was planned as a review update. Databases were searched from 
inception to find systematic reviews on fracture risk in diabetes. Several reviews were found. 
They were assessed and one review was selected as the baseline review to be updated.  The 
search for original papers then started from the date when the searches of the baseline 
review were conducted. Searches were restricted to English. For both reviews we searched 
references list from key papers in the field. 
 
Study selection  
The study selection follows a systematic flow. The retrieved records are collated. The first 
step in the process is the removal of duplicates. The following steps will assess the records 
against the inclusion and exclusion criteria described in the protocol. Firstly, records are 
assessed on the basis of title and abstract, which results in the exclusion of the majority of 
the clearly irrelevant papers. Subsequently, the remaining records undergo full text 
assessment.  
In both reviews, the initial title and abstract selection was done by a single reviewer. In the 
hip and non-vertebral fractures review, a second reviewer sift a 10% random sample of the 
retrieved records and the kappa statistics was calculated for both the systematic reviews 
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sifting and the original papers sifting.  The full text sifting was done by one reviewer in the 
peripheral fractures review and by two reviewers in the hip and non-vertebral fractures 
review. The selected papers were included in the review and underwent quality assessment 
and data extraction.  
 
Quality assessment  
Quality assessment is important to evaluate the internal and the external validity of the 
studies. The internal validity will address the risk of bias and the external validity will address 
the generalisability of the results. The quality of the results reported in any review depends 
on the quality of the data included. Multiple aspects of the study might be affected by bias 
such as the selection of the participants, the performance of the studies, the detection of the 
outcome of interest and also participant’s attrition. In observational studies, the selection 
bias can be minimised by the control for confounders. Bias in the performance of the studies 
could be minimised by adequate measurement of the exposure. Bias in the detection of the 
outcome should be minimised by appropriate detection and blindness of the outcome 
assessment. Finally, attrition bias is minimised by completeness of the follow-up.  
The Newcastle-Ottawa scale is a tool to assess the risk of bias in observational studies. The 
studies are awarded stars if they comply to each feature assessed to a maximum of nine. 
Studies that score seven or more are considered high quality. There are specific scales for 
cohort and case-control studies. The scale includes three domains; selection of participants 
and comparability (common to both cohort and case-control scales) and assessment of the 
outcome (for cohort studies) or assessment of the exposure (for case-control studies). In the 
comparability domain, the scale should be adapted to each review. The adaptation aims to 
assess if the study controls for the most important factor and for an additional factor.  
The Newcastle-Ottawa tool was used to assess the quality of the studies included in both 
reviews.  In these reviews, age and gender were selected as the most important factors to be 
controlled for. Consequently, studies were awarded one star if they controlled for age and 
one if they controlled for gender.  
 
Data extraction  
Data should be extracted using standardised forms that should be piloted. Data extraction 
should be checked. In the peripheral fractures risk review, data was extracted and checked 
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by the same reviewer, while in the hip and non-vertebral fractures review, data was extracted 
by one reviewer and checked by a second.  
 
Data Synthesis and reporting  
Systematic reviews should include a qualitative synthesis and might also include a 
quantitative synthesis, the meta-analysis. Both the reviews described in this thesis were 
reported following the Preferred Reporting Items for Systematic reviews and Meta-Analyses 
(PRISMA) guideline. The PRISMA is an evidence-based guideline that lists the minimum items 
that should be reported in systematic reviews and meta-analyses. The tool was designed to 
be used in reviews that summarise the findings of randomized trials, but it can also be applied 
to reviews of observational studies. The PRISMA reporting strategy suggest the use of a 
flowchart to describe the research process. The flow chart summarises the study selection 
process. The figure describes the number of studies screened and excluded in each phase of 
the process, the number of studies assessed for eligibility and also the number of studies 
included in the review. The PRISMA flowchart was used in both the reviews reported (Figure 
3-1 Figure 4-1) (93).  
The PRISMA guideline also includes a checklist with the main items that should be included in 
the title, abstract, introduction, methods, results and discussion. Both the reviews reported 
were checked against PRISMA checklist.  
 
Qualitative synthesis  
 In the qualitative synthesis, data is reported including the tabulation of the study 
characteristics and a narrative synthesis that summarise the data across studies. The quality 
assessment should also be tabulated and narratively described.  
In both reviews, we described the data using tables and a narrative report. The key features 
of each study were described in tables (Table 3.2, Table 3.5, Table 4.1, Table 4.2). In addition, 
we also include a narrative report, summarising the main findings. Results of the quality 
assessment were described following the same pattern.  
 
Quantitative synthesis  
In case there is available data, quantitative synthesis should be performed and studies should 
be summarised in a meta-analysis. Meta-analyses are weighted averages of the effects 
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estimates that pool together the results of the individual studies in a summary number. 
Summaries are more robust evidence than individual studies.  
Two models can be used to combine studies. The fixed-effect model assumes that the studies 
report the same effect size and any potential differences will be due to the variations in each 
sample. Conversely, the random-effects model assume that the true effect size might vary 
between studies, but this variation follows a normal distribution. The random-effects model 
considers the variation of the effect size measured due to variations in each sample and also 
the variation in each study (55).  
The data summarised reported the risk of fractures in multiple settings, such as DM types, 
age ranges, diabetes duration and several sources of patients. In addition, the studies were 
also methodologically different. There were cohort studies (some prospective and others 
retrospective) and case controls studies. In some studies data came from registries and in 
others the participants were recruited. It was expected that the effect found in the studies 
would differ and, for this reason, we have used the random-effects model.  
Clinical features could also influence the risk of fractures. Subgroup analyses should be 
planned to explore the effect of clinical features that could potentially influence the outcome, 
in this case, the fracture risk. In the diabetes scenario, age, gender, BMI, diabetes type, insulin 
use and the presence of microvascular complications are clinical features that could 
potentially influence the risk of fractures. In addition, clinical features might affect the risk of 
fractures in different ways. For example, obesity is reported to decrease the risk of hip and 
other osteoporotic fractures but it is reported to increase the risk of ankle fractures. This 
discrepancy highlighted the importance of a subgroup analysis for BMI. Subgroup analyses 
addressing the features listed above were anticipated in the hip and non-vertebral fractures 
review. It is worth mentioning that we could anticipate that these features could potentially 
affect the risk of hip and non-vertebral fracture but we could not anticipate if we would find 
enough data to perform the analyses. The peripheral fractures review did not anticipate any 
subgroup analysis.  
Sensitivity analysis can also be programmed to explore the influence of other features in the 
analyses. The influence of a specific study, or of a group of studies, with a given characteristic 
can be explored. These analyses investigate the impact on the risk estimate and also on the 
heterogeneity.  In both reviews, sensitivity analysis excluding one study at a time was 
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conducted to investigate the effect of each individual study. We also conducted sensitivity 
analysis excluding studies not considered high quality in the quality assessment.  
The variation across the studies is reported by the heterogeneity. The random-effects model 
allows for this heterogeneity, as the variation in the effects size between studies is 
considered. As the studies included in these meta-analyses are quite diverse, high 
heterogeneity could be found. Subgroup and sensitivity analyses and meta-regression were 
used to explore the heterogeneity. Subgroup analysis clusters the study in specific subgroups 
(for example diabetes type) and investigates if there are significant differences between these 
subgroups. Sensitivity analysis explores the impact of studies with a given characteristic in the 
results, by excluding these studies. Finally, meta-regression explores how much the variation 
in the results is due to one or more specific features.  
In the peripheral fractures meta-analysis, we did not anticipate subgroup or sensitivity 
analyses. In the hip and non-vertebral fractures analysis, subgroup and sensitivity analysis 
were planned and conducted. As high heterogeneity was found, meta-regression was also 
conducted.  
 
Publication bias  
Systematic reviews and meta-analysis use mainly published papers as a source of data. Larger 
studies and studies with larger effects are more likely to be published. Conversely, small 
studies with no or small effects are less likely to be published. Some tools have been 
developed to investigate if there is a relationship between sample size and effect size, also 
called the small studies effect. This relationship might be a sign of missing studies. Funnel 
plots are widely used to investigate this relationship. A funnel plot is a scatter plot of the 
effect estimate from individual studies against some measure of the study size. The standard 
error is often used and plotted in a vertical axis with a reverse scale. If the effect is the same 
in each study (fixed effects model assumption), a triangle centred on a fixed effect summary 
estimate and extending 1.96 SD each side will include about 95% of the studies. If there is no 
bias or heterogeneity, the plot will resemble a triangle, as the scatter will be due to random 
sample variation. This would be a symmetrical funnel plot. A number of reasons can cause 
asymmetry such as reporting bias (due to publication bias, selective outcome or selective 
analysis reporting), poor methodological quality leading to spuriously inflated effects in 
smaller studies, true heterogeneity, artefacts or chance.  Tests for small studies effect 
 57 
investigate whether the association between the study effect and the study size is greater 
than it would be expected to occur by chance. The Egger’s and Begg’s tests are examples. If 
the small studies effect is detected and publication bias is suspected, the Trim and Fill 
correction can be applied. The method removes small studies causing asymmetry, estimate 
the number of missing studies and add them and the estimates of their effects. Consequently, 
the method provides a RR for a symmetrical funnel plot, as if there was no publication bias 
(93).  
In both reviews, visual analysis of funnel plots was used to assess publication bias. In the non-
vertebral fractures’ analysis, publication bias was suspected. The funnel plot was asymmetric 
with an empty spot at one side and there was no important heterogeneity (another cause for 
asymmetry in funnel plots).  Hence, the Trim and Fill method was applied.  
The “trim and fill” method is a tool used to identify funnel plot asymmetry arising from 
publication bias and to correct this asymmetry. The tool assumes that the asymmetry is 
caused by publication bias, but takes no assumption in regards to the mechanisms of this 
publication bias. The method is used to remove (“trim) the smaller studies leading to funnel 
plot asymmetry. The trimmed funnel plot is used to estimate the true “centre” of the plot and 
to estimate the number of missing studies around the centre. These missing studies and their 
adjusted intervention effect are added to the calculations (“fill”). The tool provides an 
estimate of the number of missing studies and the estimated intervention effect adjusted for 
the publication bias. However, it considers that there should be a symmetric funnel plot (what 
is not always the case). In addition, it is not possible to assess if the adjusted intervention 
effect matches what would have been observed in the absence of publication bias, especially 
because the mechanism of the publication bias is unknown.  Finally, the trim and fill method 
does not consider other reasons for asymmetry besides publication bias. Therefore, results 
“corrected” by this method should be interpreted with caution. (57)  
Most of the recommendations about funnel plots are designed to meta-analyses of 
randomised trials and whether they apply to meta-analyses of epidemiological studies in 





In the discussion, the key findings are summarised and related to the current literature. The 
implications of these findings with regards to practice and polices and the strengths and 
weakness of the review are discussed. Finally, the areas to be explored by further research 









































Section 2 T1D and bone clinical study methods  
 
Study design  
This was a single-centre, observational, cross-sectional, case-controlled study to evaluate the 
effects of type 1 diabetes mellitus and diabetic neuropathy on bone health in patients with 
T1D.  T1D patients with and without diabetic neuropathy will be compared to each other and 
to healthy controls.  
 
Participants  
Participants with T1D were recruited from Sheffield Teaching Hospital outpatient clinics and 
Diabetes Database between October 2017 and October 2018. Participants were patient with 
diabetes, men and women older than 18 years, with more than 5 years of T1D diagnosis, 
without CKD (eGFR > 60 ml/min.m2) with and without diabetic neuropathy and healthy 
volunteers. Healthy volunteers were recruited from the Bone Research Unit database and 
from emails sent to the Trust employees. This resulted in three groups: T1D with neuropathy 
(T1DN+), T1D without neuropathy (T1DN-) and control. Since gender and age affect bone 
structure, we tried to match participants as close as possible by these two features. As skeletal 
size affects BMC in DXA and the site to be scanned by the HR-pQCT, we tried to match 
participants as close as possible by height. The initial plan was to match participants in a 5-
year interval and a 5 cm interval to minimise the effect of potential confounders.  
We attempted to individual match, but recruitment was a challenge and the desirable targets 
could not be achieved. Consequently, we opted to the conservative approach and the analysis 
was comparison by groups.  
This study was approved by Liverpool Research Ethics Committee (IRAS 222726, 
17/NW/0291). All participants provided written informed consent, in accordance with Good 
Clinical Practice guidelines.   
 
Sample size 
Power calculations were used to calculate the sample size. The standard deviation from 
previous studies that have reported the cortical porosity in T1D was used (3.03%) (25) and 
the clinically significant difference was estimated in 3.0%. This was the difference in cortical 
porosity previously reported between patients with diabetes with and without fractures (29).  
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This resulted in a sample size of 20 in each group. This sample size has 80% power to detect 
a difference of 3.09% in cortical porosity at p<0.05.    
 
Inclusion and Exclusion criteria  
 
Inclusion criteria  
o Male and female participants aged 18 or older; 
o Sufficiently mobile to undergo scanning; 
o Able to remain motionless for the duration of the scans; 
o Able and willing to participate in the study and provide written informed 
consent; 
o Participants with diabetes: Patients with type 1 diabetes with more than 5 
years of T1D diabetes diagnosis, without CKD (eGFR > 60 ml/min.m2). They will 
be evaluated and classified according to the presence of diabetic neuropathy. 
o Healthy controls: Haemoglobin A1c levels (HbA1c) less than 5.7% (39 
mmol/mol), according to American Diabetes Association standards.  
 
Exclusion criteria  
o Previous orthopedic surgery or fractures which preclude imaging at all sites;  
o History of any long-term immobilization (duration greater than three months);  
o High or low trauma fracture less than one year prior to recruitment;  
o History of bilateral fractures at tibia and/or radius;  
o Current pregnancy or trying to conceive;  
o Delivery of last child less than one year prior to recruitment; 
o Breast feeding less than one year prior to recruitment;  
o Women in the perimenopause period, including 5 years after menopause; 
o History of or current conditions known to affect musculoskeletal health, 
diabetes and/or neuropathy evaluation or bone metabolism including:  
▪ Diagnosed skeletal disease  
▪ Osteoarthritis at study measurement sites  
▪ Chronic renal disease  
▪ Malabsorption syndromes  
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▪ Hypocalcemia or hypercalcemia  
▪ Diagnosed restrictive eating disorder  
o Conditions which prevent the analysis of the DXA scans or the interpretation 
of their results;  
o Conditions which prevent the analysis of the HR-pQCT scans or the 
interpretation of their results;  
o Use of medications or treatment known to affect musculoskeletal health, 
diabetes and neuropathy evaluation or bone metabolism including depot 
medroxyprogesterone or the combined oral contraceptive pill; 
o Alcohol intake of greater than 21 units per week; 
o Markedly abnormal clinical laboratory parameters that are assessed as 
clinically significant by the Principal Investigator.  
o For healthy controls, abnormal levels of fasting glucose (fasting glucose levels 
> 5.6 mmol/L) or HbA1c > 5.7% (39 mmol/mol). 
 
 
Inclusion and exclusion criteria were designed to guarantee a number of features. Firstly, 
participants needed to be willing to take part on the study. Furthermore, the participants with 
T1D should have the disease for sufficient time to be affected by potential adverse effects on 
bone and healthy volunteers should not have diabetes. In addition, participants should not 
be affected by conditions that affect bone structure or bone turnover. Finally, to ensure the 
quality of the scans, participants with conditions that prevent the adequate acquisition and 
analysis of the images were excluded, in order to make the images reliable and interpretable.  
 
Study procedures  
All participants attended two visits. For the participants with T1D, the first visit was at the 
Diabetes Research Clinic at the Royal Hallamshire Hospital (RHH), where the neuropathy 
assessment was conducted. The healthy volunteers could schedule the first visit to the RHH 
or the Clinical Research Facility (CRF) at the Northern General Hospital (NGH), according to 
their convenience. All the participants attended the second visit at the CRF, NGH.  
Table 1.1Error! Reference source not found. list the procedures undertaken in each visit 
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Table 2.1 Study visits and procedures 
Visit  Procedure  
Visit 1 Informed consent, Blood sample, Height, 
weight and BMI, 
Neurophysiology evaluation* 
Visit 2  Height, weight and BMI, Pregnancy test 
(premenopausal women only), DXA (lumbar 
spine, proximal femur, HR-pQCT 
* T1D participants  
 
Visit 1  
 
Blood samples  
Blood samples were collected for screening tests (PTH, calcium, creatinine, HbA1c).   
Intact PTH (second generation) was measured using an immunoassay method by the Roche 
Cobas 8000 e602 (Roche Diagnostics GmbH, Mannheim, Germany). The interassay coefficient 
of variation (CV) measured in the laboratory is 2.2 – 3.2% at 34 ng/L, 1.6 – 1.7% at 94 ng/L 
and 1.4 – 1.8% at 839 ng/L, while the reported reference interval is 15-65 ng/L (1.6 - 6.9 
pmol/L). 
Serum calcium was measured using a Roche/Hitachi Cobas 8000 e702 automated clinical 
chemistry analyser (Roche Diagnostics GmbH, Mannheim, Germany).  This method uses 5-
nitro-5’-methyl-BAPTA (NM-BAPTA) reagent. The interassay coefficient of variation as 
measured in the laboratory is 1.1 – 1.5% at 1.52 mmol/L and 0.6 – 1.1% at 3.07 mmol/L. 
Albumin measurement was performed using a Roche/Hitachi Cobas 8000 e702 analyser 
(Roche Diagnostics GmbH, Mannheim, Germany). The interassay coefficient of variation as 
measured by the laboratory is 1.5 – 2.4% at 33.9 g/L and 1.0 – 1.7% at 59.7 g/L. 




𝑚𝑖𝑛 × 1.73 𝑚2
)











× 1.018 [𝑖𝑓 𝑓𝑒𝑚𝑎𝑙𝑒]  ×  1.159 [𝑖𝑓 𝑏𝑙𝑎𝑐𝑘] 
 63 
Scr is serum creatinine in mg/dL, κ is 0.7 for females and 0.9 for males, α is -0.329 for females 
and -0.411 for males, min indicates the minimum of Scr/κ or 1, max indicates the maximum 
of Scr/κ or 1 
The aim was to exclude calcium abnormalities and chronic kidney disease. For the healthy 
volunteers, diabetes was also excluded. 
 
Anthropometry 
Weight and height were measured in shoeless participants wearing light clothes to confirm 
eligibility (matching).  
 
Neurophysiology evaluation 
According to the Toronto Consensus meeting, DSPN is defined as length-dependent 
sensorimotor polyneuropathy, that is chronic, symmetrical and associated with longstanding 
hyperglycaemia and cardiovascular risk factors (6). Abnormalities in nerve conduction studies 
associated to signs and or symptoms of neuropathy are required to confirm the diagnosis (6). 
In order to categorise the T1D participants into the neuropathy and non-neuropathy groups 
we used standard questionnaires to investigate symptoms and a number of tests were 
performed. Small fibres were assessed thorough Sudoscan and the Toronto Clinical 
Neuropathy Score. Large fibres were assessed by nerve conduction studies and the Toronto 
Clinical Neuropathy Score.  
 
Sudoscan  
The sweat glands are innervated by sudomotor thin postganglionic unmyelinated cholinergic 
sympathetic C-fibers, also called small fibers. Sudomotor disfunction is one of the earliest 
abnormalities detected on distal small fiber neuropathy. Skin biopsy studies have shown a 
decrease in the number of these fibers in people with diabetes (58). SUDOSCAN is a non-
invasive quantitative assessment of sudomotor function. The device uses low voltage current 
to stimulate the sweat glands. The participants placed palms of their hands and the soles of 
their feet on the stainless-steel electrodes (Figure 2-1).  The sweat produced contains chloride 
ions which react electrochemically with stainless steel electrodes. The ratio between the 
current that is measured and the voltage applied is used to calculate the electrochemical skin 
conductance (ESC), and a measure of sudomotor function expressed in microsiemens (S). It 
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generates to measurements, hands electrochemical skin conductance (HESC) for the hands 
and feet electrochemical skin conductance (FESC) for the feet. The report suggests no risk of 
neuropathy, moderate risk of neuropathy or elevate risk of neuropathy (58). Several studies 
have shown good reproducibility with the method (58-60). Reproducibility was not assessed 
in this study.  
 
Figure 2-1 Sudoscan assessment (58) 
 
We used the Toronto Clinical Neuropathy Score (TCNS) to assess DSPN. The TCNS is a simple 
comprehensive method to evaluate DSPM. The assessment includes signs and symptoms 
from small and large fibres. The TCNS has been validated against nerve conduction velocities 
and amplitudes (61)  and morphological criteria of sural nerve fibre density  (62). The tool 
assesses symptoms, reflexes and sensory test in both limbs, as described on Table 2.2. The 
presence of abnormalities is graded by scores to a maximum of 19. The symptoms scores are 
assessed by the examiner in each limb as present (1) or absent (0). The sensory tests are 
graded as abnormal (1) or normal (0) and the reflexes as absent (2), reduced (1) or normal 
(0).  Patients are categorised according to the scoring in no neuropathy (0-5), mild neuropathy 
(6-8), moderate neuropathy (9-12) and severe neuropathy (>12). Previous studies have 
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reported an intra-observer variability of 7.3% and interobserver variability of 6.3% (62). 
Reproducibility was not assessed in this study. 
 
 
Table 2.2 The Toronto Clinical Neuropathy Score (TCNS) 
Symptom score  Reflexes  Sensory test scores  
Foot Pain  knee Pinprick  
Numbness ankle Temperature 
Tingling   Light touch  
Weakness   Vibration  
Ataxia   Position  
Upper limb symptoms    
 
Nerve conduction studies  
We used DPN check (Neurometrix, Waltham, MA, USA) to perform the sural nerve conduction 
assessment. The DPN check is a point-of-care device that assess nerve amplitude potential 
(sural nerve action potential - V) and conduction velocity (m/s) using principles similar to the 
standard nerve conduction studies (63). Standard nerve conduction studies stimulate the 
nerve antidromically and requires the careful positioning of the probes over the sural nerve 
area to repetitively stimulate the nerve until a valid response is detected. While using the 
DPN check, stimulating probes are placed at the lateral region of the ankle and a biosensor, 
located 9.22 cm from the probes, covers the area above the ankle to record the responses 
(Figure 2-2 Figure 2-3) (64). The device stimulates the sural nerve orthodromically and the 
responses are collected in a wider area than in the standard nerve conduction studies. 
However, the device has been validated and demonstrated excellent reliability and 
acceptable accuracy in DSPN.  In addition, intra-observer intraclass correlation coefficients 
were 0.97 for nerve amplitude potential and 0.94 for never conduction velocity and the 
interobserver was 0.83 and 0.79 respectively.  (64). Participants were accessed on the two 
limbs. Reproducibility was not assessed in this study. 
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Figure 2-2 DPN check device in use 
Sample nerve conduction recordings from standard NCS (A) and the point-of-care device (B) from a 60-year-old female with 
type 2 diabetes and an image of the point-of-care procedure (C). Panel A: Sample standard NCS recording. Sural nerve 
amplitude potential was 6.8 mV and conduction velocity was 48.3 m/s. Panel B: Sample recording from the point-of-care 
device. Sural nerve amplitude potential was 8 mV and conduction velocity was 56 m/s. Panel C: The device was placed on 
the lateral aspect of the leg and the sural nerve was stimulated and recorded by the electrical probes and biosensor, 
respectively (63).  
 
Figure 2-3 DPN check interpretation guide 
 
T1D participants’ group allocation 
We used DPSN as the main feature to categorise participants in the neuropathy or non-
neuropathy group. Participants with a TCNS indicating no neuropathy (score  5) and a normal 
nerve conduction study by DPN check were included in the no neuropathy group (T1DN-). 
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Participants with abnormal TCNS (score >6) and abnormal nerve conduction studies were 
included in the T1DN+.  
 
Visit 2  
 
Fasting blood samples  
 
Sample collection  
After overnight fast, blood samples were collected from each participant. Samples were 
allowed to clot at room temperature for 30 minutes before being centrifuged at 3000rpm for 
10 minutes. Serum samples were aliquoted and stored at -80ºC until analysis. 
 
Principles of chemiluminescence immunoassay  
For the measurements of CTX and PINP, the IDS-iSYS was used. The IDS-iSYS is a 
chemiluminescence immunoassay (CLIA). It uses two antibodies; an anti-analyte antibody 
labelled with biotin and an acridinium labelled antibody. Once the serum sample is loaded 
onto the autoanalyzer, the two antibodies are added, followed by magnetic micro-particles 
coated with streptavidin that bind to the biotin in the complex. The mixture is incubated to 
allow magnetic particles to bound to a magnet. Then, a wash step removes the unbound 
substances. The acridinium conjugate is stimulated to emit light. The intensity of the light is 
proportional to the concentration of the analyte The CTX reflects an 8 amino acid sequence 
from the C-terminal region of type I collagen; the PINP reflects only the intact (not the total 
as it doesn’t include the monomer) triple helix of the N-terminal propeptide region. 
 
 
Dual energy X-ray absorptiometry 
 
Scan acquisition and evaluation  
Dual energy X-ray absorptiometry (DXA) was used to assess aBMD of the lumbar spine (L1-4) 
and hip (total hip and femoral neck) using a Discovery A densitometer (Hologic Inc.: Bedford, 
MA, USA) and Hologic software (version 12.6). DXA provides a two-dimensional projection of 
the anatomical site of interest from which area and BMD are measured. The aBMD is used to 
calculate scores that compare the individual measure with predefined populations and helps 
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in the assessment of the results. Previous studies have shown that BMD by DXA can predict 
fracture risk and is used as surrogate of bone strength (65, 66). The scores calculated from 
DXA can be used to define osteoporosis.  
 
Principles of DXA  
DXA is based on the principle that tissues would attenuate X-ray differently, according to their 
density.   The method uses a low radiation dose. By alternating the voltage of the X-Ray tube, 
an X-ray source emits two distinct levels of energy: one high (140kVp) and one low (100kVp). 
The beams pass through a collimator that produces a fan beam. Tissues attenuate the X-ray 
beams differently according to their density: the denser a tissue, the more it will attenuate 
the X-Ray beam.  Hence, some photons are absorbed and some scattered. A detector is placed 
opposite to the X-ray source and detects the energy difference of the two original beams. The 
human body is composed by several tissues which will attenuate the beams differently. Based 
on these differences, the device is able to detect bone, differentiate it from soft tissue and to 
determine bone area and BMD. The result is a two-dimension measurement and BMD is 
expressed in g/cm2. However, this is not the most used value to assess BMD in the clinical 
setting. Usually, BMD is reported using scores.   
Since BMD follows a normal distribution, means and standard deviations (SD) are calculated 
using population databases. The score places the individual value measured in the population 
data distribution and express this value in SD from the mean population in a given database. 
To generate the Z-score, a database from a population at the same age is used for comparison. 
Consequently, the Z-score expresses in SD how far the result is from the mean for the same 
age population. Conversely, the T-score refers to a population on the peak of bone mass (20-
39 years), expressing how the results found differs from the mean of the peak bone mass 
population. The values measured by DXA are able to predict fractures and they are used to 
assess bone strength (65). 
 
DXA procedure 
The manufacture’s standard procedures for each site were used to obtain DXA images, as 
previously described by our Research group (67). A Hologic Discovery A densitometer (Hologic 
Inc, Bedford MA, USA) was used to obtain scans in a posterior-anterior (PA) projection at 




With the participant laid on the scan table in a supine central position within the scan limits, 
a head positioner was used to ensure the participant was comfort and well positioned. The 
foot on the scanned side was attached to a hip positioner to keep the leg abducted and the 
hip internally rotated by approximately 25. Arms were kept away from the scan field, and 
placed on the chest (Figure 2-4). An express scan was used to assess positioning: at least 3 cm 
of straight femoral shaft bellow the lesser trochanter was included in the scan field. 
Positioning was corrected when necessary.  
 
 
          
Figure 2-4 Participant’s positioning for DXA proximal hip scan 
For analysis, the global region of interest was positioned according to standard procedures; i) 
the lateral border was positioned 5 scan lines from the edge of the greater trochanter; ii) the 
medial border was positioned 5 scan lines form the edge of the femoral head; iii) the bottom 
border was positioned 10 scan lines bellow the lesser trochanter and iv) the upper border was 
positioned 5 scan lines from the edge of the femoral head. After correct positioning, the bone 
map was identified and the central axis of femur was used to place the midline and the neck 
box was positioned close to the great trochanter. The neck box also included equal amounts 
of soft tissue on each side of the femoral neck (Figure 2-5).  
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Figure 2-5 DXA proximal femur analysis – region of interest placement 
Lumbar spine  
For the lumbar spine scan, the hip positioner was removed and a spine positioning block used 
to elevate the legs (Figure 2-6). Scan image needs to be straight and central and the image 
should include from mid L-5 to mid T-12, as the global region of interest should include L1 to 
L4.  An express scan was used to assess positioning before the scanning.  
 
                                 
Figure 2-6 Participant’s positioning for DXA lumbar spine scan 
 
 For interpretation, the top border was positioned within the T12-L1 intervertebral space and 
the bottom border within L4-L5 intervertebral space. If needed the borders could be angled 
to accommodate the shape of the vertebrae. Lines placed in each intervertebral space would 
identify each vertebra. Bone map was identified and corrected if necessary (Figure 2-7).  
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Figure 2-7 DXA lumbar spine analysis – region of interest placement 
 
DXA quality control  
All scans were performed by a highly trained operator. In accordance with manufacturer 
recommendations, quality control assessments were performed daily to ensure stability and 
precision. An anthropometric spine phantom containing four single density semi-
hydroxyapatite ‘vertebrae’ was used for this purpose. In addition, the measurements were 
plotted in graphs against pre-specified acceptable limits set by the manufacturer. All of them 
(bone area, aBMD and BMC) were within the limits (Figure 2-8 Figure 2-9 Figure 2-10). The 
coefficient of variation (CV) were below 0.4%.  
 
 








Figure 2-10 DXA quality control plot for BMD throughout the T1D and bone study 
 
DXA precision error  
In the Academic Unit of Bone Metabolism, the long-term coefficient of variation for lumbar 
spine DXA scans is 1.6% for aBMD and 2.0% for total hip for postmenopausal women with 
normal BMI (24). The scan technician is certified by the ISCD.  
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Hight resolution peripheral quantitative computed tomography  
 
Principles  
High resolution peripheral quantitative computed tomography (HR-pQCT) provides high 
resolution images of the distal appendicular skeleton, using low radiation dose. The first 
generation XtremeCT device and the SCANCO Image Processing Language (IPL, version 5.08-
B) (SCANCO Medical AG: Brüttisellen, Switzerland) was used to quantify vBMD and bone 
microstructure at the radius and tibia. The device includes a rotating x-ray tube and a static 
2D detector array. The X-rays generated by the rotating x-ray tube pass through a section of 
the limb being scanned and is detected by a static 2D detector array. An attenuation profile 
is detected and the spatial distribution of this attenuation is computed onto a blank matrix to 
generate an image (68). The series of parallel consecutive image slices is computed into a 







Figure 2-11 HR-pQCT images 3D images A radius, B tibia 
 
In order to calculate volumetric BMD, a pre-calibration using a phantom is required. A 
phantom with five hydroxyapatite resins compartments was used to calibrate the scanner. 
The phantom has compartments with known progressively increasing densities, from 
0mgHA/cm3 (equivalent to soft tissue with no mineral content) to 800 mgHA/cm3 (Figure 
2-12). The phantom was scanned and the attenuation of the image slices were calculated. 
This pre-calibration allows the conversion of attenuation values into volumetric BMD values 
in mgHA/cm3.  
 
 
Figure 2-12 HR-pQCT calibration phantom image 
Procedure  
The non-dominant limb was scanned, unless the participants reported a previous fracture on 
the non-dominant limb. The high-resolution mode (image matrix =1536x1536) was used with 
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a source potential of 60kVp. The tube current was 900mA and the integration time 100ms. A 
reference line was placed in the site of interest to place the first scan line. From there, 110 
slices were acquired resulting in a stack height of 9.8mm.   
The technician asked the participant to remain motionless during the image acquisition. Upon 
the completion of each scan, image quality of a single slice was evaluated using the visual 
grading system reported by Engelke et al (69): 
Grade 1 = Perfect: No noticeable artefacts. 
Grade 2 = Slight artefact: small streaking. 
Grade 3 = Pronounced artefact: large streaking, particularly near the cortex. 
Grade 4 = Unacceptable artefacts: discontinuity at the cortex. 
Images graded  3 were repeated. Images graded 4 were not included in the evaluation.  
 
Distal radius  
Participants were asked to sit in a particular chair, that allows required positioning 
adjustments. A forearm cast was used to position the arm. The hand and lower arm were 
placed into the forearm cast and an arm pad was used to stabilise the arm. The arm was then 
placed into the device and secured (Figure 2-13).  The procedure was repeated for each radial 
scan.  
 
            A               B            C     
Figure 2-13 Distal radius HR-pQCT scan positioning 
A participant’s positioning; B arm cast; C participant’s arm positioned in the cast.     
 
Standard site  
Following the arm positioning, a scout scan was performed to determine the measurement 
using standard procedures. In the scout image, the notch on the articular surface of the distal 
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radius was identified. The reference line was placed on that site. The measurement started 
9.5 mm from the reference line (Figure 2-14). Participants were requested to remain 
motionless during the scan. After the scanning acquisition, the operator visually inspected 
random images to assess quality. If important motion artefact was detected, the scan was 
repeated once (69).  
           
Figure 2-14 Positioning of the reference line on the radius scout scan for standard measure 
                                                                                                             
14% site  
The forearm length was measured following standard procedures. In summary, with the 
participant’s elbow flexed and the back of his or her hand facing the technician, the length 
from the olecranon to the ulnar styloid process was measured. The total length was recorded 
and 14% of the distance was calculated.  
As the 14% site is not a usual site measured by HR-pQCT the control file was edited prior to 
each measurement. Each participant’s radius 14% length was inserted in the relative position 
to scout view reference line, ensuring that the first slice of the measurement was acquired 1 
mm proximal to the 14% site. The scan was then pre-calibrated before the participant’s arm 
was positioned within the scanner.  
The participant was then positioned and the scout view scan performed. On the scout view, 
the reference line was placed. A solid green line was positioned on the distal end of the radius. 
The dotted green lines indicate the measurement region (Figure 2-15). Following the 
reference line positioning the main scan was performed. As in the standard site, the operator 
assessed the quality of the scans after each procedure. Scans could be repeated once.  
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        A    B   
Figure 2-15 A Positioning of the reference line on the radius scout scan for 14% site measure B 3D-image radius 14% 
 
Distal tibia  
For the tibia scanning, the foot and lower leg was placed into the tibia cast with the participant 
sited in the scanning chair. With the leg rested on the leg support, the participant was 
positioned. The chair was adjusted so that the leg height was the same height as the gantry 
(Figure 2-16). 
 
A     B            C  
Figure 2-16 Distal tibia HR-pQCT scan positioning 
A participant’s positioning; B leg and foot cast; C participant’s leg positioned in the cast.     
 
 The scout scan was performed and the reference line placed at the endplate of the distal 
tibia (Figure 2-17). The first slice measured was placed 22.5 mm from the reference line, 
following standard protocols.  
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Figure 2-17 Positioning of the reference line on the tibia scout scan for standard measure 
 
14% site  
The tibia length was measured following standard procedures. In summary, with the 
participant’s sited, foot placed flat on the floor and the knee bent to form a 90 degrees angle, 
the distance from the most prominent point on the lateral malleolus to the tibial lateral 
condyle was measured and recorded. The 14% of that distance was then calculated.  
Similarly to the procedure at the radius, the control file was edited prior to each 
measurement. Each participant’s tibia 14% length was inserted in the relative position to 
scout view reference line, ensuring that the first slice of the measurement was acquired 1 mm 
proximal to the 14% site. The scan was then pre-calibrated before the participant’s leg was 
positioned within the scanner.  
The participant was then positioned and the scout view scan performed. On the scout view, 
the reference line was then placed. A solid green line was positioned on the distal end of the 
tibia. The dotted green lines indicate the measurement region (Figure 2-18). Following the 
reference line positioning the main scan was performed. As in the standard site, the operator 
assessed the quality of the scans after each procedure. Scans could be repeated once.  
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A         B    
Figure 2-18 A Positioning of the reference line on the tibia scout scan for 14% site measure; B 3D-image Tibia 14%  
 
HR-pQCT outcomes  
 
Table 2.3 HR-pQCT outcomes 
Measurement Abbrev Unit Source of measurement 
Total Area Tt.Ar mm2 Total cross-sectional area inside the 
periosteal envelope 
Cortical area  Ct.Ar mm2 Cortical bone area.cortical volume 
(Ct.V) / 
(number of slices x slice thickness) 





vBMD mg HA/cm3 Total mineral mass divided by the 
total bone volume  
Trabecular vBMD Tb.vBMD mg HA/cm3 Trabecular mineral mass divided by 








Dinn mgHA/cm3 Density of outer 60% of trabecular 
region 
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Measurement Abbrev Unit Source of measurement 
Meta/Inn trabecular 
density  
 - Meta trabecular density divided by 
inner trabecular density 
Trabecular thickness Tb.Th m Mean thickness of trabeculae within 
the trabecular compartment  
Trabecular number Tb.N mm-1 Mean number of trabeculae per mm 
within the trabecular compartment  
Trabecular separation Tb.Sp m Mean distance between trabeculae 
within the trabecular compartment  
Trabecular 
inhomogeneity 
  SD of the intra-individual distribution 
of trabecular separation  
Trabecular bone 
volume fraction 
BV/TV % Derived by dividing Tb.vBMD by an 
assumed 100% mineralisation of 1200 
mgHA/cm3  
Connectivity Density Conn.D 1/mm3 A measure of the degree of 
connectivity of trabeculae 
normalized by TV 
Cortical vBMD Ct.vBMD mg HA/cm3 Cortical mineral mass divided by the 
cortical volume  
Cortical thickness Ct.Th m Mean thickness between the 
periosteal and endosteal surfaces  
Cortical porosity  Ct.Po % Cortical porosity: In a given cortical 
region, the volume 
of pores (Po.V, mm3) / total volume of 
cortical bone 
compartment (Ct.V, mm3) 
SD of mean cortical 
pore diameter  
Ct.Po.D
m.SD 
mm Standard deviation of the mean 
cortical pore diameter 
Cortical tissue mineral 
density 
Ct.TMD mg/cm3 TMD is calculated from the average 
attenuation 
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Measurement Abbrev Unit Source of measurement 
value of the bone tissue only and does 
not include attenuation 
values from non-bone voxels 
Cortical pore volume  Ct.PoV mm3 Total pore volume 
Cortical perimeter Ct.Pm mm Cortical periosteal perimeter 
Periosteal perimeter  Ps.Pm mm Periosteal perimeter 
Endosteal perimeter  Ec.Pm mm Endocortical perimeter 
Cortical area fraction 
(calculated) 
(Ct.Ar/Tt.Ar) 
  Cortical area fraction 
Cortical area fraction 
(calculated) 
(Ct.Ar/Tt.Ar)*100 
 % Cortical area fraction 
 
Adapted from  (70) 
 
HR-pQCT strengths and limitations  
 
Strengths  
HR-pQCT produces high resolution images of peripheral sites, using low radiation effective 
dose. The high-resolution images allow the distinction between cortical and trabecular bone, 
enabling the investigation of bone microarchitecture (71). DXA does not provide the same 
level of details. The peripheral sites are less affected by soft tissue confounding and do not 
result in the exposure of extensive areas to radiation (71). These are common disadvantages 
of axial quantitative computer tomography. The procedure is quick and the total effective 
radiation effective dose is 3Sv, similar to one day background radiation exposure (71). HR-
pQCT provides microarchitectural assessment of the tibia and the radius, sites commonly 




HR-pQCT image acquisition and analysis has several limitations. The scanner has a narrow 
gantry and a restricted scanning field. This could restrict the scanning of less distal areas.  
The voxel size of the scanner (82m) is close to the average thickness of the trabecular 
structure and some of the parameters, e.g. trabecular thickness, are derived rather than 
directly measured (71). In addition, both cortical and trabecular analysis is dependent on 
resolution (72). Furthermore, the voxel size limits the detection of pores in the cortex to the 
bigger ones. Noteworthily, the voxel size is not equivalent to true spatial resolution (72).  
Furthermore, the segmentation of images is limited. One of the main benefits of HR-pQCT is 
the assessment of trabecular and cortical compartments, however, there is no clear defining 
border between the two compartments. Instead there is a transitional zone. The proper 
identification of the cortex is a challenge, especially when the cortex is thin or highly porous 
(71).  
Finally, HR-pQCT assesses peripheral sites. These sites are commonly affected by fractures; 
however, these are not the most serious osteoporotic fractures. How well peripheral 
measurements reflect axial properties is unknown. Studies that compared peripheral and 
central assessment by DXA, HR-pQCT and cQCT reported that distal radius and tibia reflect 
the stiffness of lumbar spine and proximal femur. Moderate to strong correlations (r.0.56 –
0.70) have been reported between peripheral and axial sites stiffness (73).  
 
Micro Finite Element analysis  
 
The Micro Finite Element (FE) software was used to determine bone strength from the HR-
pQCT data (version 1.13; FE-solver included in the Image Processing Language, Scanco 
Medical AG, Zurich, Switzerland). The software uses mathematical modeling to simulate 
strength-determining biomechanical tests using trabecular and cortical microarchitecture 
features. The software is fully automated and validated and provides an in vivo assessment 
of bone strength (74).  The method provides a reliable estimate of bone strength however, it 
cannot account for all bone material features, as inhomogeneity of mineralization, or all 
variations on the biomechanics of falls.  
Table 2.4 list the outcomes of FE analysis.  
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Table 2.4 FE analysis outcomes from HR-pQCT scanning 
Outcome Abreviation  Unit  Definition  
Stiffness Stiffness kN/mm Resistance to deformation when applying 




Est.Fail.Load kN Maximum load the bone can bear before 
fracture; when 2% of the bone is strained 
beyond 3500 strain  
Percent trabecular 
proximal load  
%TPL % The distribution of the load between the 




%TDL % The distribution of the load between the 




%CPL % The distribution of the load between the 




%CDL % The distribution of the load between the 
cortical and trabecular compartments  
 
Mean trabecular 
Von Mises stress  
 
Tb.VM MPa Indicates whether combined stresses in 
the x, y and z directions in the trabeculae 
will cause failure  
 
Mean cortical Von  
Mises stress  
C.VM MPa Indicates whether combined stresses in 
the x, y and z directions in the cortex will 
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The Risk of Hip and Non-vertebral Fractures in 





























The Risk of Hip and Non-vertebral Fractures in Diabetes: A Systematic Review and Meta-
Analysis update 
 
This chapter was published as a paper on Bone; 
Vilaca T, Schini M, Harnan S, et al. The risk of hip and non-vertebral fractures in type 1 and 
type 2 diabetes: A systematic review and meta-analysis update [published online ahead of 




Diabetes is a growing epidemic worldwide. Data from the World Health Organization (WHO) 
reported that the number of people with diabetes has risen from 108 million people in 1980 
to 422 million people in 2014 and the global prevalence has increased from 4.7% to 8.5%. In 
2016, 1.6 million deaths were directly caused by diabetes. Almost half of the deaths 
attributable to diabetes occur before the age of 70 years (75). In the United Kingdom (UK), 
7.7% of the population has diabetes and 10% of the NHS budget from England and Wales is 
spent on diabetes (76, 77). Estimates suggest that £14 billion is spent every year on treating 
diabetes and its complications (77). In the United States, 9.1% of the population has diabetes 
and the estimated economic cost in 2012 was $245 billion (78, 79).  
Osteoporosis is also a public health concern. Estimates suggest that osteoporosis causes 
almost 9 million fractures annually, more than half of these in Europe and the Americas (80). 
From this pool, 1.6 million fractures affect the hip, 1.7 million the forearm and 1.4 million are 
clinical vertebral fractures (80). Hip fractures are associated with the greatest morbidity and 
mortality. Estimates suggest that up to 20% of patients die in the first year after a hip fracture 
and less than half regain the previous level of function (80).Mortality after a hip fractures is 
higher in patients with diabetes than in people without diabetes (81). Besides the high 
morbidity and mortality, huge economic costs are also involved. In 2017, the fracture-related 
costs in the UK was estimated at £5.25 billion and it is expected to increase 30% by 2030 (82). 
In the US, estimates suggest a yearly $20 billion cost with fractures (83).  
Some previous reviews have reported an increase in the risk of hip fractures in both T1D and 
T2D   and an increase in the risk of vertebral fractures in T1D (10, 13, 14, 84-86). In addition, 
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a greater increase in the risk of hip fractures in T1D than in T2D has also been reported (10, 
84, 85). Although a number of reviews have assessed the risk of fractures in diabetes, no 
recent review has addressed the risk of non-vertebral fractures in this population. Hip, 
vertebral and non-vertebral fractures are common sites used in clinical trials to assess drug 
efficacy (87). Among these sites, it is known that data on hip fractures is reliable. As all hip 
fractures are treated by surgery, they are reliably captured in hospital records. Conversely, 
vertebral fractures are commonly undiagnosed and need to be identified on spinal imaging. 
This makes the registry data unreliable and inadequate to assess the risk of vertebral 
fractures. This inaccuracy could compromise the analyses not only of vertebral fracture as a 
site but also the all fractures analysis as vertebral fractures are included. In this scenario, the 
non-vertebral fractures risk emerges as an alternative for an overall picture of the risk of 
fractures in diabetes to be assessed in systematic reviews. Furthermore, the current meta-
analyses have not fully explored the effect of other features in the risk of fractures in diabetes. 
Some studies have investigated the effect of gender (10, 85, 86, 88), diabetes type (10, 84-
86), geographical location (10, 13, 85) and study design (10, 13, 86, 89). However, none of the 
previous studies has investigated the effect of age, BMI, diabetes duration, insulin use and 
the presence of complications.  We conducted a recent meta-analysis on the risk of fractures 
in chronic kidney disease and found a greater increase in younger populations, suggesting 
that the pattern of fractures might be different in chronic diseases {Vilaca      Tatiane    , 2019, 
The Risk of Hip and Non-Vertebral Fractures in Chronic Kidney Disease: A Systematic Review 
and Meta-Analysis}. In addition, there is evidence that obesity has a protective effect in the 
skeleton (67). A few studies suggested that longer diabetes duration (90, 91), insulin use (92, 
93) and the presence of complications (64, 94) were associated with a greater increase in the 
risk of fractures in diabetes. These features have not been explored in previous meta-
analyses. 
The aim of this systematic review and meta-analysis was to assess the risk of hip and non-
vertebral fractures in adults with diabetes compared to adults without diabetes in 
observational studies. We also assessed if gender, age, BMI and diabetes-related features 




This review complies with key principles from the Cochrane Handbook and the Centre for 
Reviews Dissemination Handbook (56, 95). This report followed the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (96). The protocol was 
registered in PROSPERO. The record number is CRD42018090378.  
 
Searches  
The search strategy was to identify a published systematic review that we could then update. 
This review was part of a broader project conducted in collaboration with the School of Health 
and Related Research (ScHARR)  that investigated the risk of fractures in chronic diseases 
following a mini-review previously published (97). The aim was to investigate the risk of hip 
and non-vertebral fractures in diabetes, Chronic Kidney Disease and Parkinson’s Disease. 
Where previous reviews were identified, their quality was assessed, and the best review was 
selected and updated. We conducted searches to identify systematic reviews, followed by 
primary studies searches.  The initial searches were conducted simultaneously for diabetes, 
CKD and Parkinson’s Disease. One review on the risk of fractures in diabetes was selected to 
be updated and the primary studies research was conducted from the date of the selected 
review search, June 2006. The full search strategies are described in Appendix 1. In summary, 
we combined terms for fractures and diabetes mellitus and related synonyms including free 
and thesaurus terms. We used Boolean operators and database-specific syntax.  
For both searches, the following databases were searched: Ovid MEDLINE(R); Ovid 
MEDLINE(R) Epub Ahead of Print; Ovid MEDLINE(R) In-Process & Other Non-Indexed 
Citations; Ovid MEDLINE(R) Daily Update; Embase via Ovid. For the systematic review 
searches, the following additional databases were searched: Cochrane Database of 
Systematic Reviews; Database of Abstracts of Reviews of Effect via The Cochrane Library; and 
the Health Technology Assessment Database via The Cochrane Library. For the primary study 
searches, the Cochrane Central Register of Controlled Trials was also searched. 
The reference lists of key existing reviews were searched for additional primary studies (13, 




Search results were uploaded to Endnote and the duplicates were removed. For both the 
previous reviews and primary studies searches, one reviewer excluded clearly irrelevant 
records on the basis of their title and abstracts against the inclusion and exclusion criteria. A 
second reviewer independently sifted a 10% sample and the kappa statistic for the agreement 
was calculated. The full test sift was conducted by one reviewer in the reviews search and 
independently by two reviewers in the primary study search. Disagreements were resolved 
through discussion or involvement of a third reviewer. Studies that addressed some or all of 
the same population were included if they reported different aspects of that population that 
could be used in subgroup analyses. Potential small overlaps due to nationwide surveys or 
cohorts that recruited in the same region were considered non-relevant. Table 3.1 describes 
the inclusion and exclusion criteria.  
 
Table 3.1 Inclusion and exclusion criteria for the review on the risk of fractures in diabetes 
 Inclusion criteria Exclusion criteria 
Population Adult (aged 18 years and 
above) DM patients who have 
a diagnosis of type 1 or type 2 
DM. 
Studies lacking a clear definition/diagnosis 
of DM 
Studies with heterogeneous populations 
without data on/unclear data on DM 
patients (e.g. where the population is not 
clearly defined) 
Studies where diagnosis of DM is made 
following fracture 
Studies without a clear sequence between 
diagnosis of DM and fracture  
Comparison Adults (aged 18 years and 
above) who do not have DM 
Studies lacking a clear description of the 
comparison group. 
Outcome Hip and non-vertebral 
fractures (i.e. all fracture sites 
Data only on the occurrence of 
spine/vertebral fracture 
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 Inclusion criteria Exclusion criteria 
excluding spine/vertebral), 
adjusted for age and gender* 
Studies reporting predicted fracture risk 
based on an algorithm or risk tool 
Studies with unclear/incomplete/missing 
data 
Studies where risk estimates were not 
adjusted for age and gender*. 
Study 
design 
Review of Systematic reviews:  
Systematic reviews of 
observational studies on risk of 
hip or non-vertebral fractures 
 
Primary study review:  
Observational studies on risk 
of hip or non-vertebral 
fractures 
Studies not published in full text in English 
language 
Narrative reviews, letters, editorials, 
commentaries, conference abstracts, 
animal studies, biological studies will also 
be excluded. 
 
DM, diabetes mellitus 
* The criteria relating to adjustments for age and gender was an amendment to the 
protocol, made after full text sifting had commenced but before data extraction 





We used a standardised piloted data extraction form to extract the data from the full text of 
all papers, including the ones from the selected review (Data extraction form in appendix 2). 
Data were extracted by one reviewer and checked by another reviewer and disagreements 
were resolved through discussion.  
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Quality assessment  
The Newcastle Ottawa Scales (NOS) was used to assess the quality of primary studies. The 
tool assesses the selection and comparability of the study groups, and the ascertainment of 
exposure (for case-control studies) or outcome of interest (for cohort studies). Stars are 
awarded to a maximum of nine. The scoring was adapted for the review question. We 
considered age and gender the most important factors to be controlled for and a follow-up 
of 80% or greater unlikely to introduce bias. Each study was assessed by one reviewer and 
checked by a second and disagreements were resolved through discussion or involvement of 
a third reviewer. The adapted NOS scoring template is provided in appendix 3.  
 
Meta-analysis methods  
Some studies reported the risk estimates in several categories, such as gender, age groups 
and diabetes type. Studies that reported more than two risk estimate for a given group in the 
subgroup analyses were summarised using the random-effects model. For the non-vertebral 
fracture analyses, studies that reported the risk of fractures for two or more sites were 
summarised using the random effects model. Subgroup analyses for gender, age, BMI and 
diabetes-related features such as DM type, duration, insulin use and the presence of 
complications were anticipated in the protocol and performed when enough data was 
available. An exploratory analysis by geographical location was added. Subgroup RR were 
considered significantly different if there was no overlap in the 95% CI. However, if there was 
a small overlap we used the ratio of relative risk (RRR) and the 95% CI to compare the risk. If 
the 95% confidence interval did not include the unit, the subgroups RR were considered 
statistically different (100).  
Some studies described the same population but reported the risk for different groups. These 
studies were included in different subgroup analysis, but a given population/cohort was not 
included twice in the same analysis. For the overall analysis the most comprehensive data 
was included. For subgroup analysis, the study that addressed that specific feature of interest 
was included. Conversely, the studies that did not report the risk for that specific subgroup 
analysed were not included, i.e. in the analysis by gender, studies that reported one risk 
estimate including female and male were not included.  We used the random-effects model 
to pool the studies.  
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Heterogeneity, when high, was explored by subgroup analysis, sensitivity analysis and meta-
regression. Subgroup analyses were performed when enough data was available. We 
performed a sensitivity analysis excluding one study at a time. We also excluded the case-
control studies and the studies that scored less than seven in the quality assessment. To 
explore the effect of the several risk estimates reported, such as hazard ratio, relative risk, …, 
we performed sensitivity analysis excluding the studies that reported each risk estimate.  For 
example, we performed sensitive analysis excluding all the studies that reported hazard 
ratios. In the subgroup analysis by geographic location, in contrast with other subgroups, the 
Australian subgroup showed a wide confidence interval; we performed sensitivity analysis 
excluding these studies. In the hip fracture analysis, meta-regression was performed to assess 
how much of the variation observed was due to diabetes type or age group (< 65 years vs  
65 years) individually and combined.  
We used the visual analysis of funnel plots to assess publication bias. When visual analysis 
suggested publication bias, additional tests such as Begg’s and Eggers where used (101). If the 





The search for systematic reviews identified 452 unique records. The assessment of the title 
and abstract excluded 388 records. From the remaining 64 records, one systematic review 
was selected (10). The kappa statistic for the agreement between reviewers about studies 
selection was perfect (1.00 95%CI 1.0, 1.0).   
The searches for primary studies identified 3081 records, including the 81 identified in March 
2019, in the search update. Duplicates were excluded resulting in 1794 unique papers. 
Searches in the reference lists of relevant papers and contact with experts in the field 
retrieved a further 32 records. Hence, 1826 records underwent the title and abstract sifting. 
Of these, 1609 were considered irrelevant and 217 records underwent full-text assessment 
against inclusion and exclusion criteria. A further 168 were excluded (list of reasons in 
appendix 4), resulting in 49 studies that met the inclusion and exclusion criteria. Of these, 48 
were included in the meta-analyses, 42 in the hip fractures analysis (15, 64, 90-93, 103-138) 
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and 17 in the analysis of non-vertebral fractures (90, 92, 93, 103, 113, 115-117, 119, 132, 134, 
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Additional records identified 
through other sources 
(n = 32) 
Records after duplicates removed 
(n = 1826) 
Records screened 
(n = 1826) 
Records excluded 
(n = 1609) 
Full-text articles assessed 
for eligibility 
(n = 217) 
Full-text articles excluded, with 
reasons 
(n =168) 
No data on fracture risk in diabetes 
(n=47) 
Includes vertebral fractures (n=36) 
Sequence of fracture and diabetes (14) 
No adequate control group (n=18) 
Data not adjusted for age and sex 
(n=15) 
Publication or study type (n=11) 
All or some children (n=8) 
Some or all patients included in 
another included study (n=8) 
Diabetes diagnosis unclear or 
inadequate (n=4) 
Missing data (n=3) 
Not in English language (n=3) 
Algorithm to predict risk (n=1) 
 
Studies included in 
qualitative synthesis 
(n =49) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = 48) 
Studies included in hip 
fractures meta-analysis  
(n =42) 




Figure 3-1 Search process diagram 
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Hip fracture study characteristics  
Table 3.2 summarises the study characteristics. Forty-three studies reported data on hip 
fracture risk in people with diabetes compared to people without diabetes (15, 64, 91-93, 
103-138, 144). Eleven analysed overlapping populations but reported subgroup data relevant 
to our subgroup analyses (90, 105, 106, 113, 114, 120-122, 126, 127, 144). One study reported 
the RR according to metabolic control and was not included in calculations (144). Forty studies 
were cohorts (22 prospective(90, 91, 93, 103, 107, 108, 110-112, 115, 116, 118, 119, 123, 128-
130, 133, 134, 136, 144) and 18 retrospective (15, 64, 104-106, 113, 114, 117, 120-122, 124-
127, 132, 137, 138)) and three studies were case-control studies (109, 131, 135). The study 
size varied from 238 (135) to 3,861,874 participants (15) and they were published from 1993 
(128) to 2019 (123). Nineteen studies were from North America; five from Canada (120-124) 
and others from the USA (64, 91, 92, 104, 109, 119, 125, 129-131, 133, 134, 136, 137). Sixteen 
studies were  from Europe; three from Norway (103, 108, 128), two from the Netherlands 
(90, 144), one from Austria (107), three from the United Kingdom (15, 112, 138), two from 
Denmark (113, 114), two from Sweden (93, 115), two from Spain (126, 127), and one from 
Germany (132). Five studies were from Asia (Taiwan (105, 106), Korea (117), Singapore (118) 
and Israel (135)) and three from Australia (110, 111, 116). Two studies reported data only 
from T1D participants (111, 138),  ten studies reported data only from T2D participants (90, 
92, 107, 110, 117, 126, 127, 131, 132, 144) and the others reported data from participants of 
both DM types (15, 64, 91, 93, 103, 108, 112, 120, 121, 123-125, 129) or did not specify the 
participant’s DM type (104-106, 109, 113-116, 118, 119, 122, 128, 130, 133-137). Ages varied 
from 20 to 100 years old. Six studies reported data just from women (91, 92, 107, 119, 122, 
129) and three just from men (64, 127, 131). The other studies reported data from both 
genders and the percentage of women varied from 32% (115) to 94% (135).  One study 
reported data from two cohorts separately, the Women’s Health Initiative (WHI) and the 
North Carolina Established Populations for Epidemiologic Studies of the Elderly EPESE (119). 
However, the WHI cohort was more comprehensively described by Robbins et al (133) and 
Bonds et al (139) and only the data from the EPESE cohort was used from Lee, 2015 (119).  
Not all studies reported the population ethnicity. Studies from Asia were included (105, 106, 
117, 118, 135) and some studies from North America included blacks and Hispanics (64, 104, 
119, 125, 130, 133, 134, 136, 137) , but the majority of data reported addressed white 
populations.  
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Hip fracture - Quality assessment  
We report a summary of the authors’ judgement in Table 3.3 (cohort) and Table 3.4 (case-
control). The full description of the criteria and the author’s judgement with reason is 
described in appendix 4. Overall the quality of the studies was good as most scored higher 
than seven, which is considered high quality. The main criterion not addressed by the studies 
was the adequacy of follow up; twenty-three studies did not score in this criterion, mainly 
due to the lack of information (15, 64, 90, 92, 103, 104, 107, 108, 110, 111, 116, 119, 123, 
124, 129, 130, 132-134, 136-138, 144). Another criterion in which the studies did not score 
was representativeness. Volunteers are usually healthier than people who do not volunteer 
in studies, so they were not considered representative of the community (145). One cohort 
study scored five (129).  This study is a prospective cohort that surveyed post-menopausal 
women by post for 11 years. Consequently, this study did not score in representativeness 
(volunteers), ascertainment of exposure and assessment of the outcome (both self-reported) 
and adequacy of follow-up (bellow 80% in the last survey). Five studies scored six; one case-
control and four cohort studies  (91, 110, 111, 133, 135). All these cohort studies scored 
poorly in representativeness, for recruiting volunteers and in the ascertainment of exposure 
(not reported (110, 111) or self-reported (91, 133)). Three of them lost scores in the adequacy 
of follow-up (110, 111, 133) and Janghorbani et al lost scores in the assessment of outcome 
as fractures were self-reported (91). The case-control study also lost scores in 
representativeness, ascertainment of exposure and adequacy of follow-up. In this study, 
controls were first incident fractures while cases were any fractures and data on exposure 
and follow-up were unclear (135).   
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Table 3.2 Hip fractures study characteristics 











Pop total / 
DM  






Risk estimate  




6 27,159/ 455 1249 NR 52 Calculated 
overall 
3.9 (1.19-12.8)3 
Berry, 2017  Cohort2 USA   FRAiL NS 65-
113 
1.8  419,668/ 
119,490  
14,553 White 83% 
Black 13% 








71 Overall 1.09 (1.05-1.13)4 
Chen, 2008 Cohort2 Taiwan Taiwan NHI  NS > 35 6  969,821/ 
484787 
20220 NR 53 Male 1.28 (1.21–1.34)5 
 
            
 
      Female 1.72 (1.66–1.78)4 
Lai, 2015 Cohort2 Taiwan Taiwan NHI NS ≥65  5 81,245/ 
16249 
4005 NR 48 DM < 5y 1.20(1.14, 1.26)6 
 
            
 






Study   





 771   NR  59  Overall 1.18 (0.76–1.83)
7 




T2D ≥55 12.2 
(4.2) 
4,135/ 420 1068 NR 59 ACD 1.15 (0.68-1.94)8 
  
          
 
    59 ICD 0.96 (0.52-1.75)8 
Dobnig, 2006 Cohort1 Austria Austrian 
nursing 
homes 




White 100 Overall 0.90 (0.60 –1.34)9 























Pop total / 
DM  






Risk estimate  
Gerber, 2013  Case-
control  
USA  Olsmted 
County, 
Minnesota  














T1D NR  14.5 
(5.8) 
605/ 121 14 NR 40 Overall 7.11 (2.45–20.64)4 
Hamilton, 
2017a  




T2D  NR 12.9 
(6.1) 




51 Overall 1.34 (1.06–1.69)4 
Hippisley-
Cox, 2012 







23810 White or not 
recorded 
95.3%. 
Indian 0.9%   
Pakistani 0.5%   
Bangladeshi 












Holm, 2018 Cohort2 Denmark Danish 
National 
registries 





Cohort2 Denmark Danish 
National 
registries 
NS ≥65 NR 1,276,891/ 
NR  
89150  NR 58 Overall 1.12 (1.09-1.14)14 
Holmberg, 
2006  
Cohort1 Sweden Malmö 
Preventive 
Project  
NS NR  F 11 
M 16  
33,346/ NR 3915 NR 32 Female 4.07 (1.79-9.26)3 
           
Male 7.75 (4.37- 13.7)3 
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Pop total / 
DM  






Risk estimate  
Hothersall, 
2014 




13,259 NR NR Calculated 
overall 
1.76 (1.3-2.39)15 
Ivers, 2001 Cohort1 Australia The Blue 
Montains 
Eye Study  












1398 White 98%  100 T1D 7.1 (4.4–11.4)16 
          
 T2D  1.7 (1.4–2.0)16 
Kim, 2017 Cohort2 Korea KNHIS T2D ≥50 6 51,330/ 
17,110 
1,816 NR, Korean 54 Female 2.11 (1.71–2.60)16  
           
Male 1.81 (1.30–2.52)16 










1213 NR, Chinese DM 57 
Non-DM 
56 
Overall 2.00 (1.73–2.31)17 
Lee, 2015 
(EPESE) 
Cohort1 USA   EPESE  NS   ≥ 65  6.5  2,704/ 566 hip 173 Blacks 54.5%   
White 45% 
Others 0.5% 
100 Overall 1.27 (0.80–2.02)18 
 
Cohort2 USA   VHA  Both 
(98
% 










0  Overall 1.21 (1.19–1.23)19 




Both ≥20 NR 318,776/ 
82,094 
17,342 NR but 
Aborigines 
7.2% controls, 










Both ≥40 6 62,413/ 
6,455 
1108 White 97.8% Controls 
92 
DM 86  
<60 4.67 (2.76–7.89)21 
 
            
 
      60-69 2.68 (1.77–4.04)21 
 
            
 
      70-79 1.57 (1.20–2.04)21 
 
            
 
      ≥80 1.42 (1.01– 1.99)21 
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Pop total / 
DM  














NS ≥40  7  57,938/ 
8,840 
1388 NR 100 Female 1.32 (1.03–1.69)22 




≥ 25 9.2 (4.5) 3,149/ 138 67 NR 70 Overall 2.60 (1.04–6.55)23 
Lipscombe, 
2007 






≥66  6.1  598,812/ 
197,412 
22267 NR,  49 Female 1.11 (1.08–1.15)24 
           
Male 1.18 (1.12–1.24)24 










49 Overall 1.35(0.82-2.22)25 
Martinez-
Laguna, 2015 
Cohort2 Spain SIDIAP 
database  




1220 NR 43 Overall 1.11 (0.99-1.24)26 
Reyes, 2014 Cohort2 Spain  SIDIAP 
database 






1718 NR 0 Male 1.45 (1.25–1.69)27 









 10.9   52,313/ 298 212 NR 48 Female 5.81 (2.15-15.71)
4 
           
Male 7.67 (2.40-24.53)4 
Nicodemus, 
2001 








490 NR 100 T1D 14.1 (5.85, 34.2)16 
           
T2D  1.75 (1.25, 2.43)16 
 100 











Pop total / 
DM  






Risk estimate  
Ottenbacher 
2002 
Cohort1 USA   H-EPESE NS  ≥ 65  NR 2,884/ 690 134 100% Mexican 
Americans 
58 Overall 1.57 (1.03–2.39)28 
Poor, 1995 Case-
control  
USA  Olsmted 
County, 
Minnesota  
T2D  >35  1965-
1989 
464/ 42 232 White  0 Overall 0.9 (0.5-1.7)16 
Rathmann, 
2015 








hip NR NR 49  Overall 1.56 (1.45–1.67)
29 






1132 White 83.3% 
Black 8.2% 




Islander 2.9%  
100 Overall 1.74 (1.17-2.60)30 
Schneider, 
2013  
Cohort1 USA  ARIC Study NS 45-
64 
Median 
20 years  
15,140/ 
1,800 
1078 White 74% 
Black 26%  
55 Prevalent 
DM 
1.76 (0.68, 4.60)31 
           
Newly 
diagnosed 
2.99 (1.24, 7.21)31 
Schwartz, 
2001 
Cohort1 USA   SOF T2D  ≥ 65 
year
s 






















1  238/ 41 142 NR, Israel  Cases 76 
Controls 
94 
Overall 3.9 (1.50–10.4)32 
Strotmeyer, 
2011  
Cohort1 USA   CHS NS ≥ 65 10.9 
(4.6)  
3,506/ 918 334 15.5% black; 58 Overall 1.05 (0.80–1.39)33 
Taylor, 2011  Cohort2 USA  5% random 
sample of 
Medicare  










58 Overall 1.01 (0.99, 1.02)34 
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Pop total / 
DM  






Risk estimate  
Wallander, 
2017  





36132 NR 58 Calculated 
overall 
1.12 (0.99-1.27)8 





21239 NR 44 Calculated 
overall 
3.51 (2.7-4.55)35 
Fract Fracture; Taiwan NHI National Health Insurance database; SCI-DC Scottish care information database collaboration; NHS Nurses’ Health Study; KNHIS Korean National 
Health Insurance Service; EPESE North Carolina Established Populations for Epidemiologic Studies of the Elderly; VHA Veterans Health Administration; POPULIS Population 
Health Information System; MCHP data repository at the Manitoba Centre for Health Policy; NHW non-Hispanic white; NHB non-Hispanic black; MA Mexican American; 
SIDIAP Sistema d’Informació per al Desenvolupament de la Investigació en Atenció Primària; H-EPESE The Hispanic Established Population for the Epidemiologic Study of the 
Elderly; ARIC The Atherosclerosis Risk in Communities Study;  SOF Study of Osteoporotic Fractures; CHS Cardiovascular Health Study; FRAILCO Fractures and Fall Injuries in 
the Elderly Cohort; THIN The Health Improvement Network  
 
1Prospective 2Retrospective  
Adjustments: 
3 Age adjusted, reported by sex 
4 Age and sex 
5 Age as a continuous variable, geographic area, and urbanization status 
6 Groups were matched for sex, age and the year of diagnosis of DM 
7 Age, gender, BMI, smoking, serum creatinine, visual acuity, falling frequency, lower limb disability 
8 Age, sex, height, weight 
9 Age and weight 
10 Age, BMI and daily smoking 
11 Age and sex matched controls 
12 Ethnic origin, alcohol intake, smoking, age, BMI, medical or social factors (Asthma or chronic obstructive airways disease, any cancer, cardiovascular disease, dementia, 
epilepsy diagnosis or prescribed anticonvulsants , history of falls, chronic liver disease, Parkinson’s disease, rheumatoid arthritis or systemic lupus erythematosus Chronic 
renal disease, Type 1 diabetes, Type 2 diabetes, previous fracture, endocrine disorders, gastrointestinal malabsorption, parental history of osteoporosis, any antidepressants, 
corticosteroids, unopposed hormone replacement therapy 
13 Adjusted for baseline age, BMI group (<20, 20–30, >30), modified Charlson index, estrogen deficiency, MOF, prevalent rheumatoid arthritis, former osteoporosis treatment, 
glucocorticoid use >450 prednisone eq., family fracture history, current smoking, exercise level, prevalent alcohol related diagnoses 
14 Age, gender, income, calendar year and comorbidity (ischemic heart disease, COPD, dementia, depression, diabetes, osteoporosis and stroke) 
15 Age, calendar year, SIMD, and for the overall estimate, an SIMD‐age interaction 
16 Age 
17 Age at recruitment, sex (for all), year of recruitment, dialect group (Hokkien, Cantonese), level of education (no formal education, primary, secondary or higher) 
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18 Age, race, BMI 
19 Adjusted for age, race/ethnicity, tobacco use, alcohol use, glucocorticoid use, rheumatoid arthritis, and BMI. 
20 Age, sex, income quintile, are of residence and ethnicity 
21 Age, sex, BMI, glucocorticoid use, rheumatoid arthritis, high alcohol use, any prior fracture, and femoral neck T-score 
22 Frax adjusted 
23 Adjusted for age, sex, and BMD femoral neck T-scores 
24 Age group chronic unstable disease; prior stroke; visual impairment; neuropathy; amputation; treatment with nitrates, statins, anticonvulsants, inhaled corticosteroids, 
thiazides, estrogen, and medications that increase risk of falling; and history of BMD test 
25 Age, sex and survey 
26 Age and sex matched  
27 Age, body mass index, smoking, alcohol consumption, use of oral corticosteroids, and co-morbid conditions (COPD Heart failure Chronic kidney disease, severe liver disease 
MLDa malignant tumour (without metastasis), metastasis, connective tissue disease, AIDS, paraplegia, dementia, peptic ulcer disease, myocardial infarction, cerebrovascular 
disease, peripheral vascular disease 
28 Age, gender, smoking status, BMI, and history of stroke. 
29 Age, sex, diabetologist care, depression, chronic kidney disease, peripheral vascular disease, heart failure, hyperlipidemia, obesity. 
30Age, self-reported health, height, change in height since the age of 18 years, change in weight since the age of 35 years, history of fracture after the age of 55 years, 
race/ethnicity, physical activity, smoking, history of parental fracture after the age of 40 years, diabetes treated with medications, and corticosteroid use 
31 Age, sex and race/study center, body mass index, sports-activity tertile, alcohol consumption, cigarette smoking, and medication use. 
32 Plasma PTH serum 25(OH)D3 concentration, concomitant diseases (hypertension, ischemic heart disease and diabetes mellitus), smoking status, age, gender and season. 
33 Age-sex-race adjusted 
34 Gender, race-ethnicity, age, calendar year, urban/rural, geographic location, median income, previous fracture, other predisposing conditions (glucocorticoid related, fall-
related, renal disease, depressive illness, AMI, other heart disease, bone disease, cancer) 







Table 3.3 Author’s Judgement rating on Quality Assessment for cohort studies using Newcastle-Ottawa tool 





* * * * ** * * - 8 
Berry, 2017 hip  - * * * ** * * - 7 
Bonds, 2006 NV  - * * * ** - * - 6 





* * * * ** * * - 8 
Dobnig, 
2006 
hip  - * * * ** * * - 7 
Forsen,1999 hip  * * * * ** * * - 8 
Hamilton, 
2017a  
hip  - * - * ** * * - 6 
Hamilton, 
2017b 
hip  - * - * ** * * - 6 
Hippisley-
Cox, 2012 
hip  * * * * ** * * * 9 
Holm, 2018 hip and 
NV  





* * * * ** * * * 9 
Hothersall, 
2014 
hip  * * * * ** * * - 8 
Ivers, 2001 hip and 
NV  
- * * * ** * * - 7 
Janghorbani 
2006 
hip  - * - * ** - * * 6 
Jorgensen, 
2014 
hip  * * * * ** * * * 9 
Jung, 2012 NV  - * * * ** * * - 7 
Kim, 2017 hip and 
NV  
* * * * ** * * * 9 
Koh, 2010 hip  * * * * ** * * * 9 





* * * * ** - * - 7 
Lee, 2018 hip - * * * ** * * - 7 
Leslie, 2007 hip * * * * ** * * * 9 
Leslie, 2014 hip  * * * * ** * * * 9 
Li, 2019 hip - * * * ** * * - 7 
Lipscombe, 
2007 
hip * * * * ** * * - 8 
Looker, 
2016 
hip  * * * * ** * * * 9 
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Study, year Review S 1 S 2 S 3 S 4 Comp Out 1 Out 2 Out 3 Tot 
Majumdar, 
2016 




hip * * * * ** * * * 9 
Meyer, 1993 hip * * * * ** * * * 9 
Napoli, 2014 NV  - * * * ** * * - 7 
Nicodemus, 
2001 
hip - * - * ** - * - 5 
Oei, 2013  hip and 
NV  
* * * * ** * * - 8 
Ottenbache
r 2002 





* * * * ** * * - 8 
Reyes, 2014 hip * * * * ** * * * 9 
Robbins, 
2007 
hip - * - * ** * * - 6 
Schafer, 
2010  










- * * * ** * * - 7 
Strotmeyer, 
2011  










* * * * ** * * * 9 
Weber, 
2015 
hip * * * * ** * * - 8 
S selection; Comp comparability; Out outcome; NV non-vertebral; Tot total  
 
Justification for each criterion 
Selection 1: representativeness of exposed cohort (representative of person with DM at risk 
of fractures) (where exposure is MD) 
*a) truly representative of the average person with DM in the community * 
*b) somewhat representative of the average person with DM in the community * (e.g. if some 
patient groups excluded, or used a database which only included a subset of the population, 
such as those with health insurance) 
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c) selected group of users eg nurses, volunteers (where that selection results in patients likely 
to have different outcomes to whole population) 
d) no description of the derivation of the cohort 
 
Selection 2: Selection of the non-exposed cohort 
*a) drawn from the same community as the exposed cohort * 
b) drawn from a different source 
c) no description of the derivation of the non-exposed cohort 
 
Selection 3: Ascertainment of exposure (i.e. DM) 
*a) secure record (eg surgical records) * 
*b) structured interview * 
c) written self-report 
d) no description 
 
Selection 4: Demonstration outcome of interest not present at study start 
*a) yes *  
b) no 
 
Comparability: (one star if study controls for age, two stars if study controls for gender) 
Study can score up to two stars 
*a) study controls for age (select the most important factor) * 
*b) study controls for gender* 
 
Outcome 1: Assessment of outcome 
*a) independent blind assessment * 
*b) record linkage * (e.g. hospital records) 
c) self-report 
d) no description 
 
Outcome 2: Length of follow-up (1 year minimum) 




Outcome 3: Adequacy of follow-up 
*a) complete follow up - all subjects accounted for * 
*b) subjects lost to follow up unlikely to introduce bias - small number lost - ≥80% follow up, 
or description provided of those lost) * 
c) follow up rate <80% (select an adequate %) and no description of those lost 
d) no statement 
 
 
Table 3.4 Author’s Judgement rating on Quality Assessment for case-control studies using Newcastle-Ottawa tool 
Study, 
year 
Review Sel 1 Sel 2 Sel 3 Sel 4 Comp Exp 1 Exp 2 Exp 3 Total  
Gerber 
2013 
hip  * * * - ** * * * 8 
Poor, 
1995 
hip  * * * - ** * * * 8 
Segal, 
2009 
hip  * * * - ** - * - 6 
Keegan 
2002 
NV * * * * ** * * * 9 
Sel selection; Comp comparability; Exp exposure; NV non-vertebral;  
 
 
Justification for each criterion 
 
Selection 1: Is case definition adequate? (i.e. ascertainment of fracture) 
*a) Requires some independent validation (e.g. >1 person/record/time/process to extract 
information, or reference to primary record source such as x-rays or medical/hospital 
records)* 
b) Record linkage (e.g. ICD codes in database) or self-report with no reference to primary 
record 
c) No description 
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Selection 2: Representativeness of cases 
*a) All (i.e. consecutive) eligible cases with outcome of interest over a defined period of 
time, all cases in a defined catchment area, all cases in a defined hospital or clinic, group of 
hospitals, health maintenance organisation, or an appropriate sample of those cases (e.g. 
random sample)* 
b) Not satisfying requirements in part (a), or not stated. 
 
Selection 3: Selection of controls 
This item assesses whether the control series used in the study is derived from the same 
population as the cases and essentially would have been cases had the outcome been 
present. 
*a) Community controls (i.e. same community as cases and would be cases if had 
outcome)* 
b) Hospital controls, within same community as cases (i.e. not another city) but derived 
from a hospitalised population 
c) No description 
 
Selection 4: Definition of controls 
*a) If cases are first occurrence of outcome, then it must explicitly state that controls have 
no history of this outcome. If cases have new (not necessarily first) occurrence of outcome, 
then controls with previous occurrences of outcome of interest should not be excluded.* 
b) No mention of history of outcome 
 
Comparability 1 (one star if study controls for age, two stars if study controls for gender) 
A maximum of 2 stars can be allotted in this category. Either cases and controls must be 
matched in the design and/or confounders must be adjusted for in the analysis. Statements 
of no differences between groups or that differences were not statistically significant are 
not sufficient for establishing comparability. Note: If the odds ratio for the exposure of 
interest is adjusted for the confounders listed, then the groups will be considered to be 
comparable on each variable used in the adjustment. 




Exposure 1: Ascertainment of exposure (i.e. Diabetes) 
*a) secure record (eg surgical records) * 
*b) structured interview where blind to case/control status * 
c) interview not blinded to case/control status 
d) written self-report or medical record only 
e) no description 
 
Exposure 2: Same method of ascertainment for cases and controls 
*a) yes * 
b) no 
 
Exposure 3: Non-response rate  
*a) same rate for both groups * 
b) non-respondents described 
c) rate different and no designation 
 
Meta-analysis results  
 
Hip fractures  
The overall RR of hip fractures was increased in diabetes.  Forty-three studies were included 
in the hip fractures analyses. These meta-analyses report the data of 17,575,873 participants, 
2,387,899 with DM and 321,720 fractures. As overlapping population were avoided, 37 
studies were included in the overall analysis, resulting in a RR of 1.52, 95%CI 1.42-1.63 and 
high heterogeneity (I2 96.6% p<0.001) (Figure 3-2). We explored the heterogeneity using 
subgroup and sensitivity analyses and meta-regression.  
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* Summarised using random-effects model 
Figure 3-2 Forest plot overall hip fractures risk in diabetes 
 
Subgroup analysis by gender  
The RR was significantly higher in females (RR 1.77, 95%CI 1.54-2.04) than in males (RR 1.35, 
95%CI 1.22-1.49). This analysis pooled data from ten single-gender studies (64, 91, 92, 107, 
113, 119, 122, 129, 131, 133) and the studies that reported gender-specific risk (15, 90, 93, 
103-105, 108, 112, 115, 117, 118, 124, 128, 138). One study reported an overall risk estimate 
without a gender-specific risk and the risk in females and the latter was used in this analysis 
(135). The studies that did not report a gender-specific risk were not included. In total, 25 
studies were summarised. Heterogeneity remained high (I2 94.8% p<0.001) (Figure 3-3). 
NOTE: Weights are from random effects analysis





























































































































































































































* Summarised using random-effects model 
Figure 3-3 Forest plot hip fractures risk in Diabetes by gender 
 
Subgroup analysis by age  
The RR was higher in younger populations.  The included studies reported several age-ranges 
and they were grouped in two ways; people younger and older that 65 years-old and in 
narrower age ranges, namely < 50 years, 50-59 years, 60-69 years, 70-79 years, and older than 
80 years. 
When using the cut-off of 65 years old, the RR was significantly higher in the younger 
population; RR 3.21, 95%CI 2.38-4.32 in participants younger than 65 years-old and RR 1.21, 
95%CI 1.14-1.28 in participants older than 65 years-old with high heterogeneity (I2 96.6% 
p<0.001) (Figure 3-4). Interestingly, the RR seems to decrease progressively with ageing. 
Seven studies reported the risk by similar age ranges and they were clustered in narrower age 
NOTE: Weights are from random effects analysis
.
.










































































































































































































































ranges. The relative risk decreased progressively from RR 3.33, 95%CI 2.53-4.38 in the 
population < 50 years, to RR 2.97, 95%CI 1.39-6.35 in 50-59 years; RR 2.90, 95%CI 1.61-5.22 
in 60-69 years; RR 1.41, 95%CI 1.19-1.66 in 70-79 years and reached no increase in the risk in 
the population older than 80 years RR 1.02, 95%CI 0.85-1.24. Heterogeneity was high (I2 91.2, 
p<0.001). The analysis using the RRR showed that, despite overlapping confidence intervals, 
the RR was significantly lower in the 70-79 years group compared to 60-69 years group, and 
in the  80 years group compared to 70-79 years (Figure 3-5).  
 
 
* Summarised using random-effects model 
Figure 3-4 Forest plot hip fractures risk in Diabetes by age (< 65 years vs >65years) 
 
NOTE: Weights are from random effects analysis
.
.


































































































































































































* Summarised using random-effects model 












































Subtotal  (I-squared = 78.4%, p = 0.031)


















































































































Subgroup analysis by diabetes type  
The RR was significantly higher in T1D (RR 4.93, 95% CI 3.06-7.95) than in T2D (RR 1.37, 95% 
CI 1.22-2.21). This analysis summarised the data from the 19 studies that reported the risk for 
specific diabetes type. Overall heterogeneity was high (I2 94.5% and p< 0.001) (Figure 3-6).  
 
 
* Summarised using random-effects model 








NOTE: Weights are from random effects analysis
.
.









































































































































Additional exploratory analysis by age and DM type  
 
As age and diabetes type seemed to have an important impact on the risk of fractures in 
diabetes, we ran the age subgroup analysis for each diabetes type. In the T1D group, the risk 
of hip fracture was higher in the younger than 65 years old (RR 5.21, 95%CI 3.75-7.22) than in 
the older than 65 years old (RR 2.48, 95%CI 2.13-2.89) Figure 3-7. 
 
* Summarised using random-effects model  
Figure 3-7 Forest plot hip fractures risk in T1D by type age (65 years vs > 65 years) 
 
The analysis for age ranges showed similar results. The risk of hip fractures was similar in the 
younger than 50 years old (RR 4.67, 95%CI 3.00-7.28), in the individuals between 50-59 years 
old (RR 4.45, 95%CI 2.79-7.10) and in the ones at 60-69 years old (RR 4.25, 95%CI 3.42-5.27), 
but significantly lower in the individuals older than 70 years old (RR 2.48, 95%CI 2.13-2.89). 
To allow the inclusion of more studies, we used > 70 years as the older group (Figure 3-8). 
NOTE: Weights are from random effects analysis
.
.





Subtotal  (I-squared = 57.8%, p = 0.093)
Hothersall, 2014*
















































* Summarised using random-effects model 





































Subtotal  (I-squared = 7.4%, p = 0.340)
Hothersall, 2014*
Subtotal  (I-squared = 0.0%, p = 0.576)
Hothersall, 2014
























































































In T2D, the risk of hip fractures was also higher in the younger (RR 1.74, 95% CI 1.24-2.43) 
than the older than 65 years old, (RR 1.20, 95% CI 1.07-1.34); (RRR 0.68 95%CI 0.48-0.98) 
(Figure 3-9). There were not enough studies with data by age range exclusively in T2D to 
perform the T2D analysis by age range.  
 
 
* Summarised using random-effects model 












NOTE: Weights are from random effects analysis
.
.






















































































Subgroup analysis by insulin use  
The insulin users had a higher RR of hip fractures (RR 2.87, 95%CI 2.10-3.92) than non-insulin 
users (RR 1.18, 95%CI 1.02-1.36). Ten studies were summarised in this analysis. Insulin users 
included T1D and T2D insulin users and non-insulin users included just T2D. Heterogeneity 
was high (I2 93.9%, p<0.001) (Figure 3-10).  
This analysis included patients with both T1D and T2D. Although both of them use insulin this 
is a heterogeneous group. T1D patients do not produce insulin and need exogenous insulin 
for treatment from the onset of the disease. Conversely, T2D patients have insulin resistance 
and insulin treatment is added when other treatment options fail. Therefore, these are 
patients with advanced T2D. Despite the differences, both groups are affected by 
hypoglycaemia that increases the risk of falls and fractures. Therefore, the analysis by insulin 
use probably does not reflect the effects of insulin in bone, but its indications and adverse 
effects.  
 
* Summarised using random-effects model 
Figure 3-10 Forest plot hip fractures risk in Diabetes by insulin use 
NOTE: Weights are from random effects analysis
.
.





























































































































































Subgroup analysis by diabetes duration  
The risk of fractures increased progressively with the increase in diabetes duration. Due to 
availability of data, the studies were grouped using 5- and 10-years duration thresholds.  
Data from people with diabetes for less than five years and more than five years were 
grouped, including 11 studies. People with diabetes for less than five years had a lower RR of 
hip fractures (RR 1.22 95%CI 1.03-1.45) than people with diabetes for more than five years 
(RR 1.55 95%CI 1.39-1.73), (RRR 0.79 95%CI 0.64-0.96) (Figure 3-11). Heterogeneity was high 
(I2 88.2% p<0.001).  
 
 
* Summarised using random-effects model 




NOTE: Weights are from random effects analysis
.
.
Overall  (I-squared = 88.2%, p = 0.000)
Janghorbani, 2006
Leslie, 2007























































































































































Additionally, a 10-years duration cut-off was used. Ten studies were included and a shorter 
duration (< 10 years) was associated with a lower RR of hip fractures RR 1.30, 95%CI 1.10-
1.54 than a longer duration (> 10 years) RR 2.42, 95%CI 2.08-2.81. High heterogeneity was 
observed I2 92.2% p<0.001 (Figure 3-12). 
 
 
Figure 3-12 Forest plot hip fractures risk in Diabetes by diabetes duration (10 years cut-off)   
 
We were able to show an increase in the risk of fractures with increased diabetes duration. 
However, this analysis has limitations. The number of studies that reported the risk of 
fractures according to diabetes duration was limited. In addition, studies reported the 
duration using different metrics (e.g. new diagnosis and previous diagnosis, 5 yeas, 5-11 
years, …) what made summarising the data a challenge. Finally, in T2D the diagnosis might be 
missed for years, so the data might not reflect the real disease duration.  
 
 
NOTE: Weights are from random effects analysis
.
.















Subtotal  (I-squared = 0.0%, p = 0.583)
Koh, 2010
Ivers, 2001










































































































Subgroup analysis by BMI  
Four studies reported the risk of fractures by BMI and we assessed the risk by BMI range. 
There was no significant difference between the groups, but the forest plot showed a trend 
to a decrease in the RR of hip fractures with the increase in BMI, namely in low/ normal weight 
(BMI< 25kg/m2) the RR was 1.69 95%CI 1.08-2.63; in overweight people (BMI 25-30 kg/m2) 
the RR was 1.18 95%CI 0.98-1.42, and in obese people (BMI > 30 kg/m2) RR was 0.96 95%CI 
0.58-1.59. The number of studies was limited and there was a considerable overlap in the 
confidence intervals (Figure 3-13).   
 
 










Overall  (I-squared = 93.8%, p = 0.000)
study










Subtotal  (I-squared = 87.2%, p = 0.000)







































































Subgroup analysis by continent  
The studies were grouped according to the geographical location. The risk was similar in 
Europe (RR 1.77 95%CI 1.48-2.13) and Asia (RR 1.78 95%CI 1.47-2.16) but lower in America 
(RR 1.32 95%CI 1.22- 1.43). The risk estimates from Oceania, all Australian studies, produced 
a wide confidence interval (RR 1.77 95%CI 0.57-5.47). The heterogeneity was high (I2 96.6% 
and p<0.001) (Figure 3-14).   
 
 
* Summarised using random-effects model 
Figure 3-14 Forest plot hip fractures risk in Diabetes by geographical location 
 
 

















































































































































































































































































































































Subgroup analyses not performed  
Few studies addressed the effect of diabetes control or microvascular complications on the 
risk of fractures, therefore, it was not possible to perform subgroup analysis. Oei et al 
reported data on the risk of hip, wrist and all types of fractures in diabetes by metabolic 
control. Participants with inadequate control had an increase in the risk of fractures 
compared to participants with adequate diabetic control or participants without diabetes 
(144). This pattern was observed in all fractures and wrist fractures, but the analysis for hip 
fracture subtype was inconsistent. However, the number of hip fractures in the participants 
with diabetes with adequate (n=15) and inadequate (n=11) control was small, suggesting that 
the study probably did not have the power to assess this risk.  
For microvascular complications, Lee et al investigated the effect of neuropathy in the risk of 
hip and any fractures. The authors developed a model that evaluated comorbidities as 
potential mediating factors for fractures. In this model, neuropathy explained around 20% of 
the risk of hip and any fractures, however, the analysis was not restricted to diabetic 
neuropathy (64). 
 
Sensitivity analysis  
We ran the analyses excluding one study at a time and no important variation was observed 
in the results. The RR varied from RR 1.48, 95%CI 1.38-1.58 to RR 1.57, 95%CI 1.46-1.70 and 
heterogeneity remained high suggesting that no study had an important individual impact in 
the results. We excluded the case-control studies, and the RR and heterogeneity also 
remained very similar (RR1.53, 95%CI 1.42-1.65). Sensitivity analysis excluding studies from 
Australia showed similar RR (RR 1.52, 95%CI 1.41-1.63). Finally, a sensitivity analysis excluding 
each kind of risk estimate (i.e. OR, HR) also resulted in similar results with the RR varying from 
RR 1.40 95%CI 1.30-1.50 to RR 1.58 95%CI 1.45-1.72.   
 
Meta-regression 
Meta-regression analysis suggested that diabetes type and age contribute substantially to the 
RR. In the DM type subgroup analysis, diabetes type accounted for 60% of the RR. In the age 
range analysis (65-years cut-off), age accounted for 48% of the RR. In the analysis combining 
both age and DM type, they accounted for 83% of the RR of hip fractures in diabetes.  
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Funnel plots  
Visual analysis of the funnel plot was not suggestive of publication bias, despite asymmetry 
(Figure 3-15). The plots are scattered through both the significant and non-significant results 
areas suggesting that even studies with non-significant results were published and captured 
by our research. The plots are also scattered from the apex to the bottom of the triangle, 
which reflect the size of the studies and shows that big (near the apex) and small (towards 
the bottom) studies with significant and non-significant results were included. Symmetrical 
inverted funnels are expected in data from interventional studies, in the absence of bias and 
between study heterogeneity as the scatter will be due to the sample variation (101). 
Heterogeneity might add horizontal scatter to the funnel plot and if heterogeneity is large it 
might overwhelm the sampling error and make the plot appears cylindrical (101). The high 
heterogeneity found in the analyses might have affected the funnel plots shape.  
 
 
Figure 3-15 Funnel plot studies included in the hip fractures analyses 
 
Non-vertebral fractures  
 
Non-vertebral fracture study characteristics  
Table 3.5 summarises the study characteristics. Eighteen studies reported the risk of fractures 
in two or more sites and were included in the non-vertebral fractures risk analysis (90, 92, 93, 
103, 113, 115-117, 119, 132, 134, 137, 139-144). All but one study (141) were cohorts, 12 
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prospective (90, 92, 93, 103, 115, 116, 119, 134, 139, 142-144) and five retrospective (113, 
117, 132, 137, 140). Eight studies were from the USA (92, 119, 134, 137, 139, 141-143), seven 
from Europe (one from Norway (103); two from the Netherlands (90, 144); one from Denmark 
(113); two from Sweden (93, 115) and one from Germany (132)); two Korean studies from 
Asia (117, 140) and one study from Australia (116). Nine studies did not specify diabetes type 
(115, 116, 119, 134, 137, 140-143),  while seven reported data just from T2D (90, 92, 113, 
117, 132, 139, 144) and two from both types (93, 103). There was no study reporting data just 
from T1D participants. Five studies reported data just from women (92, 113, 119, 139, 140), 
one just from men (142) and the others from both genders (90, 93, 103, 115-117, 132, 134, 
137, 141, 143, 144). The age range varied from 20 to 98 years-old and the follow-up from a 
median of 1.3 years to 20 years. The study size varied from 1,949 (143) to 1,694,051 
participants (137). Although other ethnicities were included, such as Asian, blacks, Hispanics 
and others (117, 119, 134, 139, 140, 142, 143, 146), the majority of the data addressed white 
populations. Nine studies reported the risk of non-vertebral fractures as a category (90, 92, 
93, 103, 116, 117, 140, 142, 143) and the others reported several combinations of sites 
including axial and peripheral sites. Only one study did not include the hip site in its pool (141).  
 
Non-vertebral fracture quality assessment  
We report a summary of the authors’ judgement in tables Table 3.3 (cohort) and Table 3.4 
(case-control). As in the hip fractures analysis, overall the quality of the studies was good and 
most of the studies scored higher than seven. Once more, the main criteria not addressed by 
the studies were the adequacy of follow-up (90, 92, 103, 116, 119, 132, 134, 137, 139, 140, 
142-144), not reported in most of the studies; and representativeness of the cohort (92, 116, 
134, 139, 140, 142, 143), mainly due to the recruitment of volunteers. One cohort study 
scored six and lost scores in representativeness, assessment of the outcome and adequacy of 
the follow-up. This study selected volunteers, fractures were self-reported and the follow-up 
was not reported (139). 
 125 
Table 3.5 Non-vertebral fractures studies characteristics 





















Risk estimate  
Ahmed, 
2006 











Cohort1 USA  WHI-OS T2D  50-
79 
7  93,405/ 
5285 
NR NHW 83.2% 





Islander 3.1%  


















T2D ≥55 6.8 
(2.3)  
6,655/ 792 771 NR 60   Non-vertebral  Overall 1.18 (0.92–1.52)5 





T2D ≥55 12 
(4.2) 
4,135/ 420 1,068 NR 60 Hip, wrist Calculated 
overall 
1.12 (0.83-1.53)6 
Holm, 2018 Cohort2 Denmark Danish 
National 
registries 
T2D NR  5.8 
(NR) 







Cohort1 Sweden Malmö 
Preventive 
Project  












Ivers, 2001 Cohort1 Australia The Blue 
Montains 
Eye Study  
NS ≥ 49 5 3,654/ 216 251 NR 57 Non-vertebral 
(exclude ribs) 
Overall 0.90 (0.70-1.20)4 









81 NR, Korean 100 Non-vertebral 
(hip, distal radius, 
elsewhere) 








NS ≥45  Oct 
1996  
4,528/ 472 2,615 WHite 61%  
Asian 14.9%, 
75 Foot, distal 
forearm, proximal 

































Hispanic 11.6%  
Kim, 2017 Cohort2 Korea  NHIS- 
KNHIS 
T2D ≥50 6y  51,330/ 
17,110 
3,855  Korean 54 Non-vertebral  Female 1.14 (1.02–1.25)3 
            
Male 1.14 (0.93–1.39)3 
Lee, 2015 
(EPESE) 
Cohort1 USA   EPESE NS ≥ 65 6.5  2,704/ 566 572  Blacks 54.5%  
White 45%  
Others 0.5%  















Cohort1 USA  MrOS NS ≥ 65 9.1 
(2.7)  
3,967/ 881 871 White 90% 
Black 4.07% 
Asian  3.19% 
Hispanic  2.10% 
Other  1.18%  
0 Non-vertebral  Overall 1.12 (0.94-1.34)10  
Rathmann 
2015 








11,535  NR 49 Hip, forearm, 













1,949/ 658 NR White 58% 
Black 42%  
50 Non-vertebral  Overall 1.42 (1.07–1.89)12 
Schneider 
2013 
Cohort1 USA  ARIC Study NS 45-
64  
Md 20  15,140/ 
1,800 
1,078 White 74% 
Black 26%  







Cohort1 USA  SOF T2D  ≥ 65 9.4 
(2.4) 
9,654/ 657 2,624 "mainly white" 
(black women 
were excluded 




          
Non-




Cohort2 USA  5% random 
sample of 
Medicare  
NS ≥ 65  4.2 p-y 1,694,051/ 
NR 


































Risk estimate  
Wallander 
2017 
Cohort1 Sweden FRAILCO  Both ≥65 Md 1.3  428,305/ 
84,702 
36,132 NR 58 Any (hip, wrist, 








Fol up Follow-up; Frac fractures; F female; WHI-OS Women’s Health Initiative- Observational Cohort; NHW - KNHIS Non-Hispanic white; F female; M male; NHIS- NSC National 
Health Insurance Service National Sample Cohort of the Korean National Health Insurance Service; EPESE North Carolina Established Populations for Epidemiologic Studies 
of the Elderly; ARIC The Atherosclerosis Risk in Communities Study; Md median SOF Study of Osteoporotic Fractures; p-y person-years; FRAILCO Fractures and Fall Injuries in 
the Elderly Cohort;   
 
 
1Prospective 2Retrospective  
3 Age adjusted, reported by gender 
4 Age and gender 
5 Age, gender, BMI, smoking, serum creatinine, visual acuity, falling frequency, lower limb disability 
6 Age, gender, height, weight 
7 Adjusted for baseline age, BMI group (<20, 20–30, >30), modified Charlson index, estrogen deficiency, MOF, prevalent rheumatoid arthritis, former osteoporosis treatment, 
glucocorticoid use >450 prednisone eq., family fracture history, current smoking, exercise level, prevalent alcohol related diagnoses 
8 Five-year age, gender, and race/ethnicity, as indicated by inpatient medical files (White, non-White, and unknown), and the following: age in years, self-reported 
race/ethnicity, and type of interview (in person vs. over the telephone). 
9 Age, race, BMI 
10 Adjusted for age, race, clinic 
11 Age, sex, diabetologist care, depression, chronic kidney disease, peripheral vascular disease, heart failure, hyperlipidemia, obesity 
12 Age, race, sex, clinic site, and total hip BMD 
13 Age, gender and race/study center, body mass index, sports-activity tertile, alcohol consumption, cigarette smoking, and medication use. 
14 Gender, race-ethnicity, age, calendar year, urban/rural, geographic location, median income, previous fracture, other predisposing conditions (glucocorticoid related, fall-
related, renal disease, depressive illness, AMI, other heart disease, bone disease, cancer) 
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Non-vertebral fractures meta-analysis results  
 
Overall risk  
The risk of non-vertebral fractures was increased in diabetes (RR1.20 95%CI 1.14-1.27) and 
heterogeneity was not significant (I2 15.3%, p=0.2) (Figure 3-16). Seventeen studies were 
included in this analysis, reporting data from 2,982,622 participants, 414,195 with diabetes 
and 185,363 fractures. Several subgroup analyses were anticipated in the protocol, however, 
due to the lack of data (as few studies reported specific subgroup risks), it was not possible 
to conduct age, DM type and BMI subgroup analyses.  
 
 
* Summarised using random-effects model 






NOTE: Weights are from random effects analysis
















































































































Subgroup analysis by gender 
The risk of non-vertebral fractures was similar in male (RR 1.14, 95%CI1.03-1.27) and female 
(RR 1.19, 95%CI 1.13-1.26). No heterogeneity was observed (I2 0.0% P=0.7) (Figure 3-17).  
 
 
* Summarised using random-effects model 
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Subgroup analysis by Insulin use  
The risk of non-vertebral fractures was higher in insulin users (RR1.59 95%CI 1.23-2.07) than 
in non-insulin users (RR1.02 95%CI 0.93-1.12). This analysis included eight studies. 
Heterogeneity was high (I2 78.1%, p<0.001) (Figure 3-18). 
 
* Summarised using random-effects model 
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Subgroup analysis by DM duration  
The risk of non-vertebral fractures was higher in previously diagnosed diabetes (RR 2.14 
95%CI 1.72-2.65) than in newly diagnosed diabetes (RR1.09 95%CI 0.69-1.73), (RRR 0.51 
95%CI 0.31-0.85). Four studies were included in this analysis and high heterogeneity was 
observed (I2 81.3%, p<0.001) (Figure 3-19). 
 
 
* Summarised using random-effects model 
Figure 3-19 Forest plot risk of non-vertebral fractures in diabetes by DM duration 
 
 
Subgroup analysis by geographical location  
The analysis by geographical location showed similar RR for non-vertebral fractures in Europe 
(RR 1.23 95%CI 1.11-1.36), America (RR 1.23 95%CI 1.14-1.32) and Asia (RR 1.16 95%CI 1.05-
1.28). The unique study from Oceania, an Australian study, reported a significantly lower RR 
(RR 0.90 95%CI 0.69-1.18) (Figure 3-20). 
NOTE: Weights are from random effects analysis
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* Summarised using random-effects model 
Figure 3-20 Forest plot risk of non-vertebral fractures in Diabetes by geographical location 
 
Non-vertebral fractures sensitivity analysis  
We ran the analyses excluding one study at a time and no important variation was observed 
in the results. The RR varied from RR 1.19, 95%CI 1.13-1.26 to RR 1.23, 95%CI 1.15-1.31 and 
the heterogeneity remained low, from 0.6% to 23.8%, suggesting that no study had an 
important individual impact in the results. In additional analysis, no important variation was 
observed when excluding the case-control study (RR 1.20, 95%CI 1.14-1.27) or the study from 
Australia (RR 1.20 95%CI 1.15-1.26). We also excluded each kind of risk estimate (i.e. RR, OR) 
with no important impact in the result, with the RR varying from RR 1.18, 95%CI 1.12-1.25 to 
RR 1.22, 95%CI 1.15-1.29.  
 
Funnel plot  
Visual analysis of the funnel plot suggested publication bias (Figure 3-21). The Egger’s test 
resulted in p=0.013 and the Begg’s test p=0.018 also suggestive of publication bias. As the 
heterogeneity was low and the studies had diverse sample sizes we applied the Trim and Fill 
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correction. The method removes small studies causing asymmetry, estimate the number of 
missing studies and add them and the estimates of their effect (147). Consequently, the 
method provides a RR for a symmetrical funnel plot, as if there was no publication bias. The 
Trim and Fill method included six hypothetical studies (Figure 3-22) and resulted in a RR 1.17, 
95%CI 1.10-1.24, similar to the original results (RR 1.20 95%CI 1.14-1.27), suggesting that the 
publication bias did not have an important impact in the results.  
 
Figure 3-21 Funnel plot of the original studies included in non-vertebral fractures analysis 


























Figure 3-22 Funnel plot after Trim and Fill correction in non-vertebral fractures analysis. 
The yellow dots are the included by the Trim and Fill method (1%, 5% and 10% shows the levels of significance).  
 
Discussion  
There is an increase in the risk of hip and non-vertebral fractures in diabetes, especially in 
insulin users. At the hip, the risk is higher in the younger population, females, T1D and those 
with longer disease duration. 
 
Mechanism for increased risk of fracture 
The increase in the risk of fractures in diabetes is multifactorial. Falls are probably a main 
feature. DM is associated with an increased risk of falls (93, 148, 149). Within the diabetic 
population, the risk of falls is higher in those in insulin use, those with MVD and in those with 
hypoglycaemic episodes (150-152). Bone features are also important. BMD can predict 
fractures in people with diabetes (20), however, on average, BMD is decreased in T1D and 
increased in T2D (84). Conversely, the risk of fractures is increased in both diabetes types, 
suggesting that BMD is not an important determinant of bone fragility in diabetes (153). 
These findings suggest that bone quality, rather than BMD, could be affected by diabetes. 
Several studies have investigated bone microarchitecture in diabetes and the results are not 
























described in patients with diabetes compared to patients without diabetes (25-28, 31, 32, 
154). The studies that showed favourable bone microarchitecture in the diabetes group 
reported data from cohorts with short diabetes duration and good metabolic control (31, 
154). Conversely, Shanbogue reported unfavourable microarchitectural findings in 
participants with microvascular complications (MVD) both in T1D and T2D (25, 28). 
Nonetheless, studies that compared people with diabetes with and without fractures 
reported increased cortical porosity especially in the tibia in the group with previous fractures 
(29, 32). Although more data is needed to clarify how microarchitecture influence the risk of 
fractures in diabetes, so far, evidence suggest that the abnormalities in the cortical 
compartment, especially cortical porosity, mighyt be involved.  
Bone strength in diabetes has also been investigated using reference point indentation. A 
small cohort of postmenopausal women with diabetes (n=19) showed that BMSi was 9.2% 
lower in the women with diabetes than in the controls and it was inversely associated with 
the duration of the disease (33). A population-based cohort study including 51 participants 
with T2D and 483 controls, also reported lower BMSi in the group with T2D, despite 
favourable aBMD and microarchitecture (31). These findings suggest that diabetes might 
affect bone material properties, independently of aBMD or bone microarchitecture.  
Chronic hyperglycaemia favours non-enzymatic reactions between proteins and glucose 
producing AGEs. In animal models, the accumulation of AGEs affected bone material and 
biomechanical properties (155). Pentosidine is the most widely investigated AGE. The analysis 
of hip replacement samples has shown higher pentosidine content in trabecular and cortical 
bone of people with diabetes (156). In addition, serum and urinary pentosidine were 
associated with higher risk and prevalence of fractures (49, 157). These findings suggest that 
chronic hyperglycaemia might affect bone material properties.  
Finally, antidiabetic drugs might also affect the risk of fractures in diabetes in several ways. In 
vitro evidence suggested an osteogenic effect of metformin and data from cohorts showed a 
neutral or positive effect on the risk of fractures (158-160). Sulfonylureas have no direct effect 
on bone but they were associated with an increase in the risk of fractures, probably due to 
hypoglycaemia episodes and falls (161). Conversely, data on incretin mimetics are 
inconsistent. A meta-analysis that investigated the risk of fractures associated with the use of 
glucagon like peptide 1 (GLP-1) reported a decrease in the risk of fractures with liraglutide, 
but an increase with exenatide (162). Furthermore, another meta-analysis that investigated 
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the effect of  dipeptidil peptidase 4 (DPP-4) inhibitors on the risk of fractures reported a 
protective effect (163). However, these meta-analyses are based on data from adverse events 
reports in clinical trials and the results should be interpreted with caution. Thiazolidenediones 
increase adipogenesis and impair osteoblastogenesis and were associated with an increase in 
the risk of fractures (161, 164). More recently, the sodium/glucose co-transporter2 inhibitors 
(SGLT2) canaglifozin was also associated with an increase in the risk of fractures (165). 
However, empaglifozin and dapaglifozin seem not to affect bone metabolism (161).  Insulin 
use was also associated with an increased risk of fractures (91, 93, 129, 160). This finding is 
probably associated with insulin indications in diabetes treatment and adverse effects, rather 
than with the actions of the drug. T1D patients are always treated with insulin. Furthermore, 
T2D patients using insulin are more likely to have diabetes complications and longer disease 
duration. Regardless of diabetes type, insulin users are more likely to be affected by 
hypoglycaemia than non-insulin users (161).  
 
Comparison to prior studies 
In 2007, two comprehensive meta-analyses investigated the risk of fractures in diabetes and 
reported similar results (10, 84); while the risk of hip fractures varied from 38 to 70% in T2D 
the risk reached a 6-fold increase in T1D. There was no increase in the risk of vertebral 
fractures. Since then, other meta-analyses have addressed the issue but in a less 
comprehensive approach.  Fan et al investigated the risk of hip fracture, and also reported a 
higher risk in T1D (5-fold increase) than T2D (34% increase) (86).  Dytfeld et al investigated 
the risk of hip and vertebral fractures in postmenopausal women with T2D and found a 26% 
increase in the risk of hip and no increase in the risk of vertebral fractures in this population 
(13). Conversely, Shah et al investigated the risk of fractures in T1D and reported a 3-fold 
increase in the risk of hip fractures, a 2-fold increase in the risk of spine fractures and a 3-fold 
increase in the risk of any fractures (14). Additionally, Vilaca et al investigated the risk of 
peripheral fractures in diabetes and reported an 30% increase in the risk of ankle fractures 
and a 15% decrease in the risk of wrist fractures (166). Recently, Wang et al investigated the 
risk of fractures in several sites assessing data from cohort studies. This study reported an 
increase in the risk of total, hip, upper arm and ankle fractures in diabetes but no increase in 
the risk at distal forearm and vertebra (85).  
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Our meta-analysis results are consistent with previous meta-analyses as we reported an 
overall 52% increase in the risk of hip fractures  (10, 13, 84-86), with a significant 37% increase 
in the risk in T2D and a substantial 4 -fold increase in T1D. The risk in T1D is approximately 
double the risk observed in rheumatoid arthritis (RR 2.41 95%CI 1.83–3.17) and with 
glucocorticoid use (RR 2.01 95%CI 1.74–2.29) conditions known to affect the risk of fractures 
and for which guidelines recommend specific approaches (167, 168).  
 
Burden of the disease 
Although the magnitude of the increase in the risk of fractures is different in each diabetes 
type, we estimate that the increase in the number of fractures in both populations is clinically 
relevant. The increase in the risk is smaller in T2D, but around 90% of the diabetic population 
is affected by this type of the disease. Conversely, there is a 4-fold increase in the risk in T1D, 
but this corresponds to less than 10% of the diabetic populations. According to the Clinical 
Practice Research Datalink (CPRD), in the population older than 50 years the incidence of hip 
fractures in the UK was 22.4/10,000 person-year from 1988-2012 (169). Considering that the 
prevalence of diabetes in the UK is 7.7% and that 10% of this population is affected by T1D, 
in a population of 1,000,000 people, 7,700 would have T1D and would suffer 83 hip fractures 
in one year (76). The same number of people without diabetes would suffer 17 fractures at 
the same time. Furthermore, in this 1,000,000 population, 69,300 would be affected by T2D 
and would suffer 202 hip fractures, while the same number of people without diabetes, would 
suffer 155 fractures. These estimates showed that the number of fractures associated with 
T2D is higher (202 in T2D and 83 in T1D), but the excess of fractures is higher in T1D (47 in 
T2D and 66 in T1D; 40% higher in T1D). Regardless of diabetes type, there is an excess of 
fractures that brings additional burden to patients and healthcare systems.  
 
Greater increase in fracture risk in T1D compared to T2D 
The greater increase in the risk of hip fractures observed in T1D also agrees with all the 
previous meta-analyses that investigated the risk of hip fractures in both types of diabetes 
(10, 84-86). A number of features contribute to this finding. Firstly, insulin has an anabolic 
effect in bone and T1D is characterised by a lack of endogenous insulin. Although treatment 
aims to restore glucose homeostasis, it is possible that some degree of insulin deficiency could 
affect bone health. Secondly, T1D often is diagnosed in childhood or adolescence and might 
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compromise the peak of bone mass accrual. Bone mass is not affected in children with newly 
diagnosed diabetes (170), but bone accrual is compromised in children with poor glycaemic 
control as early as one year after diagnose (171). In addition, T1D children with fractures had 
poorer glycaemic control and lower total body BMD (172). A meta-analysis that assessed BMD 
in T1D reported significantly lower BMD at total body and femur in T1D despite gender or 
age. At the spine, BMD is decreased in female younger than 20 years old and any age males 
(17). These findings suggest that early onset T1D might compromise bone quantity and 
contribute to the substantial increase in the risk of fractures in this population.  Finally, insulin 
treatment is associated with higher risk of hypoglycaemia and hypoglycaemic episodes are 
associated with higher risk of falls (173).  




In contrast with other studies, we reported a greater increase in the risk of hip fractures in 
women (77%) than in men (35%). This is probably a reflection of the greater number of studies 
included in this meta-analysis (n=37) compared with a maximum 25 studies in previous 
reviews (85). The bigger number of studies probably gave this analysis enough power to 
detect the difference. In the analysis of non-vertebral fractures, the risk was similar for men 
and women.  As the number of studies involved in the non-vertebral fractures analysis is 
smaller (n=17) it is not possible to know if the effect of gender is different at each site or if 
the non-vertebral fractures analysis did not have enough power to detect an eventual small 
difference.  
This is the first meta-analysis to assess the effect of age, insulin use, diabetes duration and 
BMI in the risk of fractures in diabetes. In the hip fractures analysis, we found a greater 
increase in the relative risk of fractures in people with diabetes younger than 65 years old, 
than in the population older than 65 years old. When stratified by age range, the risk was 
higher in younger age and decreased progressively to reach no increase in the risk in those 
older than 80. A number of features might contribute to this finding. Data from NHANES 
reported that the mean age of T2D diagnosis in 2000 was 46 years (174). Consequently, the 
younger population, especially population under 50 years old, is likely to include a higher 
proportion of T1D patients. The mean age of a hip fracture in general population is around 80 
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years-old  (175, 176) and the absolute risk of fractures varies widely across the different age 
ranges. Data from the Clinical Practice Research Datalink (CPRD), a dataset representative of 
the UK population reported that the incidence of hip fractures from 1988-2012 in the 
population aged 18-49 years was 1.0 /10,000 person-year (1.4 /10,000 person-year in men 
and 0.6 /10,000 person-year in women). At 80-84 years old, the incidence was 70.0/10,000 
person-year (40.1/10,000 person-year for men and 89.4/10,000 person-year for women) 
(169). The incidence of hip fractures in the younger than 65 years old is low (176). Considering 
that people with diabetes have an increase in the incidence of fractures, the impact on the 
relative risk will be greater when the basal incidence of fractures is lower, namely in a younger 
age-range (177). As the population at risk gets older, two concomitant phenomenon impact 
in the risk. On one side, as the population gets older and the background risk of fractures 
increases, the additional risk associated with diabetes play a less important role. In addition, 
diabetes is associated with a decrease in life expectancy. Estimates suggest that T2D 
decreases the life expectancy in 10 years and T1D decreases the life expectancy in 20 years. 
Estimates also suggest that half of the deaths associated with diabetes occurs before the age 
of 70 (75). Hence, we speculate that it is possible that the high mortality associated with 
diabetes would impact the risk of fractures in this disease, as some people with diabetes 
would not be at risk of hip fractures due to premature mortality (178).  
Since meta-regression showed that age and diabetes type account for more than 80% of the 
variation in the risk of hip fractures in diabetes, we tried to conduct the subgroup analysis by 
age in each diabetes type. The number of studies was small, as not many studies reported the 
stratified risk estimates, but the risk seemed similar in T1D until the age of 70, when there is 
a decrease in the magnitude of the risk (Figure 3-8). As previously discussed, life expectancy 
is decreased in T1D and we speculate that premature mortality might have an impact in this 
risk. There were not enough data to perform the age range analysis in T2D. 
The subgroup analysis by BMI showed no difference between the groups. The number of 
studies was small and the confidence intervals overlap, but the forest plot showed a trend to 
a decrease in the RR of hip fractures with the increase in BMI. It is known that obesity is 
protective against hip fractures (179). Mechanical and endocrine mechanisms lead to an 
increase in BMD and also fat has a cushion effect during the fall, protecting against the 
fracture (67). It is also known that obesity is highly prevalent in T2D. Data from the US 
reported that 85% of people with T2D are overweight or obese (180). Despite the high 
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prevalence of obesity in T2D, overall the risk of fractures is still increased in this population. 
The mechanisms that lead to the increase in the risk of fractures in diabetes are not fully 
elucidated so it is not possible to understand how these mechanisms interact with the 
mechanisms that decrease fractures in obesity.  
There was a 59% increase in the risk of non-vertebral fractures and a 2-fold increase in the 
risk of hip fractures in insulin users. This risk is higher than the overall risk in diabetes and it 
is also higher than the risk in non-insulin users.  This increased risk probably does not reflect 
an effect of insulin on bone but its indication and adverse effects. Insulin is the treatment 
used in T1D and data previously discussed suggest that this population has a greater increase 
in the risk of fractures within the population with diabetes. T2D can also be treated with 
insulin. However, in T2D, insulin is only used when other oral medications fail in achieving 
appropriate metabolic control. Consequently, T2D patients who use insulin are more likely to 
be affected by more severe diabetes, more likely to have diabetes for longer than non-insulin 
users and more likely to suffer from complications such as neuropathy, nephropathy and 
retinopathy. Retinopathy and neuropathy increase the risk of falls and nephropathy can lead 
to chronic kidney disease, which also increase the risk of fractures (173). In addition, people 
with diabetes treated with insulin have an increased risk of falls and fall related fractures 
(181). Lee et al,  reporting data from a cohort with more than 650,000 male veterans older 
than 65 years,  found an increase in the risk of fractures in T2D insulin users (160). 
Furthermore, there was a significant interaction with HbA1C levels.  The increase in the risk 
of fractures in insulin users was greater in individuals with HbA1c < 6.5% suggesting that a 
tight glycaemic control might have adverse effect as it increases the risk of falls and 
consequently fractures (160). Conversely, Jensen, 2019, reporting data from a Danish 
database, showed that hypoglycaemia but not insulin was associated with an increase in the 
risk of fractures in T1D (182). In this study, based on registry data, 3% of all fractures in T1D 
were preceded by a hypoglycaemia episode. These findings suggest that hypoglycaemia and 
falls might play an important role in the risk of fractures associated with insulin use.  
The subgroup analysis by diabetes duration showed a greater increase in the risk of fractures 
with longer diabetes duration both for hip and non-vertebral fractures. In the newly 
diagnosed group, probably there was not enough time for the harmful mechanisms 
associated with bone fragility in diabetes to act. In addition, in the T2D group, as obesity is 
the most important risk factor for T2D, the newly diagnosed diabetic population may be under 
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the protective effect of body weight excess on the risk of fractures. At the hip, the analyses 
showed a progressive increase in the risk with greater disease duration. People with longer 
disease duration have a longer exposure to hyperglycaemia and potentially harmful 
antidiabetic treatments. In addition, the likelihood of diabetic microvascular complications, 
and its harmful effects already discussed, also increases.  
 
Heterogeneity  
We found high heterogeneity in our analysis. Heterogeneity reflects the differences between 
studies (101). We included data from men and women, from 18 to 100 years old, with T1D 
and T2D so there was high clinical diversity. In addition, data came from prospective and 
retrospective cohorts and case-control studies, from recruited participants and registry data, 
adding substantial methodological diversity as well. Consequently, we expected that the 
effect size would vary between studies and to account for this variability, we used the random 
effects model in the analyses. We also explored this diversity using subgroup analysis, 
sensitivity analysis and meta-regression. These features should be considered while 
interpreting the results. Although we found a 52% increase in the risk of hip and a 20% 
increase in the risk of non-vertebral fracture in diabetes, this is an overall estimate. The risk 
will vary according to gender, age, diabetes type, diabetes duration and treatment. Although 
this is not the exact risk for a given patient, it is clinically useful to know that the risk is 
increased in people with diabetes and that this risk may vary, on dependence of individual 
characteristics.  
 
Clinical approach to fracture prevention 
The criteria to establish osteoporosis diagnosis in diabetes is the same as in the general 
population, based on the presence of fragility fractures and/or low BMD. BMD is one of the 
main tools used to predict the risk of fractures in clinical practice, however, BMD 
underestimates the risk of fractures in diabetes. Overall people with diabetes suffers a 
fracture with a BMD 0.5 standard deviation higher than people without diabetes (20). 
Furthermore, so far, FRAX, another fracture prediction tool used worldwide to estimate the 
risk of hip and major osteoporotic fractures, does not include the risk of fractures associated 
with diabetes in its calculation.  Evidence suggest that FRAX also underestimates the risk of 
fractures in diabetes (20, 183). The IOF Bone and Diabetes Working group acknowledge these 
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evidences. A recent report suggested that patients with diabetes should be considered for 
treatment at more favourable FRAX and BMD values than patients without diabetes (159). 
The IOF Working Group report suggested that the BMD intervention threshold should be at a 
T-score of -2 at spine or hip in western populations (159). The current risk calculated by FRAX 
should also be adjusted. Some evidence suggested that having T2D is equivalent to adding 10 
years of age or reducing the BMD T-score by 0.5 standard deviation (20).  The Workgroup 
considers that the FRAX risk assessment should be adjusted for T2D and despite limitations, 
they recommend that risk associated with T2D should be substituted by the risk associated 
with rheumatoid arthritis in the current version of FRAX (159). In addition, patients with bone 
loss greater than 5% in two years should be considered for treatment especially when 
measurements are close to the intervention threshold.  
There is no specific treatment for bone fragility in diabetes. As the risk of fractures seems to 
be associated with poor glycaemic control (144) and diabetic complications (64, 90), adequate 
metabolic control is advisable. However, the risk of hypoglycaemia should be considered, 
especially in the elderly. Two cohorts have assessed the relationship between the risk of 
fractures and metabolic control in elderly populations (160, 184). Lee et al assessed male 
veterans and reported an increase in the risk of fractures both at HbA1c< 6.5% and HbA1c> 
9.0% (160). Conversely, Conway assessed a geriatric cohort and reported the lower risk of 
fractures in the group with HbA1c 6.5-6.9%, and no significant risk increase at other HbA1c 
groups (184).  A tight metabolic control increases the risk of hypoglycaemic events. A number 
of studies have reported an increased risk of fractures associated with hypoglycaemia (173, 
181, 182). Recently, the European Association for the Study of Diabetes (EASD) and the 
American Diabetes Society (ADA) guidelines have recommended a less strict glycaemic 
control in the elderly, to avoid hypoglycemic events and falls (185). Therefore, adequate 
metabolic control is the treatment target, but tight metabolic control should be avoided.  In 
addition, antidiabetic medications with unfavourable effect on bone metabolism should be 
avoided in patients with diabetes and bone fragility (159). 
So far, no trial was developed to assess specifically the efficacy of anti-osteoporotic 
medications in diabetes. The available data from existing studies showed similar effect in 
people with and without diabetes in regards to BMD increase and anti-fracture efficacy with 
alendronate, risendronate and teriparatide (186). Although in a post-hoc analysis of one trial, 
raloxifene was more effective in reducing vertebral fractures risk in T2D than in 
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postmenopausal women without diabetes, overall no difference was observed in the anti-
fracture potential of raloxifene in the two groups. A systematic review in the topic concluded 
that diabetes did not seem to affect the fracture preventive potential of bisphosphonates 
(alendronate and risedronate), raloxifene or teriparatide (186). However, most of the data 
available assessed postmenopausal women with T2D and additional data about anti-fractures 
efficacy in other groups such as males and younger populations is required. Although 
denosumab is a potential treatment option, especially in the subgroup with impaired renal 
function, there is no specific data on the efficacy of denosumab in diabetes (159).  
 
Strengths and weaknesses 
This study has several strengths. This is the most comprehensive review on the risk of hip 
fractures, with the greater number of studies and most comprehensive subgroup analysis 
pooled so far. This is the first systematic review and meta-analysis on the risk of non-vertebral 
fractures in diabetes. A large number of studies were included and overall the quality of the 
studies was good. The high heterogeneity found in the hip fracture analysis was extensively 
explored by subgroup, sensitivity analysis and meta-regression.  
However, this study also has limitations. This is a systematic review and meta-analysis update, 
so we relied on the search done by the previous systematic review (10). The initial study 
sifting, based on title and abstract was done by one reviewer but the random 10% double 
sifting kapa statistic for agreement was perfect. We could not investigate the effect of other 
features that affect the risk of fractures in diabetes such as BMD, falls and the competing risk 
of death. In addition, we could not investigate the effect of some features associated with 
diabetes such as metabolic control, the presence of microvascular complications, the effect 
of anti-diabetic drugs and hypoglycaemia in the risk of fractures. 
 
Conclusion 
This meta-analysis highlights the complexity of the assessment of the risk of fractures in 
diabetes. Although the mechanisms are not fully established, it is clear that people with T1D 
is the population at higher relative risk. Despite growing evidence on the increased risk of 
fractures in diabetes, the skeleton is not widely recognised as a site for diabetic complications. 
A review in diagnosis and management of bone fragility in diabetes by the IOF Bone and 
Diabetes Working group is the current guidance in how to manage these patients (159). 
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However, there is limited data on the assessment of fracture risk, the impact of the increased 
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There is an increase in the risk of hip fractures in diabetes, but the risk is less well described 
for other skeletal sites (10, 84). A number of cohorts have reported an increase in the risk of 
fractures in several sites in diabetes (139, 142, 152) . The Women’s Health Initiative study 
showed an increased risk of any fracture and all the other fracture sites evaluated, except 
lower arm/wrist/hand in postmenopausal women (139). The majority of the participants 
were white, but other ethnic groups such as Black, Hispanic and minorities were also included 
(139). In elderly men, the risk of non-vertebral fracture is increased in models adjusted for 
age, race, clinic site and total hip BMD. However, in the further adjusted model, the risk 
remained increased only in insulin users (142). Diabetic men have higher BMD but lower bone 
strength and lower resistance to fractures (146). Conversely, a biracial cohort of diabetic 
elderly men and women reported a 64% increase in incident clinical fractures after 
adjustments for BMD and body composition features such as lean and fat mass, but no 
additional risk was associated with insulin use (152). Several small studies have reported 
different findings, but meta-analyses have agreed that there is an increase in the risk of hip 
fracture, in T1D and T2D (10, 12-14, 84). Results are less consistent for other skeletal sites. 
The risk of any fracture is increased in T1D (14) and T2D (10, 84). Shah  et al. reported an 
increase in the risk of vertebral fractures in T1D (14), but there was no significant increase in 
T2D (10, 13, 84). Previous evaluation of specific sites such as the distal forearm, ankle, 
proximal humerus in T2D showed significant increase only at the foot (10). More data are 
required to establish the site-specific risk of fractures in this population.  
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The increase in the risk of fractures in diabetes is not directly associated with BMD (84). The 
risk of fractures is increased in T1D and T2D, but BMD is decreased in T1D, and increased in 
T2D (17, 84, 144). The increased risk of fractures in T1D is greater than would be expected for 
the decrease in BMD, suggesting that other features (such as bone quality, increased fall risk 
or altered biomechanics) might play a role. Despite increased BMD in T2DM, BMD is still able 
to predict fracture risk, but for a given T-score, people with diabetes have a higher risk of 
fractures than people without the disease (20). Conversely, for a similar fracture risk, women 
and men with diabetes have a higher BMD than people without the disease (20, 142). 
Therefore, BMD does not fully reflect bone fragility in diabetes. 
Diabetes and osteoporosis are both major public health concerns. In 2015, the global 
prevalence of diabetes was 8.8%, and estimates suggest that it will reach 10.4% in 2040 (1). 
Type 2 diabetes (T2D) is the most common form of the disease, accounting for 90% of cases. 
Osteoporosis is estimated to cause 9 million fractures annually worldwide, resulting in 
significant disability (187). Both diseases affect mainly the elderly, their prevalence is 
increasing worldwide, and both are associated with significant morbidity and mortality (1, 
187).  As life expectancy is increasing, the prevalence of both diabetes and osteoporosis is 
expected to rise, increasing the burden for health care systems. 
Although hip fracture risk is increased in patients with diabetes, the mechanisms associated 
with bone fragility in this population are not established. Investigations so far suggest that 
accumulation of advanced glycation end-products (AGEs) and low bone turnover may impair 
bone material quality (188). Microarchitectural assessments have identified structural 
abnormalities (188). High-resolution peripheral computed tomography (HR-pQCT) was used 
to evaluate microarchitecture at the ankle and the wrist. Several studies reported a decrease 
in volumetric bone mineral density (vBMD) and an increase of cortical porosity (25-29).  To 
evaluate if there is a clinical consequence for these microarchitectural abnormalities, we 




PRISMA-P was used to develop the protocol, and PRISMA statement was used as a guidance 
(189). One reviewer searched databases like Medline, EMBASE and LILACS in March 2017. 
“Diabetes mellitus”, “fracture”, “ankle”, “wrist”, “radius” and “forearm” were used in the 
 148 
research. There were no limits in regards to languages or date of publication. In order to 
capture all the available information, studies that reported the risk of fractures in adults (>18 
years) with diabetes (type 1 and type 2) compared with healthy controls were included.  
Additionally, we reviewed references from relevant published papers. Studies were excluded 
if they included children, had unclear diabetes diagnosis criteria, did not have a comparison 
group without diabetes or if it was not possible to extract or calculate the relative risk for 
fractures. 
We extracted the data using a piloted questionnaire in Google Forms. For each study, data on 
the first author’s name, country, year of publication, study design and name, source of  
funding, source and age of population, numbers of exposed and unexposed subjects, 
numbers of events in each group, follow-up period (in cohorts), type of diabetes, gender, risk 
estimates and corresponding confidence intervals, possible confounders, and factors 
controlled for by multivariable analysis were extracted. If the relative risk was not reported, 
but there were enough data for adequate calculations, the risk was calculated using standard 
formulas. 
The Newcastle-Ottawa quality assessment tool was used (190). Specific questionnaires were 
applied for cohorts and case-control studies. We used funnel-plots to evaluate publication 
bias.  
The studies were grouped in meta-analyses, using the random-effects model. Adjusted 
relative risks controlling for potential confounders such as age, gender and race were 
combined using Stata version 14 (Stata corporation, College Station, Texas). As just a few 
studies adjusted the risk for weight or body mass index (BMI) and BMD, which were 
potentially the most important confounders, these adjustments were excluded. 
 
Results  
The research process is summarised in Figure 4-1. Initial electronic searches resulted in 756 
citations. After the evaluation of inclusion and exclusion criteria, eleven articles were 
selected, six with data about ankle fractures (distal tibia and fibula) and ten about wrist 
fractures (distal radius and ulna). Data were described as relative risk in cohorts and odds 
ratio in case-control studies. As the frequency of fractures is low, odds ratio and relative risk 
can be assumed as reporting similar risk estimates (191). 
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The Newcastle-Ottawa toll was used to evaluate the studies’ quality. The studies had good 
quality and the scores varies from 6 to 8 (out of 9). Funnel plot evaluation revealed no 
publication bias.  
 
 
Figure 4-1 Research process flowchart (adapted from PRISMA diagram) 
 
Ankle fractures  
For ankle fractures, six studies were selected: five cohorts (115, 116, 137, 192) and one case-
control study (193). In the cohorts, the mean follow-up was 7.4 years (range 1.3 to 25 y). In 
the case-control study, for each case, three controls were selected (193). The age range was 
from 27 to 109 years. One study recruited participants from 27 to 61 years (115), another one 
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from 49 to 97 years (116). Pritchard et al. evaluated registry data from people older than 50 
years (193). The remaining three studies report data from people older than 65 years (93, 
137, 192).  Two studies reported data from the United States (137, 192), one from Canada 
(193), two from Sweden (93, 115) and one from Australia (116). Most of the studies reported 
data from white populations (93, 115, 116, 193). Where other ethnicities were included, less 
than 10% were black people and 2% were other ethnicities (92, 137). Three studies reported 
data from a registry (93, 137, 193) and three recruited participants (115, 116, 192).  Two 
studies reported data only from T2D (93, 192), while the others did not state the disease type 
(115, 116, 137, 193). Three studies excluded fractures associated with high-energy/trauma 
(115, 192, 193), while the three others (registry based), did not report the energy associated 
with the fractures (93, 116, 137). Two studies reported data just from women (192, 193), two 
reported the risk specifically for men and women (93, 115) and the two others did not report 
gender-specific risk (116, 137). In the three studies which reported BMI, it was on average 
10% higher in the group with diabetes (93, 192, 193). In three studies, there was a significant 
increase in the risk of ankle fractures in diabetes [RR 1.28 (CI 1.12- 1.47) (93); RR 1.34 (CI 1.30-
1.39) (137); RR 3.36 (1.58-7.15) for women (115)]. In the other three studies, the increase in 
the risk of ankle fractures in diabetes was not statistically significant [RR1.1 (CI 0.6-1.9)(116); 
RR 1.14 (0.93-1.38) (193); RR 1.22(0.76-1.97)(192). Two studies reported a higher risk in the 
insulin-user group RR 2.35 (1.04-5.28) (192) and RR 1.47 (1.24-1.76) (93). 
Data were summarised in a meta-analysis. Two studies are reported as unadjusted data (193) 
(93), the remaining data were adjusted for age (115, 192), age and gender (116), gender, race, 
age, calendar year, urban/rural area, geographic region and median income (137). The studies 
characteristics are listed on Table 4.1.  
When the data were pooled together, we found an increased risk of ankle fractures in people 
with diabetes (RR 1.30 95% CI 1.15-1.48) (Figure 4-2). Subgroup analysis found a higher risk 
in people with diabetes who used insulin (RR 1.56 95% CI 1.15 – 2.12) than the risk in non-
insulin users (1.24 95% CI 1.07-1.45). The meta-analysis summarises data from 2,137,223 
participants and 15,395 fractures.  
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Table 4.1 Ankle fracture study characteristics 
First 
author 
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2017 Sweden  FRAILCO Cohort 
study 
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Table 4.2 Wrist fracture study characteristics 
First 
author 
Year  Country 
of study 
Setting - 
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of study 
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Holmberg 1 women; Holmberg 2 men; NI non-insulin users; I insulin users;  
Figure 4-2 Forest plot risk of ankle fractures in diabetes 
 
Wrist fracture  
Of the ten wrist fracture studies selected, nine were cohorts, six prospective (41, 90, 93, 115, 
116, 192) and three retrospective (137, 194, 195), and one study was a case-control (141). The 
follow-up ranged from 1.3 to 25 years, and the mean was 7.6 years in the cohorts. Four studies 
reported data from the United States (137, 141, 192, 195), three from Sweden (41, 93, 115), one 
from the Netherlands (90), one from Canada (194) and one from Australia (116). Most studies 
reported data from white populations (41, 90, 93, 115, 116) while the North American ones 
included other ethnicities. One study included Canadian indigenous people (194), and two others 
included around 10% of Black people (137, 192). In one study, 20% were Asiatic, 15% Black and 






































10% Hispanic (141). In another, 66% were non-white (195), although it was not specified which 
ethnicities was included, due to non-availability of the data in the registry. In six studies 
participants were recruited (41, 90, 115, 116, 141, 192) and in four studies data came from a 
registry  (93, 137, 194, 195). The age of the participants varied from 20 to 109 years. Two studies 
reported data from young people, one from people older than 20 years (194) and the other from 
27 to 61 years (115). Two studies reported data from the fifth decade, one study observed people 
older than 45 years (141) and another older than 49 years (116). One study reported data from 
people older than 55 years (90) and another one older than 60 years (195). Four studies reported 
data from elderly people, three from 65 years (93, 137, 192) and one from people older than 75 
years (41). Three studies reported the risk for men and women (90, 93, 115), two reported data 
just from women (41, 192) and the other five did not state gender-specific risks (116, 137, 141, 
194, 195). The majority of the studies did not specify the type of diabetes, although three 
reported data just from T2D (90, 93, 192). Two studies reported the specific risk in insulin-users 
(93, 192).  In two studies, high-energy fractures were excluded from the analyses (115, 192), 
while the others made no distinction. Two studies reported a significant decrease in the risk of 
wrist fractures: Taylor et al. reported RR 0.95 (95%CI 0.93-0.98) (137) and Wallander et al. 
reported  RR 0.67 (95%CI 0.59-0.76) (93). In all the other studies the association was not 
significant: RR 0.73 (95%CI 0.38-1.41) for women and RR 0.46 (95%CI 0.21-1.04) for men (115); 
RR 0.70 (95%CI 0.20-2.30) (116); RR 0.86 (95%CI 0.65 – 1.15) (194); RR 1.40 (95%CI 0.81-2.41) 
(90), RR 0.83 (95%CI 0.56-1.22) for non-insulin-users and RR 1.43 (95%CI 0.71-2.88) for insulin-
users (192);  RR 1.05 (95%CI 0.99 – 1.10) (195); RR 0.74 (95%CI 0.45 – 1.21) (41); and OR 0.88 
(0.68- 1.16) (141). The studies characteristics are described on Table 4.2.  
All the studies were pooled in a meta-analysis. We found a significant decrease in the risk of wrist 
fractures [RR0.85 (95% CI 0.77 – 0.95)] (Figure 4-3). The risk was not decreased in insulin-users 
[RR 0.91 (95% CI 0.45-1.85)]. The analysis included data adjusted for age (90, 115, 192), age and 
gender (116), gender, race, age, calendar year, urban/rural area, geographic region, median 
income (137), age, gender and ethnicity (141) and unadjusted data (41, 93, 194, 195). However, 
sensitivity analysis of adjusted and unadjusted data showed similar patterns. This meta-analysis 
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reports data from 2,773,222 subjects and 39,738 fractures. The studies included men and 
women, from 20 to 109 years, the vast majority with type 2 diabetes.    
 
 
Holmberg 1 women; Holmberg 2 men; NI non-insulin users; I insulin users;  
Figure 4-3 Forest plot risk of wrist fractures in diabetes 
 
Discussion  
There is an increase in the risk of ankle fractures, and a decrease in the risk of wrist fractures in 
diabetes. Ankle and wrist fractures have distinct epidemiological patterns.  Ankle fractures are 
not considered typical osteoporotic fractures (196, 197). Having an ankle fracture is a predictor 
of a future fracture at other sites (197). However, the risk of an ankle fracture is not associated 
with low axial BMD, but with increased weight and BMI (196, 197). Overweight and obesity are 


















































highly prevalent in T2D, the main group evaluated in this study (1).  Interestingly, 
microarchitecture abnormalities without decreased BMD were previously associated with ankle 
fractures (198). Stein et all reported disrupted microarchitecture but no BMD abnormalities in 
postmenopausal women with ankle fractures (198). Microarchitectural abnormalities were 
observed mainly in the trabecular compartment. These abnormalities were more pronounced at 
the tibia, but also observed at the wrist. The authors argue that this finding could highlight 
underlying bone fragility despite relatively normal BMD. Cortical porosity was not associated with 
ankle fractures in this study (198).   
Conversely, wrist fractures are a major osteoporotic fracture. They account for up to 18% of all 
fractures in people older than 65 years, and can be the first clinical indicator of osteoporosis 
(199).  Bone density, geometry, microstructure and strength are all determinants of wrist 
fractures (200). Melton et al reported microarchitectural abnormalities in a wrist fracture 
population, and the deficit in trabecular bone was relatively greater than in cortical bone. Cortical 
porosity was similar in cases and controls and some analyses suggested that Colles’ fractures are 
associated with disruptions of trabecular architecture (200). Some evidence suggests that obesity 
decreases the risk of wrist fractures (201).  
The discordant pattern observed in this study might reflect the weight excess in the population 
observed. Although obesity is generally considered protective against fracture, the effect on 
fracture risk is site-dependent (188, 201). Several studies reported a decrease in the risk for 
femoral and wrist fractures and an increase for ankle and upper arm fractures (201). Obese adults 
have greater BMD than normal weight controls (67). Evans et al. reported favourable 
microarchitecture features such as increased cortical and trabecular BMD in obese people when 
compared to normal-weight adults (67). Non-bone features also play an important role. The thick 
soft tissue has a protective effect in absorbing the impact in hip fractures (201). Obese people 
tend to fall backwards or sideways, which might favour the occurrence of upper arm fractures 
over wrist fractures (201). On the other hand, an increase in the mechanical strain at the ankle 
has been reported (196).  
Hyperglycaemia is present in both T1D and T2D, but the pathophysiology of each type is different. 
T1D is characterised by insulin deficiency that often starts before the peak of bone mass accrual. 
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On the other hand, in T2D there is insulin resistance which starts most frequently in adulthood, 
although a trend for a precocious start has been observed recently. Obesity is also more frequent 
in T2D than T1D, although the prevalence of obesity in T1D has been rising, especially associated 
with intensive insulin therapy (202). These features contribute to the BMD pattern observed in 
diabetes. BMD is decreased in T1D and increased in T2D (84). In a meta-analysis that evaluated 
BMD in both types of diabetes, BMI was significantly associated with BMD in T2D but not in T1D 
(84). How all these different features impact in the risk of fractures is still to be defined. The 
increase in the risk is remarkably higher in T1D, but successive meta-analyses have described a 
progressive lower risk: from RR = 6.94 (95% CI 3.25-14.78) by Vestergaard in 2007 to RR=3.78 
(95% CI2.05-6.98) by Shah in 2015 (14, 84). The absolute risk in T2D is lower than T1D but 90% of 
people with diabetes have T2D, and there are estimates for an increase of T2D prevalence 
worldwide (1). This suggests that the majority of fractures associated with diabetes will affect the 
T2D population.   
Several studies have described microarchitecture in T2D, and non-favourable findings are 
observed in the cortical compartment (26-28, 31, 32). Two studies have reported an increase in 
cortical porosity at the radius (26, 28) and two others at the tibia (27, 32). Besides, the standard 
ultradistal site, Nilsson et al evaluated a more proximal section, located at 14% of the limb length 
(a site of mainly cortical bone) and found a decrease in cortical porosity at the radius (31). The 
diabetic groups evaluated are diverse, including people with different ages, disease duration and 
complications. All these features could contribute to the non-consistent findings and make 
difficult to establish a more specific pattern for the cortical compartment findings in this 
population.     
The fracture pattern observed in this study is similar to the pattern described in obesity, despite 
different microarchitectural findings in both diseases. In diabetes, the described pattern is a 
decrease in volumetric bone mineral density (vBMD) and an increase in cortical porosity (25-29). 
In obesity, Evans et al reported greater vBMD and lower cortical porosity (67). These findings 
suggest that microarchitecture is not the main determinant of peripheral fractures in these 
populations.  
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This study has limitations. A major limitation is the combination of type 1 and type 2 diabetes in 
the same analysis. T1D is associated with the lack of insulin and T2D with insulin resistance, with 
different consequences to bone health. However, few studies addressed specifically each type of 
the disease, preventing this analysis. Although men, non-white and T1D participants were 
included they account for the minority of the groups and this should be taken in account while 
evaluating the results. The majority of the participants were white postmenopausal women, a 
group especially susceptible to fractures. A large amount of data came from registry studies, 
which do not specify the population characteristics, and many potential confounders such as age, 
weight/BMI, type, duration and age of onset of diabetes, metabolic control, and the presence or 
absence of microvascular complications could not be addressed. Different factors were used to 
adjust the risk estimates in each study. Consequently, unadjusted data and data adjusted for 
different factors were used in this analysis. As just a few studies reported data adjusted for 
weight, these adjustments were excluded.  
High heterogeneity was found in both analyses. Heterogeneity is a measure of the variability 
between studies. This review included data from cohort and case-control studies, from recruited 
participants and registry data so methodological variability is expected. In addition, data from 
T1D and T2D was collected and the age range varied from 27 to > 90 years old so clinical variability 
was also expected. These data should be considered while interpreting the results. For ankle 
fractures analysis, the risk of fracture is increased by 30% in diabetes, but this risk is an overall 
estimate that might vary according to age, diabetes type and other features. Conversely, the risk 
of wrist fractures was decreased by 15% in diabetes, but this estimate might also vary in 
individual settings.  
It was desirable to pool together data from studies with adjustments for weight/ BMI and to 
compare them with the unadjusted ones to investigate the role of BMI in the association between 
diabetes and ankle/wrist fractures. However, this comparison was not possible as just two 
studies had this adjustment for the risk of ankle fractures (92, 193) and three for wrist fractures 
(90, 92, 93). The evaluation of data adjusted and unadjusted for weight could help to elucidate 
the amount that obesity contributes to fracture risk in diabetes.  
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Therefore, there are still important questions to be answered for bone health in diabetes. The 
site-specific pattern of fractures in people with diabetes is still being established. Also, 
investigations of the effect of many features, such as the type, age of onset and duration of the 
disease, the metabolic control and diabetic complications are ongoing. More information about 
the pattern of fractures in diabetes and how these individual features affect the risk of fractures 
in this population might help to understand how the diabetes affects the skeleton. This is 
important for planning management and designing adequate interventions. 
In summary, there is an increase in the risk of ankle fractures and a decrease in the risk of wrist 
fractures in diabetes, despite adverse microarchitectural properties at both sites. Obesity, which 
is considered protective against the most fractures, but increases the risk of ankle fractures, may 
play a role in these fractures pattern in diabetes, independently from microarchitecture. More 
studies are needed to clarify the features associated with the increased risk of fractures in the 













































Chapter 5  
 
 




















Diabetes and aBMD  
A number of studies have assessed aBMD in diabetes (17)(84, 171). Two meta-analyses have 
shown an increase in aBMD in T2D and a decrease in T1D (17, 84). This disparity might be 
associated with differences on the age of onset, pathophysiology of the disease and presence of 
comorbidities, such as obesity, as previously discussed (chapter 3). In T1D, the early onset might 
compromise peak bone mass accrual and hypoinsulinemia might affect bone quantity (17).     
 
Diabetes and bone microarchitecture  
Several studies have investigated bone microarchitecture in T2D and the results are conflicting, 
as previously discussed in chapter 1. Most of the studies were conducted in T2D and there is 
substantial design variability. Despite inconsistent data, these findings suggest that bone 
microstructure might be affected by diabetes. Several individual characteristics, such as sex, age, 
BMI, BMD and also features associated with diabetes such as age of onset, disease duration, 
severity, treatment, metabolic control and the presence of complications might influence bone 
microarchitecture. All these features could have affected the results and contributed to the 
conflicting findings.  
In T1D, data are rather scarce and only one previous study assessed T1D. Shanbhogue et al 
recruited 55 T1D patients, 29 without microvascular disease (MVD-) and 26 with microvascular 
disease (MVD+). The groups were compared to age, gender and height matched controls and also 
to each other. The study did not find significant differences in the comparison between MVD- 
and controls. However, when comparing MVD+ and controls, MVD+ had lower trabecular and 
cortical vBMD at the radius and also lower vBMD and lower cortical thickness at the tibia. There 
were no differences in cortical porosity. When comparing MVD+ and MVD -, MVD+ patients had 
lower vBMD, Tb.vBMD, Tb.Th at both the radius and tibia. At the tibia, there was lower cortical 
area, higher Tb.Sp and trabecular network inhomogeneity. All the differences persisted after 
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adjusting for potential covariates (ie, age, BMI, gender, menopausal status in women, duration 
of disease, and glycemic control). Noteworthy, MVD+ had lower total hip BMD than MVD- (25). 
These results suggest an impact of MVD on bone microarchitecture.  
Evidence in microarchitecture in diabetes, both type 1 and type 2 is not consistent. Most of the 
data come from studies in patients with T2D. In these studies, the most frequent finding was in 
cortical porosity (26-29, 32). Nilsson et al has investigated an additional site, the 14% length site 
in T2D and found an intriguing decrease in cortical porosity at this site (31). In order to investigate 
the cortical compartment more extensively in T1D we decided to add the assessment of the 14% 
site to this project.  
 
T1D and bone strength  
In T1D, Shanbhogue reported several unfavorable findings in MVD + compared to MVD- and 
these deficits resulted in lower estimates of bone strength (both total stiffness and failure load).  
However, there was no difference when comparing people with diabetes and matched controls 
(25).  
This conflicting evidence suggests that additional studies need to be done to assess bone strength 
in diabetes and also the effect of MVD.  
 
Background summary 
Despite conflicting evidence in microarchitecture and bone strength analysis in diabetes, several 
meta-analyses in literature and previous chapters in this thesis reported an increase in the risk of 
fractures in diabetes, especially in T1D. The previous study that assessed bone microarchitecture 
in T1D reported no difference between diabetes and matched control groups but unfavourable 
findings while comparing T1D MVD+ with controls and T1D MVD-. This evidence suggests a role 
for microvascular complications, but there are limited data addressing the issue.  
In addition, previous evidence has also shown that T1D is the group affected by the higher risk of 
fractures. Therefore, we speculated that determinants of the increase in the risk of fractures will 
be more evident in T1D than in T2D and we conducted a study investigating bone 
microarchitecture in T1D.  
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Research question and hypothesis  
 
Main research question:   
• Is there an impact of T1D on bone microarchitecture and is this influenced by the 
presence of neuropathy? 
 
Secondary research questions: 
• Is there an impact of T1D on bone mineral density (BMD) and is this influenced by the 
presence of neuropathy? 
 
Hypothesis  
Our hypothesis is that there is an impairment in bone microarchitecture in T1D and that the 





Participants were recruited according to the inclusion criteria detailed in chapter 2. Participants 
with T1D were evaluated for the presence of neuropathy and categorised in type 1 diabetes with 
neuropathy (T1DN+) and type 1 diabetes without neuropathy (T1DN-) groups, as previously 
described in chapter 2. Individuals without diabetes were recruited as controls.  
DXA was used to measure lumbar spine and total hip aBMD (Discovery A, Hologic Inc., Bedford, 
MA, USA). HR-pQCT was used to assess bone geometry and microstructure at the distal radius 
and distal tibia (XtremeCT, Scanco Medical AG, Zurich, Switzerland) (chapter 2). 
Microarchitecture was assessed at the standard site and at 14% bone length site (chapter 2).  
Micro finite element analysis was used to estimate bone strength at standard and 14% sites at 
the radius and tibia (version 1.13; FE-solver included in the Image Processing Language, Scanco 
Medical AG, Zurich, Switzerland) (Chapter 2). 
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Statistical analysis  
The three groups’ demographics were compared using the ANOVA test. For characteristics only 
relevant to the groups with diabetes, independent t-test was used. Results are described as mean 
and standard deviations (SD).  
Variables were tested for normal distribution using Kolmogorov- Smirnov test. Logarithmic 
transformation was tried but it did not result in normal distribution, especially for bone turnover 
markers. Since not all the variables had normal distribution, the Kruskal Wallis test was used in 
the analysis. Variables are described as median and interquartile range. For these analyses p<0.05 
was considered significant.  
 When the test reported a significant difference between the three groups, the Mann Whitney 
test was applied in each pair of groups to investigate the difference. As multiple tests increase 
the risk of false positive the Bonferroni correction was considered, resulting in a p value of 0.017. 




Sixty participants were recruited; 20 participants T1DN+, 20 T1DN- and 20 healthy controls 
(control). Groups were matched by gender resulting in 8 female trios and 12 male trios.  Individual 
matching for age, height and weight was not possible, but there were no significant differences 
between the groups on these features. The population characteristics are described in Table 5.1 
 
Table 5.1 Characteristics of the study population Mean (SD) 
 
T1DN+ T1DN- Control p  
N 20 20 20 
 
Age (y) 47.7 (11.0) 49.6 (13.1) 49.1 (12.5) 0.872 
Height (cm) 172.6 (8.2) 171.4 (10.3) 170.6 (9.7) 0.792 
Weight (kg)  77.6 (18.4) 72.9 (12.0) 71.4 (10.7) 0.358 
BMI (kg/m2) 25.9 (5.2) 24.8 (3.6) 24.4 (2.5) 0.486 
HbA1c  70.2 (14.3) 62.5 (14.6) 34.7 (3.2) <0.001 
Diabetes duration 28.9 (10.6) 24.1 (15.3) NA 0.108 
HESC1 54.7 (20.3) 78.2 (7.9) NA <0.001 
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T1DN+ T1DN- Control p  
FESC1 58.1 (25.6) 86.5 (4.9) NA <0.00 
TCNS 13.3 (5.7) 2.5 (1.7) NA <0.001 
DPN sural right conduction 
velocity2 
32.1 (17.9) 48.4 (4.2) NA <0.001 
DPN sural right amplitude3 3.6 (2.3) 11.7 (6.3) NA <0.001 
DPN sural left conduction 
velocity 4 
36.5 (23.4) 49.8 (5.8) NA 0.02 
DPN sural left amplitude5 3.6 (4.0) 10.4 (4.9) NA 0.001 
HESC Hands electrochemical skin conductance; FESC Feet electrochemical skin conductance; 
TCNS Toronto Neuropathy Clinical Score  
1 n=19 for T1DN+ 2n=14 for T1DN+; n=19 T1DN- 3n=17 for T1DN+; n=19 T1DN- 4n=8 for T1DN+; 
n=19 T1DN- 5n=11 for T1DN+; n=19 T1DN- 
 
 
aBMD results  
All participants were assessed at the hip and lumbar spine (LS). Bone mineral density, bone 
mineral content and each site areas were not different for lumbar spine (LS), femoral neck (FN) 
or total hip (TH) in the three groups (Table 5.2) (Error! Reference source not found.-Error! 
Reference source not found.).  
 
Table 5.2 aBMD results for T1DN+, T1DN- and control median (IQR) 
 
T1DN+ T1DN- Control p value  
L1-L4 AREA 61.7 (59.2,69.6) 63.7 (58.5,73.6) 65.6 (59.8,74.5) 0.622 
L1-L4 BMC 65.1 (53.9,75.5) 61.9 (52.3,79.8) 67.6 (50.3,74.2) 0.977 
L1-L4 BMD 1.0 (0.9,1.1) 1.0 (0.9,1.1) 1.0 (0.8,1.0) 0.605 
LS T-score -0.3 (-1.7,0.5) -0.7 (-1.7,0.1) -0.8 (-2.0, -0.2) 0.597 
LS Z-score 0.3 (,1.7,1.5) -0.5 (-1.2,1.1) -0.5 (-0.9,0.3) 0.759 
FN AREA 5.5 (5.0,6.0) 5.4 (5.0,5.8) 5.1 (4.9,5.8) 0.49 
FN BMC 4.0 (3.4,4.9) 4.4 (3.7,5.1) 4.0 (3.5,4.6) 0.376 
FN BMD 0.8 (0.6,0.8) 0.8 (0.7,0.9) 0.8 (0.7,0.8) 0.185 
FN T-score -1.2 (-2.0,-0.5) -0.7 (-1.5,0.0) -1.2 (-1.6,-0.6) 0.181 
FN Z-score -0.2 (-1.2,0.4) 0.0 (,0.6,0.7) ,0.4 (,0.6,0.1) 0.151 
TH area 42.9 (36.4,47.5) 40.9 (35.5,46.4) 40.8 (34.7,45.5) 0.814 
TH BMC 37.5 (31.8,46.5) 39.2 (32.8,48.3) 37.7 (30.2,44.0) 0.782 
TH BMD 0.9 (0.8,1.0) 1.0 (0.9,1.0) 0.9 (0.8,1.0) 0.518 
TH T-score -0.5 (-0.9,0.2) -0.2 (-0.7,0.6) -0.6 (-1.1,0.0) 0.423 





Figure 5-1 DXA a BMD A Total Hip B Lumbar Spine 
 
HR-pQCT results  
 
All the participants were assessed at the wrist and ankle. Nine standard radial scans were 
excluded due to movement artefacts (4 in the T1DN+ group, 4 in the T1DN- group and 1 in the 
control group). Nineteen 14% length radius site scans were not available due to technical issues 
(movement artefact or the 14% site was out of the scanning area - Figure 5-2). One 14% length 
tibia was not included due to movement artefacts.  
 
 
Figure 5-2 HR-pQCT 14% site scanning site could not be placed inside the scanning area 
Standard site  
At the standard site, in the analysis of the three groups, there was a significant difference in tibial 
cortical porosity (p= 0.028) and tibial connectivity (p=0.002) (Table 5.3). The comparison 
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between the groups has shown that T1DN+ participants had greater tibial cortical porosity (56% 
higher, p=0.009) (Figure 5-3) and greater tibial connectivity than T1DN- (125% higher, p=0.001) 
(Figure 5-4). Tibial connectivity was also greater in T1DN+ than in controls (80% higher, p=0.002). 





Table 5.3 HR-pQCT standard site results Median (IQR)  
 
T1DN+ T1DN- Control p 
value  
Tibia  











































Cortical thickness Ct.Th 1.2 (0.9, 1.3) 1.2 (1.0, 1.5) 1.2 (1.1, 1.4) 0.643 



































density (no units) 
1.7 (1.5, 1.8) 1.7 (1.5, 1.9) 1.9 (1.6, 2.1) 0.251 
Trabecular BV/TV (no 
units) 
0.2 (0.1, 0.2) 0.2 (0.1, 0.2) 0.1 (0.1, 0.2) 0.225 
Trabecular number 2.1 (1.6, 2.3) 1.9 (1.7, 2.2) 1.7 (1.6, 2.0) 0.251 
Trabecular thickness 0.1 (0.1, 0.1) 0.1 (0.1, 0.1) 0.1 (0.1, 0.1) 0.895 
Trabecular separation 0.4 (0.4, 0.5) 0.4 (0.4, 0.5) 0.5 (0.4, 0.5) 0.288 
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0.2 (0.2, 0.2) 0.2 (0.2, 0.2) 0.2 (0.2, 0.3) 0.126 
Connectivity Density 0.9 (0.7, 1.4) 0.4 (0.3, 0.7) 0.5 (0.4, 0.9) 0.002* 














4.8 (3.1, 6.64)  5.81 (4.14, 7.36) 0.028* 
T Mean cortical pore 
diameter (mm) Ct.Po.V 
0.2 (0.2, 0.2) 0.2 (0.2, 0.2) 0.2 (0.2, 0.2) 0.777 
SD of mean cortical pore 
diameter (mm) 
Ct.Po.Dm.SD 


























Estimated failure load 
(F.ult in kN] 
11.7 (9.6, 14.7) 12.1 (10.2, 15.4) 11.7 (9.4, 13.6) 0.698 
% trab distal load (%) 62.4 (57.8, 
69.6) 
57.1 (54.7, 66.3) 59.9 (52.3, 64.4) 0.37 
% trab proximal load (%) 39.4 (34.6, 
48.3) 
34.5 (32.4, 42.1) 35.6 (31.9, 39.9) 0.287 
Trab average von Mises 
stress (Tb.VM, in MPa) 
6.1 (5.6, 6.5) 6.1 (5.9, 6.5) 6.2 (6.0, 6.4) 0.849 
Cort average von Mises 
stress  (C.VM in MPa) 
8.6 (8.3, 8.8) 8.7 (8.6, 8.9) 8.7 (8.5, 8.8) 0.112 
Cortical area fraction 
(calculated) 
(Ct.Ar/Tt.Ar) 
0.2 (0.1, 0.2) 0.2 (0.2, 0.2) 0.2 (0.2, 0.2) 0.314 





17.4 (15.1, 23.3) 18.6 (15.7, 19.6) 0.314 
Radius  







Cortical area (cm2) 66.8 (53.4, 
73.3) 
68.1 (49.4, 73.8) 52.4 (46.5, 71.1) 0.516 
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T1DN+ T1DN- Control p 
value  

























Cortical thickness 0.8 (0.7, 0.9) 0.8 (0.6, 0.9) 0.7 (0.6, 0.9) 0.336 
Cortical perimeter 82.3 (74.6, 
89.9) 





























density (no units) 
1.6 (1.5, 2.2) 1.7 (1.5, 1.8) 1.7 (1.5, 2.0) 0.841 
Trabecular BV/TV (no 
unts) 
0.1 (0.1, 0.2) 0.1 (0.1, 0.2) 0.1 (0.1, 0.2) 0.931 
Trabecular number 1.9 (1.7, 2.2) 2.0 (1.8, 2.1) 2.0 (1.9, 2.1) 0.604 
Trabecular thickness 0.1 (0.1, 0.1) 0.1 (0.1, 0.1) 0.1 (0.1, 0.1) 0.656 
Trabecular separation 0.4 (0.4, 0.5) 0.4 (0.4, 0.5) 0.4 (0.4, 0.5) 0.814 
Trabecular 
inhomogeneity 
0.2 (0.2, 0.2) 0.2 (0.2, 0.2) 0.2 (0.2, 0.2) 0.65 
Connectivity Density 0.6 (0.4, 0.8) 0.4 (0.2, 0.6) 0.6 (0.4, 0.9) 0.101 










Cortical porosity (no 
units) 
0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.069 
Mean cortical pore 
diameter (mm) 
0.2 (0.2, 0.2) 0.2 (0.1, 0.2) 0.2 (0.2, 0.2) 0.446 
SD of mean cortical pore 
diameter (mm) 










78.6 (70.7, 87.3) 85.5 (70.9, 92.1) 0.716 









T1DN+ T1DN- Control p 
value  
Estimated failure load 
(F.ult in kN] 
4.7 (4.1, 5.8) 4.8 (3.6, 5.8) 4.9 (3.2, 5.6) 0.376 
% trab distal load (%) 58.2 (53.8, 
63.5) 
59.8 (54.9, 63.9) 58.3 (53.8, 66.2) 0.954 
% trab proximal load (%) 27.3 (17.9, 
32.3) 
24.0 (17.9, 30.2) 24.5 (18.5, 29.0) 0.804 
Trab average von Mises 
stress (Tb.VM, in MPa) 
5.5 (4.9, 6.0) 5.6 (4.9, 5.8) 5.2 (4.7, 5.7) 0.551 
Cort average von Mises 
stress  (C.VM in MPa) 
8.0 (7.8, 8.3) 8.1 (7.8, 8.2) 7.8 (7.6, 8.2) 0.246 





18.7 (15.5, 23.2) 16.2 (14.1, 21.3) 0.647 
 
*p<0.05 **p<0.017 (p< 0.017 was used as significant for comparison between two groups due 
to Bonferroni correction for multiple comparisons).  




*p<0.05 **p<0.017 (p< 0.017 was used as significant for comparison between two groups due 
to Bonferroni correction for multiple comparisons). 
Figure 5-4 Tibia connectivity density 
14% site  
At the 14% site, significant differences were found in several trabecular features both at the tibia 
(T) and radius (R); trabecular density (tibia T p=0.013 and radius R p=0.19), inner trabecular 
density (T p=0.01 and R p= 0.007), meta/inner trabecular density (T p=0.01 and R p=0.008), 
trabecular BV/TV (T p=0.014 and R p=0.021), trabecular number (T p=0.011 and R p=0.007), 
trabecular separation (T p=0.01 R p=0.005) and trabecular inhomogeneity  (T p=0.002 R p= 0.006) 
(Table 5.4).  
 
Table 5.4 HR-pQCT 14% site results Median (IQR) 
 
T1DN+ T1DN- Control p value  
Tibia  n=20 n=20 n=19  






















T1DN+ T1DN- Control p value  



















































































Tibia 14%Meta/Inn trabecular 
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T1DN+ T1DN- Control p value  
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Tibia 14%Estimated failure 
























Tibia 14%Trab average von 








Tibia 14%Cort average von 








Radius      
 n=13 n=13 n=14  


































































T1DN+ T1DN- Control p value  































































































Radius 14%Cortical tissue 
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The comparison between each pair of groups showed that T1DN- had favorable trabecular 
microarchitecture with greater trabecular density (Error! Reference source not found. A, Error! 
Reference source not found. A), inner trabecular density (Error! Reference source not found. B, 
Error! Reference source not found. B) bone volume fraction (Error! Reference source not found. 
C, Error! Reference source not found. C) , and trabecular number (Error! Reference source not 
found. E, Error! Reference source not found. E) and lower trabecular meta/inner density (Error! 
Reference source not found. D, Error! Reference source not found. D), trabecular separation 
(Error! Reference source not found. F, Error! Reference source not found. F), and inhomogeneity 
(Error! Reference source not found. G,Error! Reference source not found. G), both at the tibia 
and radius (Table 5.5).  For most of these features, there was a trend to the T1DN+ group to 
follow the same pattern, but besides trabecular inhomogeneity it did not reach statistical 
significance (Table 5.5, Error! Reference source not found., Error! Reference source not found.). 
There were no differences in bone geometry, cortical features or bone strength measured by 
finite element analysis. (Table 5.4 














Tibial trabecular density (mgHA/cm3) 43 0.003** 35 0.046* 
Tibial inner trabecular density 
(mgHA/cm3) 
53 0.002** 64 0.034* 
Tibial Meta/Inn trabecular density (no 
units) 
19 0.002** 19 0.044* 
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Tibial trabecular BV/TV (no units) 43 0.003** 36 0.047* 
Tibial trabecular number 15 0.005** 15 0.023* 
Tibial trabecular separation 15 0.005** 18 0.021* 
Tibial trabecular inhomogeneity 25 0.001** 22 0.008** 
Radius trabecular density (mgHA/cm3) 50 0.006** 14 0.057 
Radius inner trabecular density 
(mgHA/cm3) 
113 0.002** 29 0.031* 
Radius Meta/Inn trabecular density (no 
units) 
45 0.002** 32 0.035* 
Radius trabecular BV/TV (no units) 50 0.006** 14 0.064 
Radius trabecular number 27 0.002** 11 0.072 
Radius trabecular separation 23 0.001** 9 0.076 






Figure 5-55-6 Tibia and Radius 14% site 
A Tb.vBMD tibia and radius; B BV/TV tibia and radius; C Tb.N tibia and radius D Tb.TH tibia and radius  
BTM results  
PINP and CTX were decreased in participants with diabetes (T1DN+ and T1DN-) compared to 
controls. PINP was 34% (p=0.006) and 28% (NS) lower in T1DN- and T1DN+ compared to controls, 
while CTX was 87% (p=0.016) and 90% (p=0.011) lower, respectively.  No difference was found 
between diabetic groups (T1DN+ and T1DN-). 
 
 




Summary of the main findings  
There was no difference in aBMD measured by DXA in the three groups. In the HR-pQCT 
assessment, trabecular microarchitecture was preserved in T1DN- compared to controls at  distal 
limbs. The pattern was more obvious at the 14% site, where we report robust findings of 
favourable trabecular microarchitecture both at the radius and the tibia in T1DN- in a consistent 
pattern. There was a trend for the same pattern in T1DN+. At the standard site (more distal) 
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microarchitecture was not different between T1DN- and controls in any of the features assessed. 
When we assessed the influence of neuropathy, T1DN+ had higher cortical porosity compared to 
T1DN- and also significantly higher connectivity compared to T1DN- and controls. BTM were 
decreased in participants with diabetes (T1DN+ and T1DN-) compared to controls and no 
difference was found between the diabetic groups (T1DN+ and T1DN-). 
 
aBMD  
We found no differences in the measurements made by DXA between the groups. Data in aDXA 
in diabetes are conflicting but overall a decrease in aBMD is observed in T1D (17, 84). In this 
study, the main outcome was measured by HR-pQCT. For HR-pQCT measurements gender, height 
and weight could affect the results and we chose to control these features by matching the 
participants. These features can also affect BMD. Although the matching was not fully successful 
there were no significant differences in these features between the groups. We speculate that 
the attempt to match might have influenced potential differences between the groups.  For 
example, body weight is an important determinant of BMD. Therefore, the matching for this 
characteristic might have affected the aBMD results. 
Furthermore, other features could also influence the aBMD. There is evidence that poor 
metabolic control has a negative impact on aBMD in growing children  (171). Therefore, a T1D 
onset before peak bone mass accrual and poor metabolic control during the growing period 
might have a marked negative impact on aBMD. In this study, in 17 (7 T1DN-/10 T1DN+) 
participants, T1D onset was earlier than 18 years-old. We did not have access to the metabolic 
control during growing period and we could not assess a potential impact of metabolic control in 
early onset T1D in aBMD. Additionally, the decrease in aBMD reported in T1D is not substantial. 
In a meta-analysis, Vestergaard described a decrease in BMD Z-score at spine (mean SEM -
0.220.01) and hip (-0.370.16) (84). Therefore, it is possible that our sample size was not big 
enough to detect this difference.  
 
HR-pQCT findings  
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Trabecular compartment  
 
14% site findings  
A number of significant differences in trabecular features were found in the 14% site. Greater 
BV/TV, trabecular density, inner trabecular density and trabecular number and lower trabecular 
separation and inhomogeneity were consistent findings at the radius and tibia when comparing 
T1DN- and controls and a trend when comparing T1DN+ and controls. Trabecular meta density 
refers to trabecular density of the outer 60% of the trabecular region, while trabecular inner 
density refers to density of inner 40% of trabecular region. The trabecular meta-inner density is 
the ratio between the two measurements. A decreased meta/inner density showed that the 
trabecula in the outer region are less preserved than in the inner region. Noteworthily, meta 
density was not different between the groups (T p=0.158; R p=0.08). 
 
Standard site findings   
At the standard site, no difference was found while comparing T1DN- and controls, but the T1DN+ 
group showed higher trabecular connectivity when compared to controls and T1DN. Generically, 
connectivity is a measure of the degree to which a structure is connected multitudinously to 
other structures (203). When described as in index, the index is derived from the Euler number 
(203). In bone microarchitecture, connectivity characterises the multiplex of trabecular 
connections (70). The index considers the number of objects, the number of cavities fully 
surrounded by bone and the number of connections that must be broken to separate the 
structure in two parts. Connectivity depends on structure size and it is normalised by dividing by 
the total volume resulting in connectivity density (Conn.D) (70). Connectivity does not consider 
the thickness of trabeculae and does not make a distinction between plates and rods. 
Consequently, connectivity is a measure of the degree of multiple connections, no matter the 
shape of the connections (203). Higher connectivity is often a favourable finding, however, if one 
plate is transformed in several rods connectivity will increase.  
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Despite being part of the standard bone microstructure analysis, connectivity is not one of the 
minimal set of variables reported for trabecular analysis and might not be reported unless 
specifically discussed (70). For example, Macdonald et al in the cross-sectional study that 
evaluated age-related changes in bone microarchitecture did not report connectivity (204).  
 
BTM  
PINP was decreased in T1DN- compared to controls and CTX was decreased in T1DN- and T1DN+ 
compared to controls. No difference was found between the diabetic groups (T1DN+ and T1DN-
). These findings suggested that bone turnover is low in T1D, regardless of neuropathy. These 
findings agree with previous literature. Lower levels of CTX have been described in both T1D and 
T2D in individual studies and in a meta-analysis that summarised BTM in diabetes (25, 28, 42).  
Lower levels of PINP have also been reported in T1D and T2D, but PINP was not assessed by the 
meta-analysis due to lack of sufficient data (25, 28, 42). The mechanisms involved in this decrease 
in the bone turnover are no fully understood but evidence suggest that this might be associated 
with hyperglycemia directly and indirectly. Some evidence suggest that hyperglycemia has a 
direct inhibitory effect on bone cells (205) In addition, hyperglycemia favors the formation of 
AGEs and there is also evidence that AGEs have a negative impact on bone turnover (206, 207), 




Hyperglycemia 1- direct effect  
The trabecular findings might be associated with the low bone turnover. A number of studies 
have described low bone turnover associated with diabetes (25, 28, 208) and this might be linked 
with hyperglycemia. There is evidence for a direct and indirect effect of hyperglycaemia in the 
skeleton. In vitro studies have shown that chronic hyperglycaemia inhibits osteoclast (209) and 
osteoblast differentiation and activity (205). A recent study compared histomorphometry from 
premenopausal T2D women with good (n= 10, HbA1c<7%) and poor metabolic control (n=16, 
HbA1c>7%) to age and race matched controls without diabetes. The group reported greater 
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BV/TV in T2D with good control compared to the non-diabetic control group and borderline 
findings in the poor control group (p=0.05). Furthermore, there was greater TB.N and lower 
trabecular separation in both T2D groups compared to non-diabetics regardless of the metabolic 
control. Interestingly, only the poor metabolic control group showed reduced osteoid thickness 
compared to controls without diabetes. There was a negative correlation between HbA1c levels 
and parameters of osteoid production, such as osteoid thickness and osteoid surface (40). These 
findings suggested preservation of trabecular structure in T2D and a reduction in bone formation 
associated with hyperglycaemia.  
 
Hyperglycemia 2- indirect effect via AGEs 
As previously discussed, glucose can bind to protein residues, which results in the formation of 
AGEs. The process is exacerbated by hyperglycaemia, which favours the formation and 
accumulation of AGEs, especially in long-lived tissue proteins such as collagen. AGEs might have 
a central role in the decrease in bone turnover in diabetes, especially at the trabecular 
compartment. 
In vitro studies, based on histology and in the release of products of collagen degradation have 
shown that AGEs decrease osteoclast and osteoblast activity (206, 207). In addition, 
osteoclastogenesis was also strongly inhibited by AGEs (206). Both osteoclast and osteoclast 
progenitors express AGEs receptors. This evidence suggests that AGEs could decrease 
osteoclastic differentiation, osteoclast-induced bone resorption and also osteoblast activity 
(206).  
AGEs are not exclusive of diabetes, since AGEs formation is associated with ageing. In individuals 
without diabetes, Viguet-Carrin et al assessed the association between collagen cross-links and 
trabecular microarchitecture properties of human vertebral bone. There was a positive 
correlation between pentosidine content and trabecular number and connectivity density and a 
negative correlation between pentosidine and trabecular separation. These findings were 
independent of trabecular bone volume, suggesting that pentosidine was associated with 
preserved trabecula. Pentosidine was associated with denser and rod-like, rather than plate-like 
trabecular network. This finding suggested that the preserved trabeculae contains mostly aged 
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bone that has undergone little remodeling and thus contains higher amounts of AGE cross-links 
such as pentosidine  (16).  
In vitro studies have suggested that AGEs inhibit bone turnover (206, 207). In a low bone turnover 
states, AGEs would not be cleared, resulting in the accumulation of AGEs. Therefore, the 
mechanism seems to be perpetuated. However, it is not clear if the accumulation of AGEs led a 
decrease in bone turnover or if the low bone turnover led to the accumulation of AGEs.  
AGEs formation is increased by the hyperglycemia associated with diabetes. In a small cross-
sectional case-control study of transiliac bone biopsies from subjects with T1D with a fragility 
fracture (T1DFx+, n=5) compared to healthy age- and sex-matched non-diabetic controls (n=5) 
and T1D without a fracture (T1DFx-, n=5), pentosidine content in trabecular bone was higher in 
T1DFx+ compared to controls (37). This finding agrees with in vitro evidence that suggested that 
trabecular bone is more susceptible to the formation and accumulation of glycation products 
than cortical bone (45). The T1DFx+ group had less surface covered with osteoblasts and osteoid 
and lower mineralizing surface, reflecting a lower bone formation rate and activation frequency. 
The degree of mineralization was higher in T1DFx+ compared both to controls and T1DFx (37), 
also reflecting lower bone turnover. Furthermore, there was a positive correlation between bone 
pentosidine content and HbA1C. These findings suggested that AGEs content was associated with 
hyperglycaemia, lower bone turnover and fractures in T1D.  
Taken together, this evidence suggests that AGE formation and deposition in bone might have 
an important role in the low bone turnover observed in people with diabetes. This low bone 
turnover could result in preservation of trabecular microarchitecture observed at the 14% site. 
Interestingly, there was a trend to the same pattern of microarchitecture in T1DN+. Since T1DN+ 
is considered a group with more advanced diabetes disease, as it is affected by neuropathy, a 
microvascular complication, we speculate that it is possible that other mechanisms might have 
affected this population.  
 
Impact of trabecular findings in bone strength and fracture risk  
The trabecular compartment has an important role in bone strength. A case-control study 
assessed postmenopausal women with and without fractures using HR-pQCT and reported lower 
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trabecular density, number and thickness and higher trabecular separation and inhomogeneity 
in women with fractures (210). Data from the OFELY study, that prospectively assessed the 
association of bone microarchitecture (HR-pQCT) and the risk of fractures reported that each 
quartile decrease in radius Tb.N was associated with an increase in the risk of fractures (HR 1.32 
95%CI 1.08,1.61 ). Conversely, the decrease in radius Tb.S  was associated with a decrease in the 
risk of fractures (HR 0.76 95%CI 0.63-0.92) (211). Therefore, the trabecular findings in 14% site 
are favourable findings and would be associated with a decrease in the risk of fractures 
In prospective studies that evaluated the bone microarchitecture as predictor of fracture risk in 
postmenopausal women, each quartile decrease in Conn.D was associated with an increase in 
the risk of fractures with an HR 1.49 (1.05–1.30), (adjusted HR for age, current smoking, falls in 
the past year, prior fracture, use of osteoporosis-related drugs, and total hip BMD) (211).This 
data suggest that connectivity is a favourable finding.  
 
Cortical compartment findings 
At the standard site, cortical porosity was higher in T1DN+ than T1DN-. Cortical pores are images 
of the spaces occupied by vascular structures in the cortical bone. Cortical bone is a compact 
structure formed by osteons. Osteons are the fundamental bone unit, cylindric structures formed 
by a central harversian canal where vascular capillaries and nerves are located, surrounded by 
layers of bone cells and mineralised bone matrix. These structures connect to each other by 
Volkmann’s canals. In cross-section, Harversian and Volkmann’s canals appear as a void volume, 
resembling pores. Human cortical bone displays a multiscale net of pores, which form a three-
dimensional network of interconnected canals with metabolic function and impact on bone 
biomechanics. This structure is not static as it is susceptible to remodelling. In bone morphologic 
analyses, this structure is visualised as pores, namely cortical porosity. 
The increase in cortical porosity was fond in T1DN+, the group with neuropathy. Neuropathy is a 
diabetic microvascular complication. It is characterized by abnormal nerve function caused by 
vascular and metabolic abnormalities. Neuropathy could potentially have an impact on the 
skeleton through two mechanisms; a direct impact of nerve damage or the same microvascular 
mechanism that affects the nerves could also affect the skeleton. 
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Mechanisms 1 Vascularization  
The vasculature has a key role in skeletal development, growth and maintenance (212). In animal 
models, Kusumbe et al investigated the link between angiogenesis and osteogenesis (213). The 
group reported that a specific kind of vessels mediates the growth of bone vasculature, maintains 
perivascular osteoprogenitors and couples angiogenesis to osteogenesis, highlighting the 
importance of vascularization for bone turnover. The group also reported that the abundance of 
these vessels is reduced with ageing. Transendothelial migration of cells from both the 
osteoclastic and osteoblastic lineage is likely to be tightly regulated by the endothelium (214) . 
These findings suggest that vascularization plays a key role in bone remodelling. Consequently, 
abnormalities in bone blood supply could impact in bone homeostasis.  
Low bone turnover might also have an impact on cortical porosity. In histomorphometric studies 
of people without diabetes, Andreasen et al assessed iliac bone specimens of 35 women from 16 
to 78 years old and found an increase in cortical porosity with ageing (215). This increase was 
mainly a result of an increase in pore size. The authors claim that in the remodelling process in 
existing pores, there is a delay or absence on the formation phase, resulting in large and 
coalescing pores and increase in cortical porosity (215). Diabetes is characterised by low bone 
turnover. Hence, it is possible that this delay or absence on the formation phase could be 
exacerbated, resulting in increased cortical porosity.  
 
Mechanisms 2 Innervation  
Furthermore, some evidence suggests that innervation might also play a role in bone metabolism. 
There is evidence for a neuronal control of bone remodelling, mediated mainly by the beta-
adrenergic system (51). It is also known that vascular and nerve components occupy the 
harversian canals but the role of each of these structures in bone remodelling is not 
characterised. Recent histomorphometric studies have investigated the nerve distribution in iliac 
crest of patients with primary hyperparathyroidism. In the cortical compartment, nerves were 
only visualised in the cortical pores, not in the cortical bone matrix. Moreover, the density of 
innervation was 5-fold higher in the cortical bone compared to the periosteum and bone marrow. 
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In the bone marrow, more than 90% of the nerves were associated with vascular structures and 
innervation was denser above remodelling units. The authors claim that this anatomical link 
between innervation and bone remodelling suggested a role of innervation in the bone 
remodelling process (216).  This evidence came from iliac bone in a subset of patients with high 
bone turnover and whether this would apply to long bones or individuals with normal or low 
bone turnover is unknown. However, if nerves are involved in bone remodelling, this process 
could be disrupted in patients with neuropathy. Therefore, there is evidence that both 
vasculopathy and neuropathy could have a negative impact on the bone remodelling process. As 
both vascularization and innervation might be impaired in diabetic neuropathy, we speculate 
that this could be associated with the increase in cortical porosity observed.  
 
Impact of cortical findings in bone strength and fracture risk  
 
An increase in cortical porosity is an unfavourable finding. Morphologic analyses by quantitative 
computed tomography have shown an increase in cortical porosity with ageing (204). A cross-
sectional study by Macdonald et al evaluated age-related changes in bone microarchitecture and 
strength at the distal radius and distal tibia in 644 adults aged 20 to 99 years. The study reported 
changes in bone total area, trabecular compartment (trabecular number, trabecular thickness) 
and an increase in cortical porosity both in men and women with ageing. Finite element analysis 
suggested that these findings were associated with a decrease in bone strength. Several other 
studies have reported an association between cortical porosity and bone fragility (26, 217, 218). 
Ex- vivo analyses suggest that an increase in porosity increased crack propagation thorough bone 
and decreased the peak stress that can be tolerated before a fracture. The ability of bone to 
deform without cracking also decrease when porosity increases (217). Therefore, an increase in 
cortical porosity would be associated with an increase in the risk of fractures and could contribute 
to bone fragility in diabetes. 
 
 188 
HR-pQCT in diabetes – previous literature standard site   
Conflicting results have been reported in microarchitecture in diabetes with favourable findings 
mainly in T2D and neutral and unfavourable findings both in T1D and T2D. Findings were reported 
both at cortical and trabecular compartments. However, there is an important variability in the 
study design. Some studies are cohort studies that compared T2D and non-T2D in the population 
(27, 31, 32). Others recruited participants with diabetes and age and height matched healthy 
controls (25, 26). Two studies, one in T1D and other in T2D stratified the analysis according to 
the presence of microvascular complications while the others did not take this into account. 
Some studies compare participants with diabetes with controls while others compared T2D 
participants with and without fractures.  
The results at the standard site agree with previous literature that reported no difference in 
microarchitecture when comparing people with T1D MVD- and controls (25). Similar results were 
also reported for T2D (28). Our results also agree with previous data that reported an increase in 
cortical porosity in diabetes. Previous results reported this finding in T2D regardless of MVD (26, 
27, 32) or in the group with MVD+ (28), while we report the finding in T1DN+. Shanbhogue et al, 
the previous study in T1D, reported a 25% decrease in the cortical area but no abnormalities in 
cortical porosity.  
Shanbhogue et al, in the T1D study, also reported a decrease in vBMD both in the radius and the 
tibia, while comparing T1D MVD+ with non-diabetic controls. We did not find differences in 
volumetric BMD in our study, however, our sample was 30% smaller than the previous study. 
While comparing T1D MVD+ and T1D MVD-, Shanbhogue reported several unfavourable findings 
both at the trabecular and cortical compartment and reduced bone strength at both sites. These 
findings are different from our findings when comparing T1DN+ and T1DN-. However, the study 
design is different; while we selected DSPN as the MVD of choice and performed a careful 
assessment to categorise participants into the T1DN+ and T1DN- groups, Shanbhogue used 
vibration threshold test, microfilament test, and examination of foot reflexes to establish 
neuropathy diagnosis. This clinical test isolated is much less accurate for the neuropathy 
diagnosis. None of the T1DN- participants had nephropathy, but some of them have reported 
previous retinopathy. In addition, we aimed to match the groups, so we recruited the same 
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number of males and females in each group while the groups were unbalanced in Shanbhogue. 
Finally, Shanbhogue sample size was also bigger (30% for T1DN+ group and 45% for T1DN-) (25).  
 
HR-pQCT in diabetes – previous literature 14% site   
There is only one previous study reporting the 14% site in diabetes, in T2D. Nilsson et al reported 
greater cortical area and failure load at both the tibia and radius and lower cortical porosity at 
the radius while evaluating a cohort of 75-80 years old women, 954 controls and 99 with T2D. 
This study assessed elderly women with T2D, a quarter of them with recently diagnosed T2D and 
the T2D group had greater BMI than controls. Although statistical adjustments for age and BMI 
were applied, this should be considered while interpreting the results. As in our study, favourable 
results were reported in the group with diabetes. However, while we report favourable findings 
in the trabecular compartment, Nilsson et al reported findings in the cortical compartment (31).  
Nevertheless, the great diversity in the population and study design between the two studies 
prevents further comparations.  
 
HR-pQCT sites inconsistencies 
We reported inconsistent findings at the 14% and standard sites, with several favourable findings 
at the 14% site in T1DN- and a trend in T1DN+ and only an increase in connectivity at the standard 
site.  
These differences might be associated with the proportion of trabecular bone at the sites 
measured. Schlenker and Vonseggen (219) have investigated the distribution of cortical and 
trabecular bone mass along the radius length. At distal radius approximately at the area 
measured by HR-pQCT the percentage of trabecular bone varies from 50 to 85% with an 
important variation within a small distance. For example, at 1.61 cm from radial styloid tip the 
percentage of trabecular (Tb) and cortical (Co) bone were (Tb 76.7 and Co 23.3%) while at 2.09 
cm the percentages were (Tb 46.8 and 53.2%) (Table 5.6). The standard site was measured at the 
fixed distance of 9.5/22.5 mm from the reference line placed at the notch on the articular surface, 
following standard procedures. Conversely, for the 14% site, the limb length was measured and 
the measurement site placed at the 14% length. We speculate that this might have resulted in a 
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better consistency in the site measured between the participants and have reduced potential 
noise in the measurements due to positioning variations. Although there was no difference in 
participants’ height, Schlenker and Vonseggen data on the radius suggested that even small 
differences in the measuring site could result in important variations in the trabecular content 
between the two sites.  
 
Table 5.6Percentages of trabecular and cortical bone in the radius of a 43-year-old woman according to Schlenker and 
Vonseggen 
Radius length  Trabecular bone (%)  Cortical bone (%)  
0.62 cm  68.0   32.0 
1.11 cm 85.5 14.5 
1.61 cm 76.7 23.2 
2.09 cm 46.8 53.2 
2.60 cm 19.1 80.9 
3.09 cm 9.3 90.7 
4.93 cm 1.2 98.8 
8.70 cm 3.9 96.1  
 
We found an increase in cortical porosity in T1DN+ at the tibia at the standard analysis, but not 
at the 14% site. Neuropathy is a length dependent damage process and we speculate if the 
finding only at the most distal site could reflect the neuropathy distribution pattern.  
Finally, the increase in cortical porosity was found only at the tibia. There are two potential 
reasons for this finding. Firstly, due to movement artefacts, 9 radius scans could not be included 
in the radius analysis, reducing the sample size. Additionally, neuropathy affects mainly lower 
limbs with only advanced disease affecting the upper limbs. Consequently, if neuropathy is a 
determinant of the increase in cortical porosity, it would be less likely to be detected at the radius 
than at the tibia.  
 
Limitations  
This study has limitations We aimed to match the participants in the three groups for several 
variables. For example, height could have an impact in the site measured. In addition, age and 
weight/BMI could affect microarchitecture and act as confounders. However, recruitment was a 
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challenge and participants were not fully individually matched. Although the individual match 
was not possible, the groups were similar in regards to these features.  
Furthermore, neuropathy is a disease with a broad spectrum. We used DSPN  defined by clinical 
symptoms and an objective measure of nerve conduction as the main feature to characterise the 
participants as defined by the Toronto Consensus (6). This is mainly an assessment of large fibre 
damage. It is possible that other assessments would result in different categorization. 
Additionally, some patients in the non-neuropathy group had a negative assessment for 
neuropathy but had a previous history of retinopathy (8 background retinopathy, 2 proliferative 
retinopathy). Therefore, the T1DN- group is not the same categorization as MVD-.  
Although HR-pQCT is the in vivo scanner with the highest resolution available for human bone 
measures the resolution is limited to the 82 m voxel size. This is close to the human trabecular 
dimension (71). In addition, only pores greater than 82 m would be detected and over 60% of 
cortical pores are less than 100 m in diameter (217). Therefore, only the minority of greater 
pores would be detected in the cortical porosity analysis. Finally, we assessed participants at the 
14% length of the radius and the tibia an unusual site for scanning and we used the same protocol 
used in the standard analysis to analyse these images. The standard protocol has been validated 
against the gold standard method high-resolution micro-computed tomography, using cadaveric 
samples (220).   The protocol has not been validated to this site.  
 
Conclusion 
There is an impact of T1D in bone microstructure and this impact is influenced by neuropathy.  
Diabetes is associated with lower bone turnover (associated with hyperglycaemia and AGEs) and 
this might have a paramount role on bone findings. We speculate that the low bone turnover 
would preserve trabecular microarchitecture resulting in a favourable microarchitecture pattern 
which was seen in T1DN- at the 14% site. Variations of the site measured might have prevented 
the detection of this findings at the standard site. This mechanism could also explain the aBMD 
preservation. With the disease progression and the development of neuropathy other 
mechanism associated with nerve functioning abnormalities and microvascular blood flow might 
also affect bone remodelling. These mechanisms could explain the increase in cortical porosity 
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observed in T1DN+. There is strong evidence for a crucial role of the vasculature in bone 
remodelling. However, nerves and vessels are components of the harversian canals and it is 












































































Previous literature suggested an increase in the risk of fractures in diabetes. The risk seemed to 
be higher in T1D than in T2D but the effect of several features such as fracture site, gender, age, 
BMI and diabetes-related features such as diabetes duration, insulin use and the presence of 
complications has not been fully explored. This thesis investigated the risk of fractures in 
diabetes. The first meta-analysis (chapter 3) investigated the risk of hip and non-vertebral 
fractures in diabetes and how this risk was affected by several features associated with the 
patients and the disease. The second meta-analysis (chapter 4) investigated the risk of peripheral 
fractures in diabetes (wrist and ankle), the sites assessed by HR-pQCT. Finally, a clinical study was 
conducted to assess peripheral microarchitecture in patients with T1D with and without 
neuropathy. This study investigated the effect of diabetes and also neuropathy, one of its main 
complications on bone density and peripheral microarchitecture(chapter 5). Our hypothesis was 
that the increased in the risk of fractures in diabetes would be associated with impaired 
microarchitecture.  
 
Chapter three results summary  
A systematic review and meta-analysis on the risk of hip and non-vertebral fractures in diabetes 
was conducted. We also investigated whether this risk was affected by age, BMI, diabetes 
duration, insulin use and the presence of complications. We found a significant increase in the 
risk of fracture in diabetes both for hip (RR 1.52, 95% CI 1.42-1.63) and for non-vertebral fracture 
(RR 1.20, 95%CI 1.14-1.27). The increase in the risk was greater for insulin users and longer 
diabetes duration, at both sites.  At the hip, the risk was higher in the younger population, 
women, and those with T1D. Some evidence suggests that poor metabolic control and diabetic 
complications could affect the risk of fractures, but there was not enough data to investigate the 




Chapter four results summary   
In the second meta-analysis, the risk of peripheral fractures in diabetes was investigated. There 
was a discordant pattern at the wrist and ankle. While at the wrist the risk was decreased (RR 
0.85 95% CI 0.77 – 0.95), at the ankle the risk was increased (RR 1.30 95%CI 1.15 – 1.48). The 
sample included mainly T2D participants and the pattern was similar to the risk pattern observed 
in obesity. As obesity is highly prevalent in T2D we speculated that the risk observed in diabetes 
were mainly driven by this feature. Recently, our group investigated bone density and 
microarchitecture in obesity and found greater aBMD and favourable microarchitecture in 
obesity. There is conflicting data in microarchitecture in T2D and few data in T1D. However, it 
would be interesting to investigate bone microarchitecture at these sites.  
 
Chapter five results summary  
Bone microarchitecture in T1D was also investigated. As the risk of fractures was higher in T1D I 
speculated that potential mechanisms associated with the increased risk of fractures in diabetes 
would be more evident in this population. Some evidence in literature also suggested a role for 
microvascular complications. Therefore, the study was designed to investigate the effect of T1D 
and also one of the microvascular complications. Neuropathy was the microvascular 
complication selected. Participants with T1D with and without neuropathy were recruited and 
also healthy controls without diabetes. Areal BMD and HR-pQCT were assessed. BMD was 
assessed at lumbar spine and hip and no difference was detected between the groups. HR-pQCT 
was assessed at the radius and tibia. We measured the standard site (ultra-distal) and also a less 
distal site, at 14% of the length of the radius and tibia. The ultra-distal site is rich in trabecular 
bone and the evaluation of the cortical compartment could be limited. Furthermore, previous 
studies have reported abnormalities in cortical porosity. Therefore, in order to investigate the 
cortical compartment more extensively a less distal site was also evaluated. Surprisingly, the 14% 
site showed preserved trabecular structure and no abnormalities in the cortical compartment in 
the diabetic groups, in particular in the T1DN- group. At the standard site, cortical porosity was 
increased in the group with diabetes and neuropathy at the tibia. However, there were no 
differences in bone strength estimated by finite element analysis. Since bone turnover markers 
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are decreased in diabetes, bone turnover is suppressed. I speculated that the bone turnover 
suppression could prevent bone loss and preserve trabecular microarchitecture. Conversely, 
cortical porosity was increased only at the tibia in the group with neuropathy. This finding 
suggested that vascular and/or neural integrity might also be important to bone remodelling and 
consequently, bone microarchitecture.  
Bone turnover is decreased in diabetes and this is expected to preserved trabecular structure. 
However, initially, low bone turnover seems not to be associated with cortical porosity. 
Preserved bone microarchitecture was more evident in T1DN- (a trend was found in T1DN+ but 
it did not reach statistical significance). Conversely, increased cortical porosity was found only in 
T1DN+, suggesting that features specific to this group might be involved. Neuropathy is 
associated with abnormal vascular and nerve function (7). It is possible that these abnormalities 
could compromise bone remodelling and influence cortical porosity. Neuropathy can be 
associated with abnormal muscular function and this could also affect bone structure (6). In 
addition, it is important to consider the limitations of the method; currently, HR-pQCT is able to 
detect only pores greater than 100 m and the majority of the pores are smaller than this 
threshold. Cortical porosity increases with age (204). Since the average age of the population in 
this study was around 48 years it is possible that a subtle variation in cortical porosity would not 
be detected, as we could only detect big pores. Therefore, an increase or decrease in small pores, 
smaller than this threshold would not be detected. Nilsson et al has previously assessed the 
cortical compartment at the 14% site in an elder cohort of participants with T2D, 1/4 of them 
with a recent diagnosis. Interestingly, they reported a decrease in cortical porosity in the diabetic 
population (31). It is possible that in this elder population with greater pores at baseline, the 
decrease in bone turnover would be associated with the decrease in cortical porosity reported. 
However, this was an unexpected finding, as the decrease in cortical porosity would increase 
bone strength. In addition, an increase in cortical porosity in the diabetic group with 
microvascular disease has been reported both in T1D (25) and in T2D (28). These findings suggest 
that cortical porosity is affected in diabetes and that microarchitecture is not an important 
determinant of bone fragility in this population.  
 
 197 
Peripheral fracture meta-analysis and radius HR-pQCT results  
The microarchitecture study results agreed with the peripheral meta-analysis results. At the 
radius, the meta-analysis showed a 15% decrease in the risk of fractures in diabetes. Previous 
studies showed that wrist fractures are associated with bone loss and lower BMD (221). 
Furthermore, previous studies also reported an increase in BMD and favourable 
microarchitecture in obesity (67). Consequently, a decrease in the risk of wrist fractures would 
be expected in the obese population. Obesity is highly prevalent in T2D and the studies included 
in the meta-analysis reported data mainly from T2D. Therefore, the increase in the risk of 
fractures in diabetes was initially associated with obesity. However, in the T1D clinical study, only 
participants with T1D were included and there was no significant difference on weight or BMI 
between the groups. Therefore, no influence of weight/obesity would be expected. The analysis 
showed favourable microarchitecture at the radius at the 14% site. Even though there was no 
difference in bone strength estimated by finite element analysis, favourable microarchitecture 
would be expected in a site where there is a decrease in the risk of fractures. The radius fracture 
meta-analysis result agreed with the microarchitecture pattern found in the participants with 
T1D, especially the group without neuropathy.  
 
Peripheral fractures meta-analysis and tibia HR-pQCT results  
Conversely, ankle fractures are not considered typical osteoporotic fractures (196)(197).  Ankle 
fractures are not associated with lower axial BMD and do not predict future fractures. However, 
unfavourable microarchitecture has been described in people with ankle fractures (197). 
Furthermore, ankle fracture was associated with obesity (196). The meta-analysis on the risk of 
ankle fractures in diabetes showed a 30% increase in the risk. Initially, this increased risk was 
associated with obesity, highly prevalent in T2D, the main population included in the meta-
analysis.  
In the clinical study in T1D, favourable trabecular microarchitecture was found at the 14% site 
and an increase in cortical porosity was found at the standard site. While the increase in cortical 
porosity could contribute to an increase in the risk of ankle fractures, the favourable trabecular 
pattern seemed contradictory.  
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Previously, a case-control study that compared 31 postmenopausal women with and without 
ankle fractures reported no difference in spine BMD, total or regional ankle BMD and calcaneal 
broadband ultrasound attenuation between the two groups (196). The ankle fractures group 
were 10 kg heavier than the non-fractures group. These findings suggested that ankle fractures 
are not associated with axial or local BMD. In addition, a recent consortium of several 
microarchitecture cohorts reported that ankle fractures were not associated with any measure 
of BMD or HR-pQCT (222). Finally, Evans et al has shown favourable microarchitecture in an 
obese population, despite a higher risk of ankle fractures (67). Therefore, ankle fracture risk 
seems not to be associated with microarchitectural features at the tibia. Therefore, the 
microarchitectural findings in the clinical study seem not to influence the risk of fractures at this 
site. We speculate that the increased risk of fractures found in the meta-analysis is associated 
with obesity in the T2D population. The increase in the risk of ankle fractures is due to an increase 
biomechanical forces applied to the limb during falls.  
 
Research hypothesis  
The results showed an increase in the risk of hip, non-vertebral and ankle fractures in diabetes. 
The initial hypothesis was that impaired microarchitecture could be one of the mechanisms 
associated.  
An increase in cortical porosity was found at the standard site at the tibia. However, this is an 
isolated finding, at a site where the risk of fractures is not directly associated with bone density 
or microarchitecture. In addition, in the trabecular compartment, the microarchitecture was 
favourable. Therefore, it is unlikely that unfavourable microarchitecture is an important 
mechanism associated with bone fragility in diabetes.  
 
Speculations  
There is a decrease in bone turnover in diabetes (25). Although this could result in preserved 
bone mass this could also be associated with a decrease in microdamage repair. The 
accumulation of microdamage could result in an increased risk of fractures.  
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Several studies on bone microarchitecture in diabetes have reported conflicting results. Neither 
bone quantity, assessed by DXA, nor bone quality, assessed by HR-pQCT, could explain the bone 
fragility in diabetes. The next step would be to assess bone material properties. Two studies have 
previously assessed BMSi using reference point indentation (31, 34). Both of them have reported 
a decrease in BMSi in T2D. Some evidence suggested that BMSi could correlate to bone toughness 
and it is possible that it could capture the abnormalities in bone in diabetes (223).  
We speculate that the hyperglycemia and AGEs deposition are associated with a reduced bone 
turnover. As bone turnover is low, bone damage repair would also be affected. This could be 
associated with bone fragility in diabetes. This is a speculative theory but might be supported by 
some studies in atypical femur fractures. 
Atypical femur fractures (AFF) are associated with decreased microdamage repair (224). Previous 
studies suggested that the risk of AFF is increased in diabetes (225) . Data from the SOF study has 
shown that diabetes was associated with an increase in the relative hazard (RH) for AFF (RH: 2.97, 
(1.47, 6.00) p= 0.005). Age (RH: 2.04 per 5 years, (1.59, 2.63) p < 0.001) and femoral neck BMD 
(RH/SD decrease: 1.41, (1.01, 1.96) p= 0.04) were the other significant risk factors. While 
bisphosphonates use is known to be associated with an increase in the risk of AFF, in the SOF 
analysis the association was not significant with a RH of 2.40 (0.97, 5.95). However, the number 
of AFF was low (159). 
These findings raise the concern about the use of anti-resorptive drugs in this population. 
Previous studies have shown similar efficacy of anti-resorptive drugs in diabetes. However, the 
pathophysiology of bone fragility in diabetes is not established. As the baseline bone turnover is 
suppressed, additional suppression may prevent microdamage repair. If the low bone turnover 
is the main mechanism driving bone fragility in diabetes concerns could be risen over the safety 
of anti-resorptive drugs in this population and how to address bone fragility in diabetes.  
Considering the skeleton a site of diabetic complications, it would benefit from adequate 
metabolic control. However, this study could not find evidence to support this. In the meta-
analysis, there were not enough data to investigate the impact of metabolic control on the risk 
of fractures. In the clinical study, low bone turnover was also observed in the T1DN- group. In 
addition, strict metabolic control can increase the risk of hypoglycaemia which increases the risk 
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of falls and fractures (173, 182). Therefore, adequate metabolic control is advisable and should 
benefit bone health but the risk of hypoglycaemia should not be neglected(159).  
Anti-resorptive drugs are the most common drugs used to treat osteoporosis. They are 
affordable, widely available and considered safe. Recently concerns were raised about the risk of 
atypical femur fractures as a rare adverse event in the general population. Diabetes is a risk factor 
for this adverse event (225). The low bone turnover observed in diabetes associated with the 
increase in the risk of atypical femur fractures could raise concerns about the use of anti-
resorptive drugs in this population. The available information suggests that anti-resorptive drugs 
are safe in diabetes (186). However, a post hoc analysis from the Freedom trial reported an 
increase in non-vertebral fractures in the group with diabetes in use of denosumab (226). 
Although anti-resorptive drugs seem to work in people with diabetes, the population is 
heterogeneous and we do not know how these drugs affect different subgroups of people with 
diabetes. It might be possible that people with diabetes could benefit from shorter courses of 
anti-resorptive drugs. Another possibility is that not all patients with diabetes would respond in 
the same way and that anti-resorptive drugs would be beneficial for a subgroup of patient with 
not so low bone turnover, for example. In addition, there is no information about how the 
concept of drug holiday would apply to this population.   
Another suitable option would be to use anabolic drugs. The Dance study is an observational 
study that assessed real world use of teriparatide (227). It this study the reduction in 
nonvertebral fracture incidence, increase in BMD (lumbar spine and total hip), and decrease in 
back pain were similar in T2D and non-diabetic patients in teriparatide treatment. T2D patients 
had a greater increase in femoral neck BMD. There are no specific data in regards to the use of 
bisphosphonates after the anabolic treatment in diabetes. There are no specific data if the 
decrease in the bone turnover observed in diabetes is able to maintain the gain in BMD. Since 
the mechanisms associated with bone fragility in diabetes are not established any prediction on 
the behavior of the skeleton in response to drugs is a speculation. More research is needed  to 
investigate the mechanisms associated with bone fragility in diabetes and the efficacy and safety 




It is likely that non-skeletal features might play an important role in the increased risk of fracture 
in diabetes. There is data for an increase of falls in diabetes, and there are many features that 
might contribute to that (93, 150); microvascular complications could impair vision, 
proprioception and balance increasing the risk of falls (150). In addition, medications associated 
to hypovolemia, such as SGLT2 could be associated with falls. Furthermore, oral anti-diabetic 
medications and insulin could be associated with hypoglycemia and also with falls (20).  
 
Limitations  
This thesis has limitations. For the systematic reviews, we did not have access to individual data. 
This limited the analysis of confounders such as age and weight. For the hip and non-vertebral 
fractures review, we relied on a previous review for the search of the early studies. Considerable 
amount of data came from registries, with questionable reliability. Some of the studies did not 
make the distinction between T1D and T2D. There was not enough data to assess the effect of 
metabolic control, microvascular complications, BMD, falls, hypoglycaemia or the competing risk 
of death. Non-whites were included, but the majority of the data came from whites. Finally, we 
found high heterogeneity in most analyses and this should be considered while interpreting the 
results.  
For the clinical study, we were not able to match participants individually. Neuropathy is a broad-
spectrum disease and it is possible that participants without neuropathy would have some early 
stage of the complication. Some participants included had previous history of retinopathy, and 
therefore, are not free of microvascular disease. This analysis was restricted to DXA and HR-pQCT 
in a small sample. A broader evaluation of bone health in a greater number of participants would 
be desirable.  
 
Future directions  
We reported the results of bone microarchitecture in T1D but a much broader evaluation would 
be recommended to try to understand the mechanisms associated with bone fragility in diabetes. 
This evaluation could include several features such as; 
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Bone turnover markers could be investigated explore bone turnover in this population.  Several 
other molecules associated with bone health such as vitamin D, PTH could also add useful 
information.  
We speculated that AGEs might have an important role in bone fragility in diabetes, and the 
assessment of these molecules would be desirable. AGEs can be assessed in blood or urine 
samples and also in vivo by a device that assess AGE in the skin by measuring skin fluorescence.  
We speculated that bone material properties could also be affected. Currently, Osteoprobe can 
assess bone material properties in vivo and could be used to assess bone material properties. 
There are data in T2D that showed decrease BMSi but there are no data in T1D and no data on 
the effect of MVD on BMSi.  
There are limited data on bone histomorphometry in T1D. A recent study in histomorphometry 
in T2D that compared participants with and without diabetes and within the diabetic group, 
participants with poor and good control and also with and without MVD has brought interesting 
insights (40). However, there is no similar study in T1D.  
The low bone turnover in people with diabetes and the increased in the risk of AFF raise concern 
about the safety of antiresorptive therapies in this population. The analysis of data from reliable 
databases assessing the incidence of AFF or stress fractures in this population would be desirable. 
Finally, there is no specific data on fracture prevention in diabetes. Currently, bone fragility in 
diabetes is often not detected and when detected is addressed with the same approach used for 
osteoporosis. However, the pathophysiology of bone fragility in diabetes and osteoporosis seems 
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Systematic searches of bibliographic databases were conducted to identify reviews and primary 
studies relating to the risk of bone fractures in patients with diabetes mellitus.  Search 
strategies were developed combining terms for fractures and diabetes mellitus (plus related 
synonyms) including free-text and thesaurus terms (where available).  Search terms were 
combined using Boolean Operators and database-specific syntax.  An initial search was 
conducted to identify relevant systematic reviews as a source of primary data.  Further focused 
searches were undertaken to identify additional primary studies published since the selected 
systematic review conducted their searches.  Specific details of the individual searches for the 
reviews and primary studies appear below, including any limits and search filters applies. 
 
1) Searches to identify reviews 
Searches to identify systematic reviews relating to the risk of bone fractures in patients with 
diabetes mellitus were conducted on 7th December 2017 in the following databases: 
• Ovid MEDLINE(R) 1946 to November Week 5 2017 
• Ovid MEDLINE(R) Epub Ahead of Print December 06, 2017 
• Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations December 06, 2017 
• Ovid MEDLINE(R) Daily Update December 06, 2017 
• Embase via Ovid 1974 to 2017 December 06 
• Cochrane Database of Systematic Reviews: Issue 12 of 12, December 2017 
• Database of Abstracts of Reviews of Effect via The Cochrane Library: Issue 2 of 4, April 
2015 
• Health Technology Assessment Database via The Cochrane Library: Issue 4 of 4, October 
2016 
Searches were limited to humans and English Language where database functionality allowed 
the application of such limits (Ovid MEDLINE and Embase).  The BMJ Best Practice systematic 
review filter was applied to the MEDLINE and Embase searches1.  A complete set of search 
strategies can be found in Appendix 1.  The search strategy for reviews was a broad search 
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including the two conditions from the companion rapid reviews (chronic kidney disease and 
Parkinson’s Disease). 
2) Searches to identify primary studies 
Searches to identify primary studies relating to the risk of bone fractures in patients with 
diabetes mellitus were conducted on 28th February 2018 in the following databases: 
• Ovid MEDLINE(R) 1946 to February Week 3 2018 
• Ovid MEDLINE(R) Epub Ahead of Print February 27, 2018   
• Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations February 27, 2018   
• Ovid MEDLINE(R) Daily Update February 27, 2018   
• Embase via Ovid 1974 to 2018 February 27 
• Cochrane Central Register of Controlled Trials: Issue 1 of 12, January 2018 
Searches were limited to primary studies added to the databases from June 2006 onwards 
(where database functionality allowed) based on the search date from the most recent relevant 
systematic review2 identified in Search 1 above.  The additional limits of humans, English 
Language, and the exclusion of reviews (identified in Search 1), comments, letters and editorials 
were applied where possible.  In addition to terms relating to bone fractures and diabetes 
mellitus, terms relating to risk were included in the search to achieve an acceptable balance of 
precision and recall.   A complete set of search strategies can be found in Appendix 2. 
The search strategy for primary studies was re-run on Ovid MEDLINE (including Epub Ahead of 
Print, In-Process & Daily Update) on 29 March 2019. No search limits were applied. To identify 
studies added to MEDLINE since the original search, the “Create Date” field (.dt) was searched. 




1.1 Review Search Strategies 
MEDLINE 
Database: Ovid MEDLINE(R) <1946 to November Week 5 2017> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1  exp Diabetes Mellitus/ or exp Diabetes Mellitus, Type 2/ or exp Diabetes Mellitus, Type 
1/ (416094) 
2  diabet*.ti,ab. (524556) 
3  exp Parkinson Disease/ (64032) 
4  parkinson*.ti,ab. (96405) 
5  paralysis agitans.mp. (1177) 
6  exp Kidney Failure, Chronic/ (94308) 
7  (chronic adj2 (kidney* or renal) adj2 (disease* or insufficienc* or failure*)).ti,ab. (63455) 
8  (renal adj1 insufficien*).ti,ab. (21779) 
9  exp "Chronic Kidney Disease-Mineral and Bone Disorder"/ (3515) 
10  "mineral and bone disorder".ti,ab. (529) 
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11  Renal Osteodystrophy.mp. (2200) 
12  (renal adj1 osteodystroph*).ti,ab. (2191) 
13  ((end?stage or end stage) adj2 (kidney* or renal*) adj2 (disease* or failure*)).ti,ab. 
(34642) 
14  or/1-13 (819299) 
15  exp Fractures, Bone/ (180520) 
16  fractur*.ti,ab. (210939) 
17  (bone* adj5 (injur* or break* or broken)).ti,ab. (6542) 
18  or/15-17 (260692) 
19  14 and 18 (5291) 
20  limit 19 to (english language and humans) (4246) 
21  (review or review,tutorial or review, academic).pt. (2424823) 
22  (medline or medlars or embase or pubmed or cochrane).tw,sh. (143959) 
23  (scisearch or psychinfo or psycinfo).tw,sh. (16292) 
24  (psychlit or psyclit).tw,sh. (935) 
25  cinahl.tw,sh. (16843) 
26  ((hand adj2 search$) or (manual$ adj2 search$)).tw,sh. (9831) 
27  (electronic database$ or bibliographic database$ or computeri?ed database$ or online 
database$).tw,sh. (23404) 
28  (pooling or pooled or mantel haenszel).tw,sh. (79317) 
29  (peto or dersimonian or der simonian or fixed effect).tw,sh. (5506) 
30  (retraction of publication or retracted publication).pt. (9765) 
31  or/22-30 (233649) 
32  21 and 31 (128060) 
33  meta-analysis.pt. (96815) 
34  meta-analysis.sh. (96815) 
35  (meta-analys$ or meta analys$ or metaanalys$).tw,sh. (141930) 
36  (systematic$ adj5 review$).tw,sh. (108748) 
37  (systematic$ adj5 overview$).tw,sh. (1335) 
38  (quantitativ$ adj5 review$).tw,sh. (6240) 
39  (quantitativ$ adj5 overview$).tw,sh. (244) 
40  (quantitativ$ adj5 synthesis$).tw,sh. (1865) 
41  (methodologic$ adj5 review$).tw,sh. (4609) 
42  (methodologic$ adj5 overview$).tw,sh. (322) 
43  (integrative research review$ or research integration).tw. (118) 
44  or/33-43 (214243) 
45  32 or 44 (264359) 







MEDLINE In-Process, Epub Ahead of Print, Daily Update 
Database: Ovid MEDLINE(R) Epub Ahead of Print <December 06, 2017>, Ovid MEDLINE(R) In-
Process & Other Non-Indexed Citations <December 06, 2017>, Ovid MEDLINE(R) Daily Update 
<December 06, 2017> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1  exp Diabetes Mellitus/ or exp Diabetes Mellitus, Type 2/ or exp Diabetes Mellitus, Type 
1/ (1246) 
2  diabet*.ti,ab. (63154) 
3  exp Parkinson Disease/ (183) 
4  parkinson*.ti,ab. (12113) 
5  paralysis agitans.mp. (29) 
6  exp Kidney Failure, Chronic/ (215) 
7  (chronic adj2 (kidney* or renal) adj2 (disease* or insufficienc* or failure*)).ti,ab. (8213) 
8  (renal adj1 insufficien*).ti,ab. (1104) 
9  exp "Chronic Kidney Disease-Mineral and Bone Disorder"/ (5) 
10  "mineral and bone disorder".ti,ab. (130) 
11  Renal Osteodystrophy.mp. (146) 
12  (renal adj1 osteodystroph*).ti,ab. (126) 
13  ((end?stage or end stage) adj2 (kidney* or renal*) adj2 (disease* or failure*)).ti,ab. 
(4367) 
14  or/1-13 (84861) 
15  exp Fractures, Bone/ (384) 
16  fractur*.ti,ab. (29293) 
17  (bone* adj5 (injur* or break* or broken)).ti,ab. (852) 
18  or/15-17 (29872) 
19  14 and 18 (793) 
20  (review or review,tutorial or review, academic).pt. (121998) 
21     (medline or medlars or embase or pubmed or cochrane).tw,sh. (31120) 
22  (scisearch or psychinfo or psycinfo).tw,sh. (6968) 
23  (psychlit or psyclit).tw,sh. (37) 
24  cinahl.tw,sh. (3926) 
25  ((hand adj2 search$) or (manual$ adj2 search$)).tw,sh. (1762) 
26  (electronic database$ or bibliographic database$ or computeri?ed database$ or online 
database$).tw,sh. (5438) 
27  (pooling or pooled or mantel haenszel).tw,sh. (11932) 
28  (peto or dersimonian or der simonian or fixed effect).tw,sh. (843) 
29  (retraction of publication or retracted publication).pt. (2595) 
30  or/21-29 (48293) 
31  20 and 30 (12370) 
32  meta-analysis.pt. (904) 
33  meta-analysis.sh. (904) 
34  (meta-analys$ or meta analys$ or metaanalys$).tw,sh. (24212) 
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35  (systematic$ adj5 review$).tw,sh. (29278) 
36  (systematic$ adj5 overview$).tw,sh. (401) 
37  (quantitativ$ adj5 review$).tw,sh. (794) 
38  (quantitativ$ adj5 overview$).tw,sh. (42) 
39  (quantitativ$ adj5 synthesis$).tw,sh. (409) 
40  (methodologic$ adj5 review$).tw,sh. (941) 
41  (methodologic$ adj5 overview$).tw,sh. (58) 
42  (integrative research review$ or research integration).tw. (16) 
43  or/32-42 (43000) 
44  31 or 43 (47421) 







Database: Embase <1974 to 2017 December 06> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1  exp diabetes mellitus/ (819620) 
2  exp non insulin dependent diabetes mellitus/ or exp insulin dependent diabetes 
mellitus/ (284131) 
3  diabet*.ti,ab. (787032) 
4  exp Parkinson disease/ (130483) 
5  parkinson*.ti,ab. (137835) 
6  paralysis agitans.mp. (331) 
7  exp chronic kidney failure/ (70526) 
8  (chronic adj2 (kidney* or renal) adj2 (disease* or insufficienc* or failure*)).ti,ab. (94751) 
9  (renal adj1 insufficien*).ti,ab. (28597) 
10  exp "chronic kidney disease-mineral and bone disorder"/ (4699) 
11  "mineral and bone disorder".ti,ab. (801) 
12  exp renal osteodystrophy/ (4564) 
13  (renal adj1 osteodystroph*).ti,ab. (2696) 
14  ((end?stage or end stage) adj2 (kidney* or renal*) adj2 (disease* or failure*)).ti,ab. 
(49288) 
15  or/1-14 (1266817) 
16  exp fracture/ (262538) 
17  fractur*.ti,ab. (269255) 
18  (bone* adj5 (injur* or break* or broken)).ti,ab. (8897) 
19  or/16-18 (350041) 
20  15 and 19 (12678) 
21  limit 20 to (human and english language) (10608) 
22  exp review/ (2380771) 
23  (literature adj3 review$).ti,ab. (293127) 
24  exp meta analysis/ (138660) 
25  exp "Systematic Review"/ (157871) 
26  or/22-25 (2615526) 
27  (medline or medlars or embase or pubmed or cinahl or amed or psychlit or psyclit or 
psychinfo or psycinfo or scisearch or cochrane).ti,ab. (201096) 
28  RETRACTED ARTICLE/ (8836) 
29  27 or 28 (209768) 
30  26 and 29 (157826) 
31  (systematic$ adj2 (review$ or overview)).ti,ab. (154238) 
32  (meta?anal$ or meta anal$ or meta-anal$ or metaanal$ or metanal$).ti,ab. (161788) 
33  30 or 31 or 32 (313975) 





Cochrane Library (CDSR, DARE, HTA) 
Last Saved: 07/12/2017 15:09:49.810 
ID Search  
#1 MeSH descriptor: [Diabetes Mellitus] explode all trees 
#2 MeSH descriptor: [Diabetes Mellitus, Type 1] explode all trees 
#3 MeSH descriptor: [Diabetes Mellitus, Type 2] explode all trees 
#4 diabet*:ti,ab,kw  (Word variations have been searched) 
#5 MeSH descriptor: [Parkinson Disease] explode all trees 
#6 parkinson*:ti,ab,kw  
#7 paralysis agitans:ti,ab,kw  
#8 MeSH descriptor: [Kidney Failure, Chronic] explode all trees 
#9 (chronic near/2 (kidney* or renal) near/2 (disease* or insufficienc* or failure*)):ti,ab,kw  
#10 (renal near/1 insufficien*):ti,ab,kw  
#11 MeSH descriptor: [Chronic Kidney Disease-Mineral and Bone Disorder] explode all trees 
#12 "mineral and bone disorder":ti,ab,kw  
#13 Renal Osteodystrophy:ti,ab,kw  
#14 (renal near/1 osteodystroph*):ti,ab,kw  
#15 ((end?stage or end stage) near/2 (kidney* or renal*) near/2 (disease* or 
failure*)):ti,ab,kw  
#16 {or #1- #15}  
#17 MeSH descriptor: [Fractures, Bone] explode all trees 
#18 fractur*:ti,ab,kw  
#19 (bone* near/5 (injur* or break* or broken)):ti,ab,kw  
#20 {or #17-#19}  
#21 #16 and #20  
 
Appendix 1.2  
Primary Study Search Strategies 
MEDLINE 
Database: Ovid MEDLINE(R) <1946 to February Week 3 2018> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1  *Diabetes Mellitus/ or *Diabetes Mellitus, Type 2/ or *Diabetes Mellitus, Type 1/ 
(210381) 
2     diabet*.ti,ab. (472855) 
3  *Fractures, Bone/ (44874) 
4  fractur*.ti,ab. (193070) 
5  (bone* adj5 (injur* or break* or broken)).ti,ab. (6039) 
6  or/3-5 (205375) 
7  1 or 2 (490336) 
8  6 and 7 (2843) 
9  limit 8 to (english language and humans) (2280) 
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10  (200606* or 200607* or 200608* or 200609* or 200610* or 200611* or 200612* or 
2007* or 2008* or 2009* or 2010* or 2011* or 2012* or 2013* or 2014* or 2015* or 2016* or 
2017* or 2018*).dt. (8295229) 
11  9 and 10 (1586) 
12  (review or review,tutorial or review, academic).pt. (2215441) 
13  (medline or medlars or embase or pubmed or cochrane).tw,sh. (129074) 
14  (scisearch or psychinfo or psycinfo).tw,sh. (14868) 
15  (psychlit or psyclit).tw,sh. (865) 
16  cinahl.tw,sh. (15491) 
17  ((hand adj2 search$) or (manual$ adj2 search$)).tw,sh. (8980) 
18  (electronic database$ or bibliographic database$ or computeri?ed database$ or online 
database$).tw,sh. (21132) 
19  (pooling or pooled or mantel haenszel).tw,sh. (70838) 
20     (peto or dersimonian or der simonian or fixed effect).tw,sh. (4876) 
21  (retraction of publication or retracted publication).pt. (8664) 
22  or/13-21 (209746) 
23  12 and 22 (114932) 
24  meta-analysis.pt. (84714) 
25  meta-analysis.sh. (84714) 
26  (meta-analys$ or meta analys$ or metaanalys$).tw,sh. (124788) 
27  (systematic$ adj5 review$).tw,sh. (97811) 
28  (systematic$ adj5 overview$).tw,sh. (1228) 
29  (quantitativ$ adj5 review$).tw,sh. (5689) 
30  (quantitativ$ adj5 overview$).tw,sh. (228) 
31  (quantitativ$ adj5 synthesis$).tw,sh. (1715) 
32  (methodologic$ adj5 review$).tw,sh. (4175) 
33  (methodologic$ adj5 overview$).tw,sh. (292) 
34  (integrative research review$ or research integration).tw. (105) 
35  or/24-34 (190198) 
36  23 or 35 (235348) 
37  11 and 36 (109) 
38  11 not 37 (1477) 
39  COMMENT/ (663372) 
40  LETTER/ (925475) 
41  EDITORIAL/ (404627) 
42  39 or 40 or 41 (1477944) 
43  38 not 42 (1445) 
44  *RISK/ or *RISK FACTORS/ (4951) 
45     *INCIDENCE/ (472) 
46  *PREVALENCE/ (720) 
47  (risk or inciden* or prevalen* or predict*).ti,ab. (3116451) 
48  44 or 45 or 46 or 47 (3118222) 





MEDLINE In-Process, Epub Ahead of Print, Daily Update 
Database: Ovid MEDLINE(R) Epub Ahead of Print <February 27, 2018>, Ovid MEDLINE(R) In-
Process & Other Non-Indexed Citations <February 27, 2018>, Ovid MEDLINE(R) Daily Update 
<February 27, 2018> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1  *Diabetes Mellitus/ or *Diabetes Mellitus, Type 2/ or *Diabetes Mellitus, Type 1/ (668) 
2  diabet*.ti,ab. (64842) 
3  *Fractures, Bone/ (44) 
4  fractur*.ti,ab. (29992) 
5  (bone* adj5 (injur* or break* or broken)).ti,ab. (857) 
6  or/3-5 (30528) 
7  1 or 2 (64869) 
8  6 and 7 (614) 
9  (200606* or 200607* or 200608* or 200609* or 200610* or 200611* or 200612* or 
2007* or 2008* or 2009* or 2010* or 2011* or 2012* or 2013* or 2014* or 2015* or 2016* or 
2017* or 2018*).dt. (2851574) 
10  (review or review,tutorial or review, academic).pt. (134047) 
11  (medline or medlars or embase or pubmed or cochrane).tw,sh. (32543) 
12  (scisearch or psychinfo or psycinfo).tw,sh. (6950) 
13  (psychlit or psyclit).tw,sh. (43) 
14  cinahl.tw,sh. (3982) 
15  ((hand adj2 search$) or (manual$ adj2 search$)).tw,sh. (1812) 
16  (electronic database$ or bibliographic database$ or computeri?ed database$ or online 
database$).tw,sh. (5576) 
17  (pooling or pooled or mantel haenszel).tw,sh. (12006) 
18  (peto or dersimonian or der simonian or fixed effect).tw,sh. (882) 
19  (retraction of publication or retracted publication).pt. (2872) 
20  or/11-19 (49851) 
21  10 and 20 (13179) 
22  meta-analysis.pt. (571) 
23  meta-analysis.sh. (571) 
24  (meta-analys$ or meta analys$ or metaanalys$).tw,sh. (24599) 
25  (systematic$ adj5 review$).tw,sh. (30576) 
26  (systematic$ adj5 overview$).tw,sh. (391) 
27  (quantitativ$ adj5 review$).tw,sh. (800) 
28     (quantitativ$ adj5 overview$).tw,sh. (41) 
29  (quantitativ$ adj5 synthesis$).tw,sh. (433) 
30  (methodologic$ adj5 review$).tw,sh. (966) 
31  (methodologic$ adj5 overview$).tw,sh. (52) 
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32  (integrative research review$ or research integration).tw. (18) 
33  or/22-32 (44368) 
34  21 or 33 (49160) 
35  *RISK/ or *RISK FACTORS/ (6) 
36  *INCIDENCE/ (1) 
37  *PREVALENCE/ (2) 
38  (risk or inciden* or prevalen* or predict*).ti,ab. (515867) 
39  35 or 36 or 37 or 38 (515868) 
40  8 and 9 (603) 
41  40 not 34 (556) 








Database: Embase <1974 to 2018 February 27> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1  *diabetes mellitus/ (209761) 
2  *non insulin dependent diabetes mellitus/ or *insulin dependent diabetes mellitus/ 
(171830) 
3  diabet*.ti,ab. (787953) 
4  or/1-3 (822257) 
5  *fracture/ (35807) 
6  fractur*.ti,ab. (269828) 
7  (bone* adj5 (injur* or break* or broken)).ti,ab. (8909) 
8  or/5-7 (281383) 
9  4 and 8 (5821) 
10  exp review/ (2367906) 
11  (literature adj3 review$).ti,ab. (292926) 
12  exp meta analysis/ (139554) 
13  exp "Systematic Review"/ (159878) 
14  or/10-13 (2603229) 
15  (medline or medlars or embase or pubmed or cinahl or amed or psychlit or psyclit or 
psychinfo or psycinfo or scisearch or cochrane).ti,ab. (203676) 
16  RETRACTED ARTICLE/ (8904) 
17  15 or 16 (212347) 
18  14 and 17 (159933) 
19  (systematic$ adj2 (review$ or overview)).ti,ab. (154595) 
20  (meta?anal$ or meta anal$ or meta-anal$ or metaanal$ or metanal$).ti,ab. (161804) 
21  18 or 19 or 20 (315894) 
22  9 not 21 (5585) 
23  letter/ (954030) 
24  editorial/ (569837) 
25  23 or 24 (1522748) 
26  22 not 25 (5553) 
27  *risk factor/ or *risk/ (115621) 
28  *incidence/ (7856) 
29  *prevalence/ (43211) 
30  (risk or inciden* or prevalen* or predict*).ti,ab. (4886202) 
31  27 or 28 or 29 or 30 (4894128) 
32  26 and 31 (3756) 
33  limit 32 to (human and english language) (3046) 
34  (200606* or 200607* or 200608* or 200609* or 200610* or 200611* or 200612* or 
2007* or 2008* or 2009* or 2010* or 2011* or 2012* or 2013* or 2014* or 2015* or 2016* or 
2017* or 2018*).dc. (15219003) 
35  33 and 34 (2714) 
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Cochrane Central Register of Controlled Trials 
Last Saved: 27/02/2018 11:13:39.099 
 
ID Search  
#1 MeSH descriptor: [Diabetes Mellitus] this term only 
#2 MeSH descriptor: [Diabetes Mellitus, Type 1] this term only 
#3 MeSH descriptor: [Diabetes Mellitus, Type 2] this term only 
#4 diabet*:ti,ab  
#5 #1 or #2 or #3 or #4  
#6 MeSH descriptor: [Fractures, Bone] this term only 
#7 fractur*:ti,ab  
#8 (bone* near/5 (injur* or break* or broken)):ti,ab  
#9 #6 or #7 or #8  




Update Search (conducted 29 March 2019) 
Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily 
1946 to March 28, 2019 
1     *Diabetes Mellitus/ or *Diabetes Mellitus, Type 2/ or *Diabetes Mellitus, Type 1/  
2     diabet*.ti,ab.  
3     *Fractures, Bone/  
4     fractur*.ti,ab.  
5     (bone* adj5 (injur* or break* or broken)).ti,ab.  
6     or/3-5  
7     1 or 2  
8     6 and 7  
9     (review or review,tutorial or review, academic).pt.  
10     (medline or medlars or embase or pubmed or cochrane).tw,sh.  
11     (scisearch or psychinfo or psycinfo).tw,sh.  
12     (psychlit or psyclit).tw,sh.  
13     cinahl.tw,sh.  
14     ((hand adj2 search$) or (manual$ adj2 search$)).tw,sh.  
15     (electronic database$ or bibliographic database$ or computeri?ed database$ or online 
database$).tw,sh.  
16     (pooling or pooled or mantel haenszel).tw,sh.  
17     (peto or dersimonian or der simonian or fixed effect).tw,sh.  
18     (retraction of publication or retracted publication).pt.  
 229 
19     or/10-18  
20     9 and 19  
21     meta-analysis.pt.  
22     meta-analysis.sh.  
23     (meta-analys$ or meta analys$ or metaanalys$).tw,sh.  
24     (systematic$ adj5 review$).tw,sh.  
25     (systematic$ adj5 overview$).tw,sh.  
26     (quantitativ$ adj5 review$).tw,sh.  
27     (quantitativ$ adj5 overview$).tw,sh.  
28     (quantitativ$ adj5 synthesis$).tw,sh.  
29     (methodologic$ adj5 review$).tw,sh.  
30     (methodologic$ adj5 overview$).tw,sh.  
31     (integrative research review$ or research integration).tw.  
32     or/21-31  
33     20 or 32  
34     COMMENT/  
35     LETTER/  
36     EDITORIAL/  
37     34 or 35 or 36  
38     *RISK/ or *RISK FACTORS/  
39     *INCIDENCE/  
40     *PREVALENCE/  
41     (risk or inciden* or prevalen* or predict*).ti,ab.  
42     38 or 39 or 40 or 41  
43     8 and 42  
44     33 or 37  
45     43 not 44  
46     (2018 03* or 2018 04* or 2018 05* or 2018 06* or 2018 07* or 2018 08* or 2018 09* or 
2018 10* 2018 11* 2018 12* or 2019*).dt.  





Appendix 2  
 
Data extraction form (Hip and non-vertebral fractures risk in diabetes)  
Data extraction field Definition 
Study number  
 
Number in spreadsheet, starting with 1 
First author (year) 
 
To identify study 
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Title & biblio   
 
Title and bibliographic information 
Study design 
 
Cohort (identifies patients with/without 
DM, follows forward); Case-control 
(identifies patients with fractures, looks 
back); y the definition in the study report; 
(any doubts, add a comment) 






Name of cohort (e.g. MrOS)  
 
This should ideally be a single phrase, not a 
sentence 
Details of database/recruitment process To include information to allow judgment 
of representativeness, such as what 
population the database recruited, 
coverage of the database for that 
population, process of contacting and 
recruiting patients etc 
 
Cases inclusion/exclusion criteria For case-control studies  
Cases (people with fractures) 
 
For Cohort studies 
Exposed (people with DM) 
 
For case-cohort studies: 
Cases (people with fractures) 
 
Controls inclusion/exclusion criteria For case-control studies  
Controls (people without fractures) 
 
For Cohort studies 
Unexposed (people without DM) 
 
For case-cohort studies: 
Cohort (reference population) 
Method of recruitment (e.g. random 
sample, age matched etc) 
Give details for both groups 
Method of Diagnosis (definition of DM) e.g. self reported, medical records, blood 
tests, registry 
Type of diabetes (code) T1D (type 1 diabetes) 
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T2D  (type 2 diabetes) 
All/both  
Not specified (when the study does not 
differentiate) 
Differential diagnosis T1D vs T2D (definition of T1D and T2D) 
Inclusion criteria relating to Age  e.g. ≥65 
Time of Study Years of recruitment 
Years of follow-up 
Case-control studies years of fracture 
records 
Average duration of cohort follow-up Mean & Range (specify if not full range,e.g. 
IQR) 
Fracture assessment/method of diagnosis How were fractures ascertained in the 
study? 
Does the study reports number of fractures 
or number of people with fractures?  
Y/N 
Has the study excluded people with 
previous fractures? 
Y/N 
Sample size (Total N) This number should be the whole study, 
not the number in a subgroup.  N patients with DM 
N patients without DM 
N patients with incident  fractures 
N patients without fractures  
Ethnicity If not reported, add notes about probable 
ethnicity, e.g. if study from Japan, can 
assume a large proportion are Japanese 
Sex at baseline % Female 
Age (years) at enrollment Mean, error & Range (specify if not full 
range,e.g. IQR) 
Bone mineral density at baseline mean (error) (range) 
Diabetes at baseline % T1DM 
%T2DM 
Insulin use at baseline specify categories and provide % 
 
If other medication is reported for the DM 
group, please describe with % 
Diabetes duration at baseline specify categories and provide mean (error) 
and (range, specify if IQR) or nearest 
equivalents 
 
Microvascular complications at baseline specify categories and provide % 
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BMI at baseline mean (error) (range) 
HbA1c level in diabetics  
Other comments If need to make any comments 
Vertebral fractures reported? Y/N 
do not extract the data, just indicate it is 
available 
Subgroups reported?   (Code - one per row) 








Fracture site subgroup, name fracture site Name fracture site 




Sex subgroups Male 
Female 
All 
Age subgroups Specify, e.g.  age range (e.g. 18-40) 




Diabetes duration subgroup specify duration or NR 
Microvascular complications subgroup specify type of MV complication 
BMI subgroup specify, e.g. BMI range 
N fractures in patients with DM for this 
subgroup 
These numbers relate to the subgroup 
being reported on this row of the 
spreadsheet.  Number of people with DM (subgroups) 
N fractures in patients without DM for this 
subgroup 
Number of patients without DM 
(subgroups) 
Type of risk estimate reported HR, OR, IRR etc 
Reference group for risk estimate Which group was the reference group in 
the multivariable analysis? 
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Age and sex adjusted risk estimate  (95%CI) If the risk estimates ONLY for age and sex is 
not available, report the least adjusted 
(95% CI)   
If not only age and sex, report adjustments 
made 
Report which adjustments were made in 
cases where an age-and-sex-only adjusted 
analysis was not available  
Most fully adjusted risk estimate (95%CI)  
Adjusted variables List which variables were adjusted for in the 
analysis 
Any additional data adjustments reported Flagged for information. Where Y, brief 
details given 
Notes e.g analyses that were excluded from data 
extraction 
Data double checked by second reviewer? Data checker to add their initials once the 
data was checked.  
Linked studies  Study ID for any studies that may include 
some or all of the same patients.  
Additional comments Any additional comments that might need 








NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE 
 CASE CONTROL STUDIES 
 
Note: A study can be awarded a maximum of one star for each numbered item within the Selection and 
Exposure categories. A maximum of two stars can be given for Comparability. 
 
Selection 
1) Is the case definition adequate? 
a) yes, with independent validation * 
b) yes, eg record linkage or based on self-reports 
c) no description 
2) Representativeness of the cases 
a) consecutive or obviously representative series of cases * 
b) potential for selection biases or not stated 
3) Selection of Controls 
a) community controls * 
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b) hospital controls 
c) no description 
4) Definition of Controls 
a) If cases are first occurrence of outcome, then it must explicitly state that controls have no history 
of this outcome. If cases have new (not necessarily first) occurrence of outcome, then controls with 
previous occurrences of outcome of interest should not be excluded * 
b) No mention of history of outcome 
 
Comparability 
1) Comparability of cases and controls on the basis of the design or analysis 
a) study controls for age * 
b) study controls for gender** 
 
Where an analysis only included one gender, this was considered as an adjustment for gender. Where 
an analysis reported only a narrow spectrum of age, this was considered as an adjustment for age. Note, 
all studies in this review will score positively on this item as the selection criteria for the review specified 
that adjustments for age and sex should have been performed.   
 
Exposure 
1) Ascertainment of exposure 
a) secure record (eg surgical records) * 
b) structured interview where blind to case/control status * 
c) interview not blinded to case/control status 
d) written self-report or medical record only 
e) no description 
2) Same method of ascertainment for cases and controls 
a) yes * 
b) no 
3) Non-Response rate 
a) same rate for both groups * 
b) non-respondents described 




 NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE 
 COHORT STUDIES 
 
Note: A study can be awarded a maximum of one star for each numbered item within the Selection 
and Outcome categories. A maximum of two stars can be given for Comparability 
 
Selection 
1) Representativeness of the exposed cohort 
a) truly representative of the average population with diabetes in the community*  
b) somewhat representative of the average population with diabetes in the community * 
c) selected group of users eg nurses, volunteers 
d) no description of the derivation of the cohort 
Note: Downgrade if they excluded people with previous fractures (outcome of interest) 
2) Selection of the non-exposed cohort 
a) drawn from the same community as the exposed cohort * 
b) drawn from a different source 
c) no description of the derivation of the non-exposed cohort  
3) Ascertainment of exposure 
a) secure record (eg surgical records) * 
b) structured interview * 
c) written self report 
d) no description 
4) Demonstration that outcome of interest was not present at start of study 
a) yes * 
b) no 
Comparability 
1) Comparability of cohorts on the basis of the design or analysis 
a) study controls for age * 
b) study controls for gender * 
 
Where an analysis only included one gender, this was considered as an adjustment for gender. 
Where an analysis reported only a narrow spectrum of age, this was considered as an adjustment for 
age.  Note, all studies in this review will score positively on this item as the selection criteria for the 
review specified that adjustments for age and sex should have been performed.   
 
Outcome 
1) Assessment of outcome  
a) independent blind assessment *  
b) record linkage * 
c) self-report 
d) no description 
2) Was follow-up long enough for outcomes to occur 
a) yes (1 year or more) * 
b) no 
3) Adequacy of follow up of cohorts 
a) complete follow up - all subjects accounted for *  
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b) subjects lost to follow up unlikely to introduce bias - small number lost - > 80 % follow up, or 
description provided of those lost) * 
c) follow up rate < 80% and no description of those lost 
d) no statement 
 
Note: where a study was a comprehensive registry or databases where it could be assumed that 
emigration was low, a study was scored well for this item.  
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Appendix 3  
Wrist and Ankle Fractures Review Protocol  
 
1. Title of review: 
Is the risk of ankle fractures increased in patients with diabetes? 
 
2. Reviewer Contact Details: 
Tatiane Vilaca  
Academic Unit of Bone Metabolism- University of Sheffield;  
Metabolic Bone Centre - Northern General Hospital  





Systematic review –Background  
 
Recent studies have suggested that bone could be affected by diabetes. A number of meta-
analyses have shown an increased risk of fractures in diabetic populations (Janghorbani et al., 
2007, Vestergaard, 2007, Shah et al., 2015). The risk varies depending on the site and type of 
the disease, the highest reported at the hip for type 1diabetes (DM1) (relative risks –RR- from 
3.78 to 6.94) (Shah et al., 2015, Vestergaard, 2007).  A number of factors could contribute to 
this finding: the lack of insulin and its anabolic actions in bone; the frequent early onset of 
the disease, which could compromise the peak bone mass accrual; the reduced bone mineral 
density (BMD) observed in DM1 (Pan et al., 2014) and the increased risk of falls related to 
diabetic complications. However, the role of each of them is still to be defined.  
In type 2 diabetes (DM2), the context is different. DM2 patients have increased BMD related 
mainly to increased body mass index (BMI) (Vestergaard, 2007, Bonds et al., 2006). Weight 
excess is a risk factor for DM2, and is highly prevalent in this population (2014). In addition, a 
protective effect against fragility fractures is attributed to weight excess (Johansson et al., 
2014). Despite the expected protective effect of weight excess, DM2 patients present an 
increased risk of fractures (Janghorbani et al., 2007, Vestergaard, 2007). The increase is less 
than that observed in DM1 (RR 1.38 – 1.7 for hip fracture, for example). However, as DM2 is 
highly prevalent, it is still remarkable.  
The reason for the increased fracture risk observed in DM1 and DM2 is yet to be defined.  
 
Rationale for this review  
Ankle fractures are not considered osteoporotic fractures because its occurrence is 
independent of BMD. High BMI, physical activity and diabetes are risk factors. (Giannini et 
al., 2013) 
On the other hand, distal radius fracture is one of the most common osteoporotic fractures. 
The incidence is associated with low BMD and increase with age. Although there is a 
significant immediate morbidity and impact in life quality, there is no increase in 
mortality.(Porrino et al., 2014) 
Although widely used to evaluate fracture risk in the general population, BMD is not 
effective in detecting the particularities of bone health in diabetic patients, as previously 
reported. Evaluations of bone microarchitecture by high-resolution peripheral quantitative 
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computed tomography (HR-pQCT) have shown an increase in cortical porosity in distal 
radius and tibia, which is more pronounced in the group of diabetic patients with previous 
fracture (Patsch et al., 2013, Burghardt et al., 2010). In addition, finite element analysis 
show impairment of stiffness in distal tibia and radius, related to higher cortical porosity 
(Patsch et al., 2013).   
Until now, the increase in cortical porosity is the main structural abnormality observed in 
bone in diabetic patients. As the distal region of long bones such as the radius and tibia are 
rich in cortical bone, an increase in fracture rates would be expected at these sites in the 
diabetic population as a . clinical effect of this structural abnormality.  
The aim of this review is to identify if there is an increase in the risk of radius and tibia 
fractures in patients with diabetes  
 
 
4. Focused review question 
 
Question: 
Is the risk of ankle and radius fractures increased in patients with diabetes? 
 
Population: Adults  
Intervention: -> epidemiological study -> exposure: diabetes (type 1 and type 2)  
Comparators: non diabetic patients  
Outcomes: ankle fractures  
 
5. Search Strategy 
Search terms 




Adults    
Intervention (s) 
Exposure 
Diabetes mellitus Type 1 diabetes  




















Cohort studies  
Case control studies  
Registry studies  
Epidemiological studies  
Publication types 
 
Primary studies  
Date of publication 
 
No limits  
Language 
 












Medline (via Ovid)  
LILACS  
















6. Study Selection 
Inclusion and exclusion criteria 
 










Studies that include data 
of children fracture;  
Studies that do not specify 




Patients with diabetes: 
-Type 1 or type 2; 
-Diagnosis stablished by 
self report, medical 
records, or exams 
results according to 
WHO or ADA diabetes 
diagnostic criteria  
 
Studies that uses different 
diagnosis criteria for 
diabetes;  
Studies lacking a clear 
condition of the medical 




Male and female adult 
patients without 
diabetes  
Studies without a 





Occurrence of ankle 
fracture  
Diagnosis criteria:  
-Self report;  
medical records (report 
or radiology exams)  
Studies reporting 
predicted fracture risk 
based on an algorithm or 
risk tool;  
Studies that report mainly 






Portuguese, Spanish  




 Studies lacking data or 
mean to calculate OR/RR 




7. Quality assessment strategy 
There is no standard international tool to evaluate quality control in observational studies. 
Review papers suggest to avoid the use of scales, and to prefer the use of checklists with 
comments.  
Features to be addressed:  
DM diagnosis  
Fracture diagnosis  
Type of study  
Patients selection  
Control of confounders  
Statistical analysis  
In order to try to evaluate most of these aspects, the Newcastle-Ottawa quality assessment 
tool will be used.  
 
 
8. Data Extraction 
Data will be extracted by one reviewer (with no blinding to authors or journal) using a data 
extraction form (google forms). Any doubts will be discussed with a supervisor.  
Should multiple publications of the same study be identified, data will be extracted and 
reported from a single one.  
Data items to be extracted:  
 Author, year; 
 Study design; 
 Population size and characteristics;  
 Relevant clinical features; 
 Additional factors that may affect the risk of fractures or falls;  
 Mode by which the fracture occurred;  
 Fracture site;  
 Fracture diagnostic methods;  
 Risk of fracture reported as relative risk (RR) or odds ratio (OR);  
 
9. Proposed Data synthesis 
A narrative review will be performed. If the data collected is sufficient, a meta-analysis will 








10. Review Timetable 
 
Task Completion date 
Focus question 29/02/16 
Draft protocol 15/03/16 
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Scoping search 16/03/16 
Final protocol 30/03/16 
Full searches 30/03/16 
Order papers 30/03/16 
Study selection 13/04/16 
Quality assessment 27/04/16 
Data extraction 27/04/16 
Data synthesis 25/04/16 
Draft review submission 01/06/16 
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